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This thesis is divided into eight chapters, including this one: 
 
Chapter 1: This is an introductory chapter that addresses the background, rationale and 
relevance of the study and the aim and objectives. The general outline and structure of the 
thesis conclude this chapter. 
 
Chapter 2: This chapter provides a comprehensive literature review on the two GPCR family 
studied in this thesis.  
 
Chapter 3: This chapter provides the theoretical underpinnings of biomolecular simulations 
and computational drug design approaches applied in the thesis. The chapter introduces the 
general applications of computational approaches in pharmaceutical research. The chapter 
further discusses biomolecular simulations and the molecular mechanics force fields that 
govern the simulations of membrane-bound proteins.  
 
Chapter 4: Published work- this chapter is presented in the journal’s required format and is 
the final version of the published manuscript. (Appendix I: Proof of Published Article) 
 
Chapter 5: Published work - this chapter is presented in the journal’s required format and is 
the final version of the published manuscript. (Appendix II: Proof of Published Article) 
 
Chapter 6: Published work - this chapter is presented in the journal’s required format and is 
the final version of the published manuscript. (Appendix III: Proof of Published Article) 
 
Chapter 7: Submitted work - this chapter is presented in the journal’s required format and is 
the final version of the submitted manuscript. (Appendix IV: Proof of Submitted Manuscript) 
 
Chapter 8: This final chapter presents a general discussion, concluding remarks, limitations 









G protein-coupled receptors (GPCRs) are the largest membrane protein receptor superfamily 
involved in a wide range of physiological processes. GPCRs form the major class of drug 
targets for a diverse array of pathophysiological conditions. Consequently, GPCRs are 
recognised as drug targets for the treatment of various diseases, including neurological 
disorders, cardiovascular conditions, oncology, diabetes, and HIV. The recent advancement in 
GPCR structure resolutions has provided novel avenues to understand their molecular basis of 
signal transduction, ligand recognition and ligand-receptor interactions. These advances 
provide a framework for the structure-based discovery of new drugs in targeting GPCRs 
implicated in the pathogenesis of various human diseases.  
In this thesis, the interactions of inhibitors at two dopamine receptor subtypes and C-C 
chemokine receptor 5 (CCR5) of the Class A GPCR family were investigated. Dopamine 
receptors and CCR5 are validated GPCR targets implicated in neurological disorders and HIV 
disease, respectively. The lack of structural information on these receptors limited our 
comprehension of their antagonists’ structural dynamics and binding mechanisms. The recently 
solved crystal structures for these receptors have necessitated further investigations in their 
ligand-receptor interactions to obtain novel insights that may assist drug discovery towards 
these receptors.   
This thesis comprehensively investigated the binding profiles of atypical antipsychotics (class 
I and class II) at the first crystal structure of the D2 dopamine receptor (D2DR). The class I 
antipsychotics exhibited binding poses and dynamics different from the class II antipsychotics 
with disparate interaction mechanistic at D2DR active site. The class II antipsychotics were 
remarkably observed to establish a recurrent and vital interaction with Asp114 via strong 
hydrogen bond interactions. Furthermore, compared to class I antipsychotics, the class II 
antipsychotics were found to engage favourably with the deep hydrophobic pocket of D2DR. 
In addition, the structural basis and atomistic binding mechanistic of the preferential selective 
inhibition at D3DR over D2DR were explored. This study investigated two small molecules 
(R-VK4-40 and Y-QA31) with substantial selectivity (> 180-fold) for D3DR over D2DR. The 
selective antagonists adopted shallow binding modes at D3DR while demonstrating a deep 
hydrophobic pocket binding at D2DR. Also, the vital roles and contribution of critical residues 




binding free energy analyses further discovered distinct stabilising effects of the selective 
antagonists on the secondary architecture and binding profiles of D3DR relative to D2DR. 
Furthermore, the atomistic molecular interaction mechanism of how slight structural 
modification between novel derivatives of 1-heteroaryl-1,3-propanediamine (Compd-21 and -
34) and Maraviroc significantly affects their binding profiles toward CCR5 were elucidated. 
This study utilised explicit lipid bilayer molecular dynamics (MD) simulations and advanced 
analyses to explore these inhibitory disparities. The thiophene moiety substitution common to 
Compd-21 and -34 was found to enhance their CCR5-inhibitory activities due to 
complementary high-affinity interactions with residues critical for the gp120 V3 loop binding. 
The study further highlights the structural modifications that may improve inhibitor 
competitiveness with the gp120 V3 loop.  
Finally, structure-based virtual screening of antiviral chemical database was performed to 
identify potential compounds as HIV-1 entry inhibitors targeting CCR5. The identified 
compounds made pertinent interactions with CCR5 residues critical for the HIV-1 gp120-V3 
loop binding. Their predicted in silico physicochemical and pharmacokinetic descriptors were 
within the acceptable range for drug-likeness. Further structural optimisations and biochemical 
testing of the proposed compounds may assist in the discovery of novel HIV-1 therapy. 
The studies presented in this thesis provide novel mechanistic and in silico perspective on the 
ligand-receptor interactions of GPCRs. The findings highlighted in this thesis may assist in 
further research towards the identification of novel drug molecules towards CCR5 and D2-like 
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1.1 Background and Rationale of the study 
G protein-coupled receptors (GPCRs) are physiologically essential membrane proteins 
involved in the signal transduction of chemicals from the extracellular matrix into the cell. 
They are implicated in many diseases (Latorraca et al., 2017). The GPCRs family represent 
one of the significant successful drug targets due to their direct role in major physiological 
processes regulations. They account for nearly 34% of marketed drugs (Santos et al., 2017). 
The recent explosion in GPCR structures serves as a reliable starting point for in silico drug 
discovery and biomolecular simulations in accelerating drug design opportunities and 
mechanistic understanding of these receptors. As a significant prominent family of drug targets 
known to date, GPCRs continue to be the subject of considerable research efforts directed 
towards discovering improved therapeutics.   
Dopamine receptors and C-C chemokine receptor 5 (CCR5) are validated GPCR drug targets 
implicated in neurological disorders and HIV disease, respectively (Rangel-Barajas et al., 
2015; Tan et al., 2013). Dopamine receptors are an integral member of the family of GPCRs 
that play vital functions in central nervous system neurotransmitters. Numerous neurological 
disorders, such as attention deficit hyperactivity disorder, Parkinson’s disease, depression, and 
schizophrenia, have been associated with dysfunction of the dopaminergic system (Klein et al., 
2019; Rangel-Barajas et al., 2015; Beaulieu & Gainetdinov, 2011). The existing antipsychotic 
drugs that target the different dopamine receptors show poor selectivity between the respective 
dopamine receptor subtypes. Significant adverse effects stem from the lack of selectivity of 
these antipsychotics. These include metabolic syndrome, cardiovascular hypertension, and 
neurological side effects, including extrapyramidal reactions and tardive dyskinesia due to the 
distinctive function of these receptor subtypes, thus reducing the utility of these essential 
groups of drugs. (Álvarez et al., 2013; Ballon et al., 2014; Kaar et al., 2020). The recent 
advancement in the structure determination of the D2-like dopamine receptor provides new 
research opportunities in understanding binding mechanistic and interactions of antipsychotics 
at dopamine receptors (Fan et al., 2020; Wang et al., 2018; Chien et al., 2010; Wang et al., 
2017).  
Another member of the GPCR family involved in the modulation of immune response and as 




cells, CCR5 serves as the essential co-receptor of HIV-1. An attractive therapeutic approach to 
blocking HIV-1 infection and replication is preventing the entry of HIV into host cells 
(Arimont et al., 2017). The quest to develop inhibitors with the capability of inhibiting HIV 
entry by targeting CCR5 resulted in the approval of the first and only CCR5 antagonist 
(Maraviroc) in 2007 (FDA, 2007). Many CCR5 antagonists have been documented, but very 
few have advanced into clinical use before being discontinued, mainly due to challenging drug-
like properties (Qi et al., 2020). The prescription of Maraviroc is limited due to identified 
factors such as its drug-drug interactions (especially when co-administrated with CYP3A4 
inhibitors), CYP450 inhibition, and viral resistance (Garcia-Perez et al., 2015; Peng et al., 
2018). Therefore, the rapid global rise in patients diagnosed with HIV necessitates discovering 
novel therapeutics for HIV treatment with fewer side effects and better efficacy. Recently, 1 
Heteroaryl-1,3-propanediamine derivatives have been identified as a series of novel CCR5 
antagonists compared to Maraviroc with low cytotoxicity, exceptional in vitro anti-HIV-1 
profile, and good pharmacokinetic properties (Peng et al., 2018).  
In selecting compounds for synthesis or further optimisation, the application of molecular 
modelling methods in drug design and development plays an essential role. These techniques 
further provide an atomistic basis in directing further design efforts (Aminpour et al., 2019; 
Cavasotto et al., 2019). Biomolecular simulations are proven methods for exploring the 
conformational landscape of GPCRs at the atomic level and inhibitor/drug binding mechanisms 
for biological targets (Latorraca et al., 2017; Alfonso-Prieto et al., 2019). A molecular level 
insight into how small molecules interact with their GPCRs and how drugs/small molecules 
can selectively target subfamily receptors is critical for discovering novel treatments of 
conditions implicated in the GPCR family.  
 
1.2 Aims and objectives 
The purpose of this thesis is to provide novel mechanistic insights into how dopamine receptors 
and CCR5 receptors interact with their small molecule inhibitors and to apply a structure-based 
discovery approach to identifying new potential CCR5 inhibitors. The following objectives 
were followed to achieve the above goal: 
1. To provide a comprehensive investigation of the molecular recognition and binding 
mechanistic of atypical antipsychotics drugs at D2 dopamine receptor.  
1.1 Predict the binding modes of the selected atypical drugs through molecular docking. 




1.3 Estimate the free energies of the drug-receptor complexes upon binding using 
MMGB/SA end-point free energy approach. 
1.4  Analyse the drug-receptor interactions and characterise residues critical for drug 
binding.  
 
2. To explore the structural basis and atomistic binding mechanistic of the selective 
antagonist blockade at D3 dopamine receptor over D2 dopamine receptor. 
2.1 Predict the binding modes of the D3 selective antagonists at both D2DR and D3DR 
binding site. 
2.2 Perform MD simulations in a lipid bilayer environment to elucidate the structural 
and conformational changes associated with the selective binding.  
2.3 Identify residues that drive the selectivity and higher binding affinity of the studied 
compounds.  
   
3. To elucidate the molecular mechanism and structural dynamics of 1-Heteroaryl-1,3-
propanediamine derivatives interactions with CCR5 in HIV inhibition.  
3.1 Perform all-atom MD simulations of protein-ligand complexes in a lipid bilayer.  
3.2 Post-process MD data to estimate the binding free energy. 
3.3 Identify residues critical for the higher affinity of the novel derivative relative to 
Maraviroc.   
 
4. To identify novel potential HIV-1 entry compounds targeting CCR5  using structure-
based drug discovery techniques.  
4.1 Perform a structure-based virtual high-throughput screening using compounds from 
the Asinex antiviral database. 
4.2 Predict ligand-binding poses and affinities, assess ligand binding mode modes and 
interactions at receptor target. 
4.3 Perform MD simulations on the best hits in a lipid bilayer to evaluate their stability 
at the CCR5 binding pocket. 
4.4 To apply in silico techniques in predicting the molecular properties and 







1.3 Novelty and Significance of the Study 
The crystal structures of the D3 dopamine receptor (D3DR) bound to eticlopride and D4 
dopamine receptor (D4DR) bound to antipsychotic nemonapride were resolved in 2010 (Chien 
et al., 2010) and 2017 (Wang et al., 2017), respectively. However, the lack of crystallised 
ligand-bound D2DR structures before 2018 limited the molecular understanding of ligand 
recognition and receptor function. The first crystal structure of the D2 dopamine receptor bound 
with risperidone solved in 2018 (Wang et al., 2018), followed by haloperidol in 2020 (Fan et 
al., 2020), provided novel insights. An unanticipated binding mode of risperidone was 
discovered by the crystal structure of D2DR bound to atypical antipsychotic risperidone (Wang 
et al., 2018). The observed unexpected binding mode was different from earlier docking studies 
based on a D2DR homology model that used D3DR, or D4DR solved structures as templates 
(Duan et al., 2015; Salmas et al., 2017).  
Interestingly, the recent crystal structure of the risperidone-bound serotonin 2A receptor (5-
HT2AR) also shows the same risperidone binding mode, as observed in D2DR (Kimura et al., 
2019). However, the observed distinct risperidone binding mode and interaction in the crystal 
structure of D2DR and 5-HT2AR could not be replicated by molecular docking approach using 
a homology modelled structure of D2DR (Wang et al., 2018). The related antipsychotic drugs 
binding modes at D2DR, therefore, remained uncertain. There is a need to define risperidone 
and related antipsychotic drugs at the binding pocket D2DR in order to make significant 
progress in the structure-based design of these drug classes. To further clarify the binding 
mechanistic of atypical antipsychotics at D2DR, paper I of this thesis addresses this research 
gap. In this paper, the binding mechanistic and conformational changes associated with six 
atypical antipsychotics targeting D2DR have been elucidated (Appiah‐Kubi et al., 2019).  
The current marketed antipsychotic drugs lack selectivity toward a given D2-like receptor 
subtype (Li et al., 2016). They are associated with considerable adverse effects, including 
metabolic syndrome, cardiovascular hypertension, and neurological side effects, including 
tardive dyskinesia and extrapyramidal reactions (Kaar et al., 2020; Ballon et al., 2014; Álvarez 
et al., 2013). The selective antagonist inhibition of D3DR over D2DR have been demonstrated 
to lessen drug-seeking behaviour and associated side effects compared to non-subtype selective 
antagonists (Andreoli et al., 2003; Higley et al., 2011; Galaj et al., 2015; Manvich et al., 2019). 
However, the high degree of sequence conservations between D2DR and D3DR, particularly 
at the ligand-binding pockets and within the transmembrane (TM) domains, remains a 




The discovery of two small molecules, R-VK4-40 and Y-QA31, that substantially inhibited 
D3DR with >180-fold selectivity over D2DR was reported in recent studies (Shaik et al., 2019; 
Kumar et al., 2016; Sun et al., 2016). Contrary to the side effect of GSK598,809 and 
SB277011A, which in the presence of cocaine increase blood pressure (Appel et al., 2015; 
Appel & Acri, 2018), R-VK4-40, when administered with cocaine, displays no cardiovascular 
side effects (Jordan et al., 2019). Also, Y-QA31 exhibit antipsychotic effects in cognitive 
dysfunction, negative and positive symptoms without inducing extrapyramidal side effects in 
preclinical models of schizophrenia (Sun et al., 2016). However, the structural determinant and 
atomistic molecular mechanistic by which R-VK4-40 and Y-QA31 achieved their selectivity 
at D3DR over D2DR have not been elucidated. To address this gap, the paper II of this thesis 
provides molecular and structural insights into these differential binding mechanistic using 
meta-analytic computational simulation methods.  
Recently, new 1‑Heteroaryl-1,3-propanediamine derivatives, Compd-21 and  Compd-34 (Peng 
et al., 2018), were synthesised as CCR5 antagonists. These inhibitors have displayed ~3 times 
more potency than Maraviroc, with improved pharmacokinetic profiles (Peng et al., 2018). The 
main structural variation between Maraviroc, Compd-34, and Compd-21 is the substitution of 
the phenyl group in Maraviroc with thiophen-2-yl and thiophen-3-yl moieties in Compd-21, 
and Compd-34, respectively. However, atomistic molecular details of the interaction 
mechanisms of how slight structural variance between these inhibitors (Compd-21, Compd-34, 
and Maraviroc) significantly affects their binding profiles at the CCR5 receptor was lacking. 
Paper III of this thesis provided atomistic understanding by identifying molecular properties 
and receptor interactions, which may be useful in designing more potent HIV-1 entry inhibitors 
targeting CCR5. 
The application of a structure-based virtual screening approach successfully identified novel 
potential scaffolds from the unexplored Asinex antiviral compound database toward CCR5. 
The identified compounds provide a basis for further structural optimisation and/or 
biochemical testing of the identified compounds against CCR5.  
Findings from this thesis will expand our understanding of inhibitor binding interactions at the 
D2-like dopamine and CCR5 receptor as well as assist in identifying novel compounds for 
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2.1 Overview to G protein-coupled receptors   
The largest transmembrane receptor superfamily encoded in the human genome are the G 
protein-coupled receptors (GPCRs), which control several major physiological processes. The 
human genome alone account for about 800 unique GPCRs and are important therapeutic 
targets of many potent drugs (Ghosh et al., 2015; Odoemelam et al., 2020). GPCRs can sense 
the presence of a diverse range of molecules outside the cell and, in response, activate various 
intracellular signals (Latorraca et al., 2017). The direct role of GPCRs in controlling major 
physiological processes has made them one of the most effective drug targets and account for 
almost 35% of all FDA-approved drugs (~700 drugs) (Sriram & Insel, 2018). However, these 
drugs target only 134 unique GPCRs, primarily the Class A (Rhodopsin) receptors such as 
histamine receptors, muscarinic receptors, dopamine receptors, adrenoceptors, and serotonin 
receptors (Garland, 2013; Hauser et al., 2018; Sriram & Insel, 2018).  
 
The ability of GPCRs to convey signals via the cell membrane relies on their potential to 
undergo conformational changes. Diverse extracellular ligands varying from proteins (such as 
chemokines) to neurotransmitters to small hormones, bind to the extracellular region and 
induce structural changes to allow signalling proteins (e.g. arrestins and G proteins) to bind to 
the intracellular surface of GPCR (Figure 2.1) (Latorraca et al., 2017). The structural basis for 
GPCR’s ligand recognition and the understanding of the process of their dynamic signalling 
had been a challenge in the past two decades, especially for rational drug design. However, 
recent progress in GPCR structure biology has provided a novel understanding of GPCRs 
dynamics, signalling pathways, and ligand binding interactions. Thus, providing novel 
opportunities for structure-based drug discovery and selective drug development among 
receptor subtypes.   
 
2.1.1 Classifications of GPCRs 
Based on GPCRs amino acid sequence homology and functional similarity, the commonly used 
classification scheme is the A-F system (Kolakowski Jr, 1994; Attwood & Findlay, 1994). This 
classification scheme identifies six classes (A-F) of GPCR sequences from humans, animals 
and plants, with only four categories (A, B, C, and F) identified in humans. Class A, also called 




representing about 80 % of GPCRs. Class A is generally distinguished structurally by seven 
TM helices, an eighth helix, a C-terminal tail, and a short N-terminus. 
 
 
Figure 2.1 GPCR signalling: The binding to an inactive GPCR by an orthosteric agonist ligand 
(in orange); (B) the active state of the ligand-bound GPCR due to conformational changes in 
complex formation; and (C) the active state of the GPCR complex binds to a G protein, which 
then activates the G protein’s alpha-subunit (Image adapted from (Latorraca et al., 2017)). 
 
Class B, commonly called the “secretin receptor family”, consists of approximately 70 
receptors. The structural characteristics of Class B are a seven-transmembrane and an N-
terminal of about 120 residues. The metabotropic glutamate family, taste receptors, the GABA 
receptor and calcium-sensing receptors constitute the Class C GPCRs. Seven TM helices and 
an N-terminal domain of around 500 residues structurally define these receptors. The fungal 
pheromone mating receptors, the slime mold cAMP receptors and frizzled/smoothed receptors 
constitute Class D, Class E and Class F, respectively.   
 
Another GPCR classification system is grouping the human GPCRs into five families known 
as “GRAFS” (Schiöth & Fredriksson, 2005; Fredriksson et al., 2003). The GRAFS system 
comprises the families of Class C (Glutamate), Class A (Rhodopsin), Class B2 (Adhesion), 
Class F (Frizzled/Taste2) and Class B1 (Secretin), based on a phylogenetic analysis of nearly 
800 sequences from the human GPCR (Fredriksson et al., 2003) (Figure 2.2). The GRAFS 
system differs from the A-F system in that it further divides Class B receptors into two families, 




that the evolutionary background of the families of Secretin and Adhesion differs from one 
another. Furthermore, it also adds the Taste2 receptors in the Frizzled receptor family. 
 
 
Figure 2.2 Phylogenetic relationship in the human genome of GPCRs (TMI–TMVII). This 
phylogenetic analysis is based on the “GRAFS” classification system. The different colours of 
the tree represent the different families (Image adapted from (Fredriksson et al., 2003)).   
 
 
2.1.2 Structural characteristics of G protein-coupled receptors 
Three divisions primarily characterise GPCR structures: (i) an extracellular section consisting 
of three extracellular loops and the N-terminus forming the opening to the ligand-binding site; 
(ii) seven alpha-helical transmembrane regions (TM1-TM7); and (iii) an intracellular section 
consisting of the intracellular amphipathic helix (H8), the three intracellular loops (ICL1-
ICL3), and the C-terminus (Figure 2.3) (Heifetz et al., 2020; Latorraca et al., 2017). In general, 
ligand entry is regulated by the extracellular region; the transmembrane (TM) domain binds 




changes to the intracellular part; and the intracellular region couples with signalling proteins 
such as G proteins and arrestins (Heifetz et al., 2020).  
 
Figure 2.3 GPCRs’ general design and structural characteristics. (A) the three extracellular 
loops (ECLs) and the N-terminus (in orange), the seven transmembrane helices region (in 
grey), and the three extracellular loops and the C-terminus (in purple). (B) GPCR general 
architecture displayed in cartoon representation (Image adapted from (Latorraca et al., 2017)).  
 
When triggered by the binding of G protein and an agonist ligand, GPCRs usually change from 
inactive state to active state conformations. Hydrophobic patterns and different functionally 
structural signature motifs characterise the strongly conserved transmembrane domains of 
GPCRs. The NPxxY motif (connecting TM7 and helix 8), the CWxP motif (TM6), and the 
D(E)RY motif (TM3) compose these motifs. To retain the receptor in its ground state, the ionic 
interaction (ionic lock) of the TM3 conserved D(E)RY motif has been observed (Rovati et al., 
2007).  
 
2.1.2.1 Transmembrane and extracellular residue indexing methods for GPCRs 
Superscripts are assigned to residues of the transmembrane regions (TM1-TM7) based on the 
Ballesteros-Weinstein numbering system (Ballesteros & Weinstein, 1995) to enable 
comparison of residues among the different GPCRs. The residues of the extracellular and 
intracellular loop regions are not applied with the Ballesteros-Weinstein numbering approach 
because of the high variation in sequence and length. The developers of the GPCRdb (Isberg 




based on the Ballesteros-Weinstein approach for some regions. The Ballesteros-Weinstein 
nomenclature assigns each transmembrane residue with an index number corresponding to the 
position of the residue in that transmembrane domain. For example, the conserved GPCRs Asp 
residue in TM3 (which is Asp1103.32 in D3DR and Asp1143.32 in D2DR) is denoted as Asp3.32 
where 3 stands for TM3 and 32 stands for the position of the Asp residue in TM3.  This 
technique enables the different GPCRs to be compared using the most conserved residues as a 
reference point. The Ballesteros-Weinstein and the GPCRdb numbering schemes are used in 
this thesis. 
 
2.1.3 GPCR function, activation, and signal transduction pathways 
The physiology of most vertebrate relies on GPCR signal transduction. GPCRs can recognise 
different types of signals, such as small molecules, peptides, photons of light, lipids, hormones, 
and proteins. GPCRs are crucial nodes of information exchange between the extracellular and 
intracellular environment of cells. The mechanisms of GPCR activation, signalling and 
regulation are markedly conserved and exemplify evolutionary convergence (Deupi et al., 
2012; Reiter et al., 2012; Reiter & Lefkowitz, 2006) (Figure 2.4).  
Generally, in GPCR activation, ligand binding involves the N-terminus, the exposed 
transmembrane helices, and the extracellular loops. In contrast, G protein-coupling and signal 
transduction involve the intracellular regions and loops. GPCRs have the classical role of 
coupling the binding of an extracellular ligand to the binding pocket and activating distinct 
heterotrimeric G proteins (subunits of Gβ and Gγ,  Gβ and Gα), resulting in modulations of 
downstream effector proteins. The heterotrimeric G proteins subsequently dissociate from the 
receptor sending signals that produce second messengers, including Ca2+, cAMP, and inositol 
phosphates (e.g. IP3), which then activates various cellular responses.   
The activated GPCR can bind to β-arrestins with high affinity when phosphorylated (Kang et 
al., 2014; Tian et al., 2014). To desensitise G protein signalling, β-arrestins avert the additional 
coupling of G proteins to the activated receptor. β-arrestins have been identified as independent 
signal transducers, controlling signalling processes such as protein synthesis, apoptosis, cell 
migration and the activation of mitogen-activated protein kinases that regulate the 
cytoskeleton. GPCRs play a vital role in controlling diverse physiological functions, such as 
taste, secretion, nervous system control, smell, vision, metabolism, immune response, 
embryonic growth, cell differentiation, and cell differentiation. As a consequence, GPCR 




disorders (Guimarães & Thathiah, 2020; Azam et al., 2020; Huang et al., 2017), diabetes 
(Gupta & Vasudevan, 2019; Sebastiani et al., 2018), cardiovascular disease (J. Wang et al., 
2018), obesity (Riddy et al., 2018), cancer (Cerchio & Chen, 2020; Gad & Balenga, 2020), 
HIV (Brelot & Chakrabarti, 2018), and inflammation (Lin et al., 2017), making GPCRs crucial 
drug target for pharmaceutical developments.  
 
Figure 2.4 A schematic representation of GPCR activation and signalling (Image adapted 
from (Ghosh et al., 2015)). 
 
2.1.4 Advances in GPCR structure determination 
Structural knowledge of GPCRs offers a deeper understanding of their molecular mechanisms 
for cell signalling and ligand recognition, which assist in the novel development of effective 
drugs for severe human diseases treatment. The crystallisation and determination of GPCR 
structures were deemed to be almost impossible before the recent revolution. This was due to 
the inherent conformational flexibility of GPCRs which posed a challenge in the efforts to 
obtain their crystal structures. Considerable challenges that hampered the structure 
determinations and molecular understanding of GPCRs were the inability to get pure, stable, 
and functional samples.  
 However, significant progress has been made in GPCR structure determination since the first 
solved bovine rhodopsin receptor structure in 2000 (Palczewski et al., 2000). This was followed 
by the first high-resolution crystal structures of the non-rhodopsin-like GPCR of the human β2-
adrenoceptor (β2AR) bound with the inverse agonist (carazolol) and Fab5 (Rasmussen et al., 
2007), and β2AR in complex carazolol (Cherezov et al., 2007) in 2007. Aside from the detailed 




also provided novel strategies for optimising and crystallising GPCR structures. The 
advancements in X-ray crystallographic data collection methods, including X-ray free-electron 
lasers (XFELs) and micro-focus X-ray sources at synchrotrons, were included in the novel 
strategies. Also, advances in protein engineering (e.g., thermo-stabilizing mutations (Tate, 
2012) and fusion proteins, for instance, T4 lysozyme (Chun et al., 2012)), data acquisition (Liu 
et al., 2014), and structural biology (e.g., lipid cubic phase (LCP) crystallisation (Caffrey & 
Cherezov, 2009; Caffrey, 2015) and cryo-electron microscopy (cryo-EM) (Liang et al., 2017)) 
have increased the number GPCR structures. The application of these novel techniques and 
guidelines has propelled GPCR structure determination’s progress in less than two decades 
(Table 2.1 and Figure 2.5).  
Table 2.1 Statistics of solved GPCR structures obtained from the PDB database, includes 
multiple receptor complexes (Table extracted from https://gpcrdb.org/structure/statistics 
accessed on 20 October 2020; Last updated 2020-09-30).  
Class Class A Class B1 Class B2 Class C Class F Total 
Unique Receptor complexes# 70 10 0 4 3 87 
Receptors* 404 46 0 17 19 486 
Receptor-ligand structures* 397 45 0 17 19 478 
Active-state structures* 106 31 0 2 6 145 
G protein-Receptor structures* 9 30 0 0 0 39 
*Orthologues receptors are counted more than once. # A receptor with more than one 
structure bound to diverse ligands was counted once. The active state is characterised as an 
intracellular TM bundle that is agonist-bound and open. 
 
Recently, cryo-electron (cryo-EM) microscopy has emerged as a modern technique for 
determining membrane protein structures (Thal, Vuckovic, et al., 2018; García-Nafría & Tate, 
2020), causing a surge in the quality and number of available GPCRs. Several high-resolution 
solved structures have been solved for chemokine receptors, aminergic receptors, nucleotide 
receptors, lipid receptors, and peptide receptors. These structures provide insights into receptor 
function and ligand-recognition of GPCRs and enable the possible comparison of important 
details between various GPCR subtypes (Qu et al., 2020). Consequently, computational 
investigations of biomolecules have greatly benefited from the increased crystal structures as 






Figure 2.5 The increase in the number of GPCR structure determinations over time for each 
receptor of the various classes of GPCRs obtained from the GPCRdb database (Image adapted 
from https://gpcrdb.org/structure/statistics, accessed in October 2020).  
 
2.1.5 G protein-coupled receptors as targets for drugs. 
The substantial involvement of GPCRs in various pathophysiological processes makes them 
an important drug target and constitutes the largest FDA-approved drug family (Allen & Roth, 
2011; Rask-Andersen et al., 2014; Santos et al., 2017). The high proportion of drugs targeting 
the GPCR family can be attributed to various factors, including their ability to bind to drugs 
with higher affinity, their interactions with several types of chemical entities, and their plasma 
membrane expression facilitates extracellular molecular interactions (Sriram & Insel, 2018). It 
is projected that there are nearly 700 validated drugs that target 134 GPCRs, which accounts 
for about 35% of all FDA approved drugs (Sriram & Insel, 2018). It is estimated that two-thirds 
of the current drugs targeting GPCRs frequently targets the cyclic adenosine monophosphate 
(cAMP) signalling pathways (Sriram & Insel, 2018). Drugs targeting GPCRs may act as 
antagonists or agonists (inverse or neutral agonist), with the majority acting as an antagonist.  
The rhodopsin α-subgroup receptors such as the cannabinoid, adrenergic, muscarinic, 
dopamine, serotonin, and histamine receptors are vital drug targets for anti-histamines, 




rhodopsin β-subgroup are drug targets pursued in conditions such as hormone-related cancer 
(Kotake et al., 1999) and pulmonary arterial hypertension (Barst et al., 2004). The chemokine 
receptors are drug targets because of their function as coreceptors in HIV-1 strain (Onuffer & 
Horuk, 2002), chronic and acute inflammations (Kraneveld et al., 2010; Elemam et al., 2020) 
and in cancer immunotherapy (Mollica Poeta et al., 2019). The opioid receptors are vital drug 
targets for pain, alcoholism and cough treatment (Tyndall & Sandilya, 2005).  
 
2.1.6 GPCRs and Structure-based drug discovery  
The current rise in structures of GPCRs has offered valuable knowledge to facilitate structure-
based drug design and discovery. These structural insights into the binding of ligands and 
activation of the receptor, when combined with computational approaches, can significantly 
accelerate the discovery of new ligands for GPCRs (Qu et al., 2020). Structure-based virtual 
screening and lead optimisation have proved their immense potential in discovering drugs 
targeting GPCRs.  
Katritch et al. and Carlsson et al. have applied successfully structure-based virtual screening in 
identifying novel ligands targeting adenosine A2A receptor (A2AAR) (Katritch et al., 2010; 
Carlsson et al., 2010). The screening of 1.4 million compounds by Carlsson et al. using 
molecular docking against A2AAR resulted in the experimental validation of 20 high-ranking 
molecules. Finally, seven of the hits were validated as new selective ligands of A2AAR 
(Carlsson et al., 2010). On over four million compounds, Katritch et al. also used structure-
based virtual screening techniques and reported 53 hits against A2AAR (Katritch et al., 2010). 
In another structure-based study, Rodríguez et al. identified nine experimentally confirmed 
novel serotonin (5-hydroxytryptamine [5-HT]) subtype-selective ligands with a preference for 
5-HT1B over 5-HT2B subtype from 1.3 million compounds (Rodríguez et al., 2014). The nine 
demonstrated selective compounds exhibited up to 300-fold selectivity towards 5-HT1B with 
three compounds been agonist of the G protein pathway (Rodríguez et al., 2014).  
Other successful structure-based discoveries include the identification of novel ligands at Beta-
2 Adrenergic Receptor (β2AR) (Yakar & Akten, 2014; Kolb et al., 2009); the discovery of the 
potent opioid analgesic PZM21 with reduced side effects targeting at μ-Opioid-Receptor 
(µOR) (Manglik et al., 2016); and novel effective HIV entry inhibitors targeting C-C 
chemokine receptor 5 (Peng et al., 2018). Also, fragment-based screening was performed by 
Christopher et al. on 3500 compounds at metabotropic glutamate receptor 5 (mGlu5) and 




candidate drugs developed via structure-based techniques are presently in clinical trials or 
preclinical development for conditions varying from neurological disorders to cancer (Hauser 
et al., 2017; Congreve & Marshall, 2010). More recently, the D2 dopamine receptor crystal 
structure bound with haloperidol aided in identifying two novel D2DR subtype-selective 
agonists (O4SE6 and O8LE6) that exclude agonism at D4DR and D3DR (Fan et al., 2020). 
 
2.2 Overview of Dopamine Receptors 
Dopamine is a crucial and dominant catecholamine neurotransmitter in the brain. The 
dopaminergic receptors mediate the physiological actions of dopamine. Dopamine receptors 
are essential members of the GPCRs superfamily of Class A membrane receptors (Beaulieu & 
Gainetdinov, 2011; Thal, Glukhova, et al., 2018). There are five closely related but different 
dopamine receptor subtypes to date, namely: D5, D4, D3, D2, and D1 dopamine receptors. These 
subtypes are classified further into D2-like receptors (D4, D3 and D2) and D1-like receptors (D5 
and D1) based on structure and pharmacological role (Baik, 2013). The D1 and D2 dopamine 
receptors are primarily and abundantly expressed in the brain (D1 is highly expressed), and the 
two are rarely co-expressed in the same cells (Missale et al., 1998; Baik, 2013). Two D2 
dopamine receptor (D2DR) isoforms are available, namely the long (D2L) and the short (D2S) 
isoforms produced by alternative splicing (Giros et al., 1989; Dal Toso et al., 1989; Shioda, 
2017). These isoforms are similar, except that they differ in the insertion of only 29 amino 
acids in the D2L intracellular loop, which has been posited to assist in determining the 
specificity of the second messenger (Żuk et al., 2020; Baik, 2013; Giros et al., 1989).  
Dopamine receptors expression is mainly abundant in the central nervous system (CNS) and 
the peripherals such as kidneys, blood vessels, retina, heart, the renin-angiotensin system, and 
adrenals controlling the release of catecholamine (Beaulieu & Gainetdinov, 2011). Figure 2.6 
depicts the dopaminergic pathways, dopamine receptors and dopamine distributions in the 
central and peripheral systems. Four dopaminergic pathways have been established in the 
mammalian brain, namely: mesocortical, mesolimbic, nigrostriatal, and tuberoinfundibular 
(Figure 2.6B). These neurons play an essential function in the CNS, such as 
cognition, locomotor activity, emotion, appetite, reward, attention, sleep, learning, and 
working memory. Dopamine can regulate endocrine, heart rate, kidney function, 
cardiovascular function, gastrointestinal motility and so on in the periphery (Vallone et al., 
2000). For D2-like dopamine receptors, dopamine has a higher affinity ranging from 10 to 100-
fold than for D1-like dopamine receptors. The D1 dopamine receptor has the lowest dopamine 






Figure 2.6 The peripheral expression of dopamine receptors and dopamine (A) and the central 
nervous system distribution of four major dopaminergic pathways (B). The ventral tegmental 
area (VTA) is the centre of the mesocorticolimbic system: dopaminergic neurons are 
transmitted by the mesocortical pathway (blue) to the cortex and by the mesolimbic pathway 
(red) to the nucleus accumbens. The tuberoinfundibular pathway (green) is formed by 
dopaminergic neurons projecting from the hypothalamic nuclei to the pituitary. In contrast, in 
the projection of the substantia nigra (SN) to the striatum, dopamine neurons form the 
nigrostriatal pathway (orange) (Klein et al., 2019)).  
 
2.2.1 Dopamine receptor signalling  
The binding of dopamine to a receptor produces intracellular responses depending on the kind 
of dopamine receptor stimulated. The downstream signalling of dopamine primarily includes 
G proteins, although G protein-independent signalling pathways can also be involved in 
dopamine receptor signalling (Luttrell & Lefkowitz, 2002). The D2-like and D1-like dopamine 
receptors are functionally different in the manner they modulate their intracellular signalling 
pathways.  
The adenosine triphosphate (ATP) is converted into 3'-5'-cyclic adenosine monophosphate 
(cAMP) as a result of adenylyl cyclase (AC) protein activation induced by the coupling of D1-
like receptors to Gαs/olf protein (Sunahara & Taussig, 2002). The cAMP then stimulates the 
activity of the protein kinase A (PKA) by interacting with the catalytic and regulatory subunits 
of PKA, which then induce the release of catalytic subunits for the phosphorylation of various 
substrates (Akimoto et al., 2013) (Figure 2.7). The DARPP-32 phosphorylation at the Thr34 
residue causes inhibition of phosphatase-1 (PP1) protein (Nishi, Snyder, et al., 1999). In 




inhibits PKA activity and thus suppresses the signalling of D1-like dopamine receptors (Bibb 
et al., 1999; Undieh, 2010). It has also been documented that activation of the D1-like dopamine 
receptor controls the electrochemical gradient through Na+K+-ATPase, pumping potassium in 
and sodium out of cells. It has also been shown that activation of D1-like dopamine receptors 
inhibits Na+K+-ATPase through PKA and PKC signalling pathways in the striatum (Gomes & 
Soares-da-Silva, 2002; Nishi, Fisone, et al., 1999) (Figure 2.7). 
 
Figure 2.7 The intracellular signalling pathways of D1-like dopamine receptors, showing 
dopamine-mediated effects through complex activation of intracellular signals. Red arrows 
indicate stimulatory effects, blue lines ending with circles for inhibitory effects, and plausible 
activation indicated by the dashed red arrow (Image adapted from (Rangel-Barajas et al., 
2015)). 
 
The Gαi/o class of G proteins is the central mediator of D2-like signalling (i.e., D4, D3, and 
D2 dopamine receptors). Contrary to D1-like receptors, D2-like receptors coupling to Gαi/o 
protein inhibits (AC) and decrease the intracellular concentration 3'-5'-cyclic adenosine 
monophosphate (cAMP), resulting in the blocking of protein kinase A (PKA) activity (Beaulieu 
& Gainetdinov, 2011; Akimoto et al., 2013) (Figure 2.8). After the stimulation of D2-like 







Figure 2.8 The intracellular signalling pathways of D2-like dopamine receptors, showing 
dopamine-mediated effects through complex activation of intracellular signals. These signals 
relate to functions including proteasomal degradation, cell proliferation, neurodevelopment, 
and cognitive process. Red arrows indicate stimulatory effects, blue lines ending with circles 
for inhibitory effects, and plausible activation indicated by the dashed red arrow (Image 
adapted from (Rangel-Barajas et al., 2015)). 
 
2.2.2 Structure determination of dopamine receptors 
Advances in GPCR structure determination have led to the crystallisation of all the D2-like 
dopamine receptors; however, none of the D1-like receptors has crystallised yet (Table 2.2 and 
Figure 2.9). The first experimental structure of G Protein coupled to D2DR embedded in a lipid 
membrane was resolved recently by cryo-electron microscopy (cryo-EM) (Yin et al., 2020). 
These resolved structures have provided novel insights into the recognition of ligands and the 





Figure 2.9 Crystal structures: (A) human D2 dopamine receptor in complex with risperidone 
antagonist (orange carbon spheres) and haloperidol antagonist (yellow carbon spheres). (B) 
human D2 dopamine receptor–G-protein complex with the bromocriptine agonist (yellow 
carbon sphere). The receptor is shown in cyan, Gαi in magenta, Gβ in green, and Gγ in orange. 
(C) Human D4 dopamine receptor (cyan) in complex with nemonapride (yellow carbon 
spheres) and the mouse D4 dopamine receptor bound to the subtype-selective antagonist 
L745870 ( orange carbon sphere) and (D) the human D3 dopamine receptor bound to the D2/D3 
















Figure 2.10 2D chemical structures of commonly prescribed first-generation (typical) 
antipsychotic medications (Image prepared by author). 
 
The existing FDA-approved antipsychotic drugs lack selectivity toward a given D2-like 
receptor subtype, and they also interact with other GPCRs, for instance, serotonergic, 
adrenergic, cholinergic, and histaminergic receptors (Li et al., 2016; Moritz et al., 2018). 
Consequently, there has been a recent paradigm shift towards selective drug targeting of the 
diverse dopamine receptor subtypes in the treatment of neurological conditions, such as drug 
addiction, Parkinson’s disease, and schizophrenia. The recent shift is imperative since the 
approved antipsychotics are accompanied by substantial adverse effects such as metabolic 
syndrome, cardiovascular hypertension, and neurological side effects, including 
extrapyramidal reactions and tardive dyskinesia (Kaar et al., 2020; Ballon et al., 2014; Álvarez 
et al., 2013). These undesirable effects reduce patient compliance with medications and the 
quality of life (Novick et al., 2010; Lieberman et al., 2005). The selective targeting of each D2-
like receptor subtype has been shown to produce fewer side effects (Li et al., 2016; Holmes et 
al., 2004). Antagonists with higher selectivity for D3 dopamine receptor (D3DR) over D2 
dopamine receptor (D2DR) have been shown to show promising results in reducing cocaine 
and opioid reward and are highly effective in mitigating relapse to drug-seeking behaviour in 
preclinical models (Andreoli et al., 2003; Higley et al., 2011; Galaj et al., 2015). The 




point for the rational design of novel scaffold molecules toward D2-like subtype-selective 
drugs.  
 
Figure 2.11 2D chemical structures of commonly prescribed second-generation (atypical) 
antipsychotic medications (Image prepared by author). 
 
2.3 Overview of CC Chemokine receptors 
Chemokines are chemotactic cytokines that signal proteins that regulate different functions, 
such as recruitment of immune cells and immune surveillance. Approximately 50 chemokine 
endogenous ligands are identified in mice and humans, making chemokines the most common 
class of cytokines (Griffith et al., 2014). They have been shown to be essential for human 
immune system development and homeostasis and are necessary for all destructive or 
protective immune and inflammatory activities (Hughes & Nibbs, 2018). These chemokines 
are categorised into the CX3C, CXC, CC, and XC subfamilies based on the structure and the 
number of N-terminal cysteine residues. The chemokines are also designated as “R” to denote 
the receptor and consist of seven N-terminus and C-terminus transmembrane helices common 
to the GPCR family (Murphy, 2002).  
CCR5 with endogenous antagonists including MIP-1α (CCL3), MIP-1β (CCL4), and RANTES 
(Regulated upon Activation, Normal T cell Expressed and Presumably Secreted, CCL5) has 
been recognised as a functional GPCR (Combadiere et al., 1996; Samson et al., 1996). The 






Figure 2.12 Superposition of CCR5 crystal structures in complex with gp120 and antagonists. 
(A) The full length unmodified CCR5 (cyan) in complex with gp120 (yellow) and CD4 (green) 
(PDB ID: 6MEO); CCR5 (sky blue) in complex with Maraviroc (orange) (PDB ID: 4MBS): 
CCR5 (light green) in complex with Compound 21 (Magenta) (PDB ID: 6AKX); and CCR5 
(plum) in complex with Compound 34 (Purple) (PDB ID: 6AKY). (B) gp120 V3 loop overlaps 
with CCR5-antagonists (Maraviroc, Compound 21 and Compound 32) at CCR5 binding pocket 
(Image prepared with UCSF Chimera program by author). 
 
The first crystal structure of CCR5 was determined bound with Maraviroc in 2013 (Tan et al., 
2013). The solved CCR5 structure served as the basis in a structure-based optimisation and 
design of novel 1‑Heteroaryl-1,3-propanediamine derivatives relying on the functional and 
binding properties of Maraviroc at CCR5 (Peng et al., 2018). Two of these novel compounds 
(Compound 21 and Compound 34) demonstrated their potential as candidate drugs as HIV 
entry inhibitors with improved anti-HIV-1 activity and tolerable pharmacokinetic profile 
compared with Maraviroc (Peng et al., 2018). Additionally, the Structure of the full-length 
unmodified Structure of CCR5 in complex with gp120 and CD4 was solved, providing novel 





2.3.2 CC Chemokine receptors 5 (CCR5) in HIV Infection 
CCR5 is a member of the GPCR family of signal transducers and plays a significant function 
in the initial stages of HIV-1 infection as a functional coreceptor for HIV-1 viral entry (Tan et 
al., 2013). CCR5 constitutes an extracellular N-terminus, a C-terminus, three extracellular 
loops (ECLs), three intracellular loops (ICLs), and seven transmembrane helices. The CCR5 
second extracellular loop (ECL2) and N-terminus are crucial for HIV interactions during viral 
entry. Compared to the viral coreceptor CXCR4 and receptor CD4, the CCR5 has an additional 
advantage as a cellular target since it is relatively redundant for normal immune function 
(Askew et al., 2016). CXCR4 and CD4 are involved in vital processes in immune function 
(Berger et al., 1999; Nagasawa et al., 1996), limiting their effectiveness as antiretroviral 
therapeutic targets. The critical role played by CCR5 in HIV-1 infection was demonstrated 
when the CCR5 gene (CCR5-Δ32) naturally occurring mutation conferred resistance to HIV-1 
infection (Allers et al., 2011). Additionally, individuals possessing heterozygous Δ32 more 
slowly progressed to AIDS than do homozygous individuals with the wild-type gene (Liu et 
al., 1996; Paxton et al., 1998). Also, the density levels of CCR5 on CD4+ T cells correlates 
positively with RNA viral loads (de Roda Husman et al., 1997) and, when untreated, progresses 
to AIDS (Reynes et al., 2000). CCR5 is essential in stabilising the conformational changes 
induced by CD4, which are competent for promoting fusion (Shaik et al., 2019).  
The infection of HIV into a new host requires entry into susceptible target cells. Viral entry 
into host cells is facilitated by the HIV envelope glycoproteins gp120 (receptor binding) and 
gp41 (fusion). The mechanism of HIV entry occurs in several steps (Figure 2.13). The initial 
stage of viral entry is the attachment of gp120 to the CD4 receptor. The binding to CD4 induces 
a conformational change exposing the binding pocket of the coreceptor (CCR5 or CXCR4) 
(Tran et al., 2012). The CD4 binding site and the V1 and V2 regions shift from the trimer 
centre, causing the central gp41 stalk and the V3 loop to be exposed (Liu et al., 2008). The 
gp120 bridging sheet and the V3 loop then attach to either CCR5 or CXCR4 coreceptor 
exposed binding pocket subject to the R5 or R4 virus, respectively. The coreceptor engagement 
induces a second conformational change that activates gp41 fusion into the host cell membrane 
(Cormier & Dragic, 2002; Wilen et al., 2012b). In detail, a pre-fusion intermediate is formed 
by gp41 whereby extended helices are formed by the N-terminal heptad repeat-1 (HR1) (light 
green) and the C-terminal heptad repeat-2 (HR2) (dark green) of gp41, with the fusion peptide 
(FP) (yellow) been inserted into the host cell membrane (Figure 2.13)(Chan & Kim, 1998; 




leading to the formation of a six-helix bundle. The viral and cellular membranes are brought 
together by this conformational change which causes viral membranes and cellular lipids to 
mix. After the creation of a fusion pore resulting from lipid mixing, the content of virions is 
released into the cytoplasm (Wilen et al., 2012a).  
 
Figure 2.13 A schematic diagram of HIV entry mechanism. The gp41 HR1, HR2, and FP are 
depicted in light green, dark green, and yellow, respectively (Image adapted from (Falkenhagen 
& Joshi, 2018)). 
 
2.3.3 Advances in drug discovery towards CCR5 in HIV therapy 
The validation of CCR5 as a promising drug target in HIV-1 treatment resulted in the 
development of several approaches to block HIV-1 interaction with CCR5, including 
covalently modified natural CCR5 ligands, small molecule antagonists, and monoclonal 
antibodies (mAbs) (Berro et al., 2011; Henrich & Kuritzkes, 2013). However, several small-
molecule CCR5 antagonists have advanced to phase 2 or 3 clinical trials, with many proving 
effective inhibition of HIV-1 replication (Figure 2.14). CCR5 small molecules have shown 




to significantly block HIV-1 entry (Ji et al., 2007; Westby et al., 2007; Lalezari et al., 2008; S 
Latinovic et al., 2016).   
Maraviroc (MVC) was the first CCR5 small-molecule antagonist to be approved and marketed 
as a CCR5 HIV-1 entry inhibitor (FDA, 2007; Carter, 2013). The oral administration of 
Maraviroc has resulted in a substantial decrease in viral loads (Westby et al., 2007; Schlecht et 
al., 2008); however, the prescription of Maraviroc is limited due to identified factors such as 
its drug-drug interactions (especially when co-administrated with CYP3A4 inhibitors), 
CYP450 inhibition, and viral resistance (Garcia-Perez et al., 2015; Peng et al., 2018). The 
prodrug Fostemsavir (formerly BMS-663068/BMS-626529 and marketed as Rukobia) has 
emerged as the first-in-class HIV attachment inhibitor approved by the US FDA, mainly for 
HIV positive patients with multidrug-resistant HIV-1 and intolerance or safety issues with 
other therapies (FDA, 2020). Fostemsavir binds to HIV envelope glycoprotein 120 (gp120) 
when hydrolysed to its active form temsavir, which prevents the conformational change needed 
by gp120 for attachment to CD4 cell surface receptor of the host (Lalezari et al., 2015; 
Thompson et al., 2017; Kozal et al., 2020).  
 
Figure 2.14 Representative approved drugs and clinical antagonists as HIV-1 entry inhibitors 
targeting CCR5 (Image prepared by author). 
 
Aplaviroc (APL) and Vicriviroc (VCV) were two promising CCR5 small molecule antagonist 
but were both discontinued for varied reasons. Aplaviroc showed a substantial decrease of 




2005); however, development was discontinued due to reversible drug-induced hepatitis 
observed during phase II and III trials in five subjects (Nichols et al., 2008). Vicriviroc (VCV) 
also displayed substantial HIV-1 suppression but was terminated prior to phase II study due to 
increasing virologic failure rates compared with the control group (Gulick et al., 2007; 
Landovitz et al., 2008; Schürmann et al., 2007; Caseiro et al., 2012). Cenicriviroc (CVC) is 
another small molecule under development for inhibiting the CCR5 receptor in phase III trials 
(Klibanov et al., 2010). Cenicriviroc has a longer half-life than Maraviroc and shows a 
substantial decrease in plasma HIV-1 RNA load among HIV positive patients. Cenicriviroc 
further displayed favourable efficacy and safety in treating  HIV-1 naive infected patients and 
has made progress to phase III trials (Thompson et al., 2016). Additionally, INCB009471 is 
also a CCR5 coreceptor investigational antagonist being developed as a selective HIV-1 entry 
inhibitor (Shin et al., 2011). INCB009471 showed limited adverse effect with no identified 
dose-limiting toxicity (Troy et al., 2007).  
Genome editing techniques such as the clustered regularly interspaced short palindromic 
repeats (CRISPR), the zinc-finger nucleases (ZFN), and CRISPR associated nuclease 9 
(CRISPR-Cas9) are emerging as an alternative approach in blocking CCR5 by deleting the 
CCR5 gene ex vivo. Recent results suggest that the concurrent gene modification of CXCR4 
and CCR5 by CRISPR-Cas9 protect CD4+ T cells from HIV-1 infection and holds the potential 
to provide a safe and effective functional cure for HIV-1 infection (Liu et al., 2017).  
Recent structure-based optimisation of the functional and binding properties of Maraviroc lead 
to the design of novel 1-Heteroaryl-1, 3-Propanediamine analogues (Peng et al., 2018). The 
compounds (Compound 21 and Compound 34) have proven to be potential drug candidates 
with improved anti-HIV-1 activity and tolerable pharmacokinetic profile compared with 
Maraviroc (Peng et al., 2018). The binding of CCR5 inhibitors, including Maraviroc, Aplaviroc 
and Vicriviroc, has been considered an allosteric inhibitor (Arts & Hazuda, 2012). However, 
the recent crystallisation of the full-length CCR5 in complex with gp120 V3 loop suggests that 
Maraviroc blocks gp120 binding to CCR5 via direct competitive inhibition in contrast to earlier 
views of noncompetitive allosteric inhibition through conformational availability restriction 
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Membrane-Protein Simulations and Computational Methods in Drug Discovery 
3.1 Introduction 
The traditional approach to drug discovery is costly, time-consuming, risky, and based on 
multidisciplinary approaches in producing effective and safer medicines. Computational drug 
design and discovery, and biomolecular simulation techniques, are used widely in modern drug 
discovery to study drugs and bioactive compounds interactions with their biological targets. As 
powerful tools for studying receptor-inhibitor interactions, structure-activity relationships 
(SAR) and conformational dynamics of complex molecular systems, pharmaceutical research 
has increasingly used modern medicinal chemistry methods, including computational and 
molecular modelling. Also, in silico predictions of physicochemical properties (e.g., molecular 
weight, polar surface area, solubility, hydrogen bond donor and acceptor, rotatable bonds etc.), 
and pharmacokinetic properties (absorption, distribution, metabolism, excretion and toxicity) 
have significantly contributed to the success rate of modern drug discovery.   
 
3.2 Molecular Mechanics (force fields) in Biomolecular Simulation of GPCRs 
The application of quantum mechanical (QM) approaches, though more accurate, remains 
suitable only for performing computations on small systems consisting of few atoms 
(Steinbrecher & Elstner, 2013). The investigation of the structure and dynamics of a 
biomolecular system of interest comes at an extremely high computational cost that cannot be 
handled with QM methods (Habgood et al., 2020; Steinbrecher & Elstner, 2013). On the other 
hand, the accuracy of QM and the speed (less expensive) of MM are combined by the quantum 
mechanics/molecular mechanics (QM/MM) method (Saura et al., 2019). The QM/MM 
approach treats the inhibitor and few active site residues (where the chemical process takes 
place) with QM level of theory and the remaining macromolecular system treated with 
Molecular Mechanics (MM) (Saura et al., 2019) (Figure 3.1).  
Molecular Mechanics (MM) are mathematical expressions that describe the potential energy 
of a system particle coordinates. MM methods (also called force field methods) utilises the 
Born-Oppenheimer approximation to estimate the energy of a system based only on the 







Figure 3.1 A QM/MM model for treating part of an enzyme with QM theory (ligand and few 
active site residues) and the remaining part of the macromolecular system with MM theory 
(Image adapted from https://bioexcel.eu/software/cp2k/).  
 
The realistic simulation of a biomolecular complex system largely depends on the availability 
of reliable and accurate force fields. Most classical force fields consist of five different terms 
describing a molecular system and are represented as the bonded (bond stretching, bending of 
angles and rotation of the dihedral/torsional angle) and nonbonded (electrostatics and Van der 
Waals) interactions (Monticelli & Tieleman, 2013) (Figure 3.2) 
 
A slight variation may exist in the force field terms of the available different MM packages. 
The force field terms of the AMBER molecular dynamics package used in this thesis are 
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                                             𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏 
 
The first term of  equation 3.1 defines bond stretching based on Hooke’s law, and the energetic 
penalty for the bond stretching from its reference bond length  𝑟0 determine by force constant 
𝑘𝑟. Similarly, the second term defines angle bending based on Hooke’s law, and the energetic 
penalty for the distortion of the angle from its reference angle  0 determine by force constant 
k. The third term also denotes the dihedral or torsion angle rotation signified by a dihedral 






Figure 3.2 The bonded interactions and nonbonded interactions underlying molecular 
mechanics force field in the potential energy determination of a system (Image prepared by 
author). 
 
The fourth and fifth parameters consist of the nonbonded interactions terms – the van der Waals 
(vdWs) interactions depicted by a 6-12 Lennard-Jones potential and the electrostatic 
interactions by the Coulombic potential. Molecular dynamics force fields development has 
made a significant stride in the past decades to accurately describe proteins, nucleic acids, 
lipids, and small molecules (Nerenberg & Head-Gordon, 2018). 
   
3.2.1 Protein Force Fields 
The pairwise additive approximation underlies the existing all-atom fixed-charge protein force 
fields for biomolecular simulation (Demerdash et al., 2014). Earlier protein force fields such 
as OPLS-AA, AMBER ff94 and CHARMM22 were successfully employed in short peptide 
and globular protein simulations. However, deficiencies in these force fields such as their 
inability to simulate intrinsically disordered proteins (Henriques et al., 2015; Rauscher et al., 
2015; Levine & Shea, 2017), and incorrect identification of protein folding 
intermediates/pathways (McKiernan et al., 2017) were revealed by detailed experimental data. 
The backbone torsion potential modifications, which were subsequently included in the Amber 
ff99SB (Hornak et al., 2006) and the CMAP backbone energy correction to CHARMM22 
(Mackerell Jr et al., 2004), improved their accuracy compared with the previous versions, as 




The torsion potential that regulates both side-chain dihedral angles and backbone behaviour 
has been a common approach to improving protein force fields. The methods used to derive 
these potentials included matching structural database data or only experimental NMR as used 
in AMBER ff99sb*/ff03*/ff03w (Best & Hummer, 2009; Best & Mittal, 2010) and ff99sbnmr1 
(Li & Brüschweiler, 2010) or matching to only ab initio quantum chemistry data such as in 
AMBER ff14SBonlysc (Maier et al., 2015), AMBER ff99SB-ILDN (Lindorff‐Larsen et al., 
2010), AMBER-FB15 (Wang et al., 2017) and OPLS-AA/M (Robertson et al., 2015). 
However, the CHARMM 36 (Best, Zhu, et al., 2012; Best, Mittal, et al., 2012) and 
AMBERff14SB (Maier et al., 2015) utilised a combination of both data sources. 
 
3.2.2 Lipid Force Fields 
The all-atom lipid force field explicitly describes in detail all the atoms of a molecule. Some 
of the most frequently used lipid force fields include the AMBER Lipid11 (Skjevik et al., 
2012), AMBER Lipid14 (Dickson et al., 2014), and AMBER Lipid17 (Gould et al., 2018), the 
CHARMM36 (C36) (Klauda et al., 2010) and CHARMM36 united atom FF (C36-UA) (Lee et 
al., 2014), the OPLS OPLS-UA and OPLS-AA, the GROMOS (53A6-CPK) (Piggot et al., 
2012) and GROMOS54A7/54B7 (Schmid et al., 2011), and the MARTINI force field (Marrink 
et al., 2007). Loschwitz and colleagues have reviewed the detailed applications of these force 
fields and other emerging force field. (Loschwitz et al., 2020). Before the specific parameter 
set for lipids in AMBER was introduced, AMBER force fields were rarely used in the 
simulation of membrane proteins (Jójárt & Martinek, 2007). The AMBER lipid force fields 
have been tested for lipids bilayers such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(POPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine  (POPE), 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), and 1,2-dimyristoyl-d54-sn-glycero-3-
phosphocholine (DMPC) (Dickson et al., 2014).  
 
3.2.3 Small Molecule Force Fields 
The application of force fields in parameterising small molecules has played an essential role 
in the simulation of both natural and synthetic inhibitors. Presently, the force fields widely used 
for small molecules are the General AMBER Force Field (GAFF/GAFF2) (Wang et al., 2004; 
Wang et al., 2006), the CHARMM General force field (CGenFF) (Vanommeslaeghe et al., 
2010; Vanommeslaeghe & MacKerell Jr, 2012; Vanommeslaeghe et al., 2012; Yu et al., 2012), 




OPLS-All-Atom (OPLS-AA) (Jorgensen et al., 1996), OPLS3 (Harder et al., 2016), and the 
Merck Molecular Force Field (MMFF) (Halgren, 1996a; Halgren, 1996b; Halgren, 1996c; 
Halgren & Nachbar, 1996; Halgren, 1996d).  
The AMBER GAFF charges for small molecules are computed from the AM1-BCC  semi-
empirical model (Jakalian et al., 2000; Jakalian et al., 2002) or QM ab initio such as HF/6-
31G* RESP charge (Bayly et al., 1993) charge models are used in the AMBER GAFF. The 
recent reparameterization of the Lennard-Jones and bonded parameters in the GAFF yielded 
the GAFF2. The default charge model of the OPLS3 is the CM1A-BCC or 1.14*CM1A-LBCC, 
which is similar to the GAFF AM1-BCC charge model (Dodda et al., 2015; Dodda et al., 2017). 
The CGenFF utilises a charge model known as the moiety-specific charge deviation protocol 
(Vanommeslaeghe et al., 2010). The GROMOS charge model is considerably different 
compared to the above charge models as used in the most recent release known as the 2016H66 
(Horta et al., 2016).  
The above force fields for small molecules have frequently been improved and actively 
maintained to involve new parameters for a broader range of chemical entities. The program 
for generating the CGenFF parameters and CHARMM topologies is accessible via the 
ParamChem website (Vanommeslaeghe & MacKerell Jr, 2012; Vanommeslaeghe et al., 2012). 
The Antechamber module (Wang et al., 2006) was designed by the AMBER developers and is 
used to generate GAFF and AMBER topologies for MD simulations. Most of the existing force 
fields used in the parameterisation of small molecules depend on non-polarisable or additive 
force fields for empirical potential energy functions. The common characteristics shared 
between these force fields are their potential energy function and the energy function 
parameters.  
 
3.3 Molecular dynamics simulations of biomolecules  
Molecular dynamics (MD) simulation has increasingly become an essential tool in providing 
deeper microscopic mechanistic insights into the structure, function, and dynamics of 
biological molecules (Cournia et al., 2015; Torrens-Fontanals et al., 2020). Experimental 
methods, including nuclear magnetic resonance (NMR) spectroscopy, cryo-electron 
microscopy (cryo-EM), and X-ray crystallography, have often been used to provide atomistic 
insight into the interactions of protein receptors with lipids. However, the single and static 




the dynamics of macromolecules due to the highly dynamic nature of drug binding and 
molecular recognition of macromolecules (Torrens-Fontanals et al., 2020; Saurabh et al., 2020; 
X. Liu et al., 2018). Thus, MD simulation obtain extrapolated dynamical information on the 
biomolecular structure such as proteins and DNA.   
 
3.3.1 Principles of MD Simulations 
Molecular dynamics is a theoretical technique that depends on Newtonian mechanics. Solving 
Newton’s movement equations makes it possible to model the physical motions of atoms in a 
molecular system over time. The forces between the system’s potential energy and the particles 
are then measured using the MM force field (Monticelli & Tieleman, 2013). MD simulations 
generate dynamical trajectories of the interacting particles of a biomolecular structure over the 
desired time frame allowing the dynamics of interacting particles to be studied. Figure 3.3 
shows the basic MD algorithm simplified. 
 
3.3.1.1 Energy minimisation 
Poor interaction sometimes characterises the starting structure of biomolecules to be used in 
MD simulation. Large repulsive interaction, for example, may arise when two atoms are too 
close to each other. Thus, the energy minimisation of the starting structure is required to remove 
bad atom contacts before MD simulations. The three commonly used energy minimisation 
methods are the conjugate gradient (CG), the Limited-memory Broyden–Fletcher–Goldfarb–
Shanno (L-BFGS), and the steepest descent (SD) algorithm. The robust and efficient steepest 
descent algorithm is sufficient for most minimisation processes. The SD algorithm uses 
potential energy and forces in updating the positions of the atomic particles in an iterative 
manner and halts when it has iterated for the number of cycles specified by the user or when 
the specified value is larger than the maximum force. Compared with the steepest descent 
algorithm, the conjugate gradient is more efficient when the system is near the energy 
minimum. The L-BFGS algorithm has been observed to have a faster convergence than the 






Figure 3.3 Simplified MD simulation algorithm. Where potential energy = Epot; time of 
iterations = dt; simulation time = t; For N simulated atoms of each spatial coordinates (i): atom 
coordinates = x; force component = F; a = acceleration, atom mass = m; and velocity = v (Image 
modified from (Hospital et al., 2015)). 
 
3.3.1.2 Integration Algorithm 
Integration methods used in MD simulation codes include the leap-frog algorithm, the Verlet 
algorithm, and velocity Verlet. The leap-frog algorithm is the often-used integration algorithm 
updating the position r and velocity v of a simulation particle by:  
𝑣 (𝑡 +  
1
2
Δ𝑡) = 𝑣 (𝑡 +  
1
2
Δ𝑡) +  
Δt
𝑚
F(t),                                 𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟐 
 
𝑟(𝑡 +  Δ𝑡) = 𝑟(𝑡) +  Δ𝑡𝑣 (𝑡 +  
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2
Δ𝑡) .                                 𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟑 
 
3.3.1.3 Regulation of Temperature and Pressure  
The regulation of pressure only applies when a system is simulated under constant pressure 
periodic boundary condition. A “barostat” or a “pressure bath” is utilised to regulate the 
pressure of the simulating system. Available pressure coupling algorithms include the 




Monte Carlo barostat (that rigorously samples from the isobaric-isothermal ensemble (NPT)) 
and the Parrinello-Rahman barostat. 
Temperature coupling is applied under a constant temperature (NVT ensemble) MD 
simulation. The commonly used temperature regulation thermostats include the Berendsen 
thermostat (Berendsen et al., 1984), Andersen thermostat (Andersen, 1980), and the Nosé-
Hoover thermostat (Nosé, 1984; Hoover, 1985).  
 
3.3.1.4 Constraint algorithms 
Constraints are introduced to hold bonds in fixed length in classical MD simulation. The 
SHAKE algorithm approach has traditionally been used to apply constraints in numerous MD 
simulation codes (Ryckaert et al., 1977). Using a reference set, the SHAKE algorithm works 
by modifying a set of unconstrained coordinates to a new set that satisfies a list of distance 
constraints. The LINear Constraint Solver (LINCS) is another approach available besides the 
SHAKE algorithm (Hess et al., 1997). After an unconstrained update in a non-iterative fashion, 
the LINCS algorithm resets the bond lengths. 
 
3.3.1.5 Periodic Boundary Conditions 
Periodic boundary conditions (PBC) are used to minimise the interface with the vacuum of a 
finite molecular system in an MD simulation (Schultz, 1999). To measure short-range 
nonbonded interactions with other particles, PBC is often applied following the minimum 
image convention, which regulates that only the closest image of a particle is selected. Usually, 
for short-range interactions, a cut-off is set. Beyond the cut-off, long-range van der Waals 
interactions are typically ignored. In contrast, long-range electrostatic interactions are usually 
recovered using the Particle-Mesh-Ewald (PME) method (Darden et al., 1993). The system is 
first put into a box when using PBC, which is then copied to fill the entire space in every 
direction. The most frequently used box types include rhombic dodecahedrons, cubes, and 
truncated octahedrons. 
 
3.3.2 System Setup and MD Simulations of GPCRs in Lipid Bilayer  
There are various computational approaches for membrane protein simulations that seek to 
balance accuracy and the size of the molecular system under investigation (Cui, 2014; Chavent 
et al., 2016). Generally, MD simulation studies begin with an experimental or homology 
modelled protein structure and simulated over time based on classical mechanics principle. 




available in their native lipid bilayer. Hence, presenting one of the most significant challenges 
in constructing and embedding membrane proteins in lipid bilayer for use in MD simulation. 
This shortcoming gives an additional responsibility for appropriate modelling and insertion of 
the protein structure in a native lipid bilayer. Thus, membrane protein simulation compared to 
globular protein simulation system setup for simulation may be challenging, especially for the 
novice.   
Biomolecular simulation software packages such as GROMACS and CHARMM have their 
membrane builder. The membrane builder for GROMACS, whereas MemBuilder 
(Ghahremanpour et al., 2014) and CHARMM-GUI (Wu et al., 2014) are for CHARMM. 
However, the AMBER MD package lacks its membrane builder and relies on external 
programs for embedding membrane proteins in a lipid bilayer. The Visual Molecular Dynamics 
(VMD) (Humphrey et al., 1996) package also has a plugin for setting up a simple membrane 
system. Other online servers packages such as PACKMOL (Martínez et al., 2009), 
MemProtMD (Newport et al., 2019) and PACKMOL-memgen (Schott-Verdugo & Gohlke, 
2019) allows the user to build a membrane system to suit their system’s needs. Recently, 
Khanna and colleagues (Khanna, 2018) developed an “in-house” membrane builder code 
known as AMBAT-Amber Membrane Builder and Analysis Tool specifically for the AMBER 
MD simulation package and has been employed in a recent study (Toroz et al., 2019). However, 
AMBAT has not yet been integrated into the AMBER MD simulation package.  
Embedding a membrane protein in lipid bilayer using the CHARMM‐GUI Membrane Builder 
remote server arguable appears to be more user-friendly; nevertheless, the user will need to 
perform some modifications for residue and atom naming compatibility before using it in the 
AMBER MD package. The charmmlipid2amber.py introduced in AMBER, therefore, provides 
a vigorous atom and residue renaming of CHARMM-GUI PDB structure format into Leap and 
Lipid14 PDB readable format. The CHARMM‐GUI Membrane Builder was initially used to 
embed the membrane proteins used in this thesis in a lipid bilayer, prepared with the 
charmmlipid2amber.py and simulated with the AMBER MD package. Figure 3.4 represents 






Figure 3.4 The systematic workflow in the overall embedding of membrane protein in a lipid 
bilayer with water molecules and ions using the CHARMM-GUI membrane-builder for 
AMBER MD simulation (Image modified by author from (Jo et al., 2008)). 
 
3.3.3 Molecular Dynamics Trajectory Analyses 
3.3.3.1 Atomic displacement analysis 
The average change in the displacement of selected atoms for a trajectory frame relative to a 
reference frame is measured using the root mean square deviation (RMSD). To test the 
convergence/stability of the MD simulation, RMSD is computed for all the trajectory frames. 
The RMSD computation for trajectory frame x is:   








                              𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟒 
where 𝑁 is the selected number of atoms, 𝑟𝑖 (𝑡𝑟𝑒𝑓) denotes the average referenced position of 
an atomic particle 𝑟𝑖 at referenced time 𝑡𝑟𝑒𝑓 and 𝑟𝑖
′(𝑡𝑥)describes the position of specified atoms 
in the frame 𝑥 recorded at the time 𝑡𝑥 after reference frame superposition. This calculation is 







3.3.3.2 Residue positional mobility analysis 
The root mean square fluctuation (RMSF) for specified atoms (e.g. Cα atoms) is a measure of 
atomic deviation between particle 𝑛 position relative to a reference position: 
RMSFi =  √
1
T
   ∑(𝑟𝑖




                               𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟓 
where 𝑇 is the specified trajectory time to computed for RMSF, 𝑟𝑖 (𝑡𝑟𝑒𝑓) denotes the average 
referenced position of an atomic particle 𝑟𝑖 at referenced time 𝑡𝑟𝑒𝑓 and 𝑟𝑖
′(𝑡) describes the 
position of a specified atom in residue i at time t after reference frame superposition. The 
RMSF is computed to observe the mobility/fluctuations of residues in the macromolecular 
system.  
 
3.3.3.3 Structural compactness analysis 
The radius of gyration (RoG or rGyr), which estimates the compactness of a molecular structure 
is computed as:  






                                                          𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟔 
where 𝑚𝑖 denotes the mass of atom i and 𝑟𝑖 describes the position of atom i relative to the 
molecule’s centre of mass.  
 
3.3.3.4 Principal Component Analysis and Conformational Clustering 
 
Principal Component Analysis (PCA) is an advanced technique of trajectory analysis used to 
describe a given macromolecule’s collective motion. PCA is performed by constructing a 
covariance matrix Ci defined by an averaged MD trajectories ensemble as:  
Ci =< (qi−< qi >)(qj−< qj >) >   (i, j = 1,2 … … ,3N)                        𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟕                            
Where N signifies the number of C-α atom, 𝑞𝑖 denoting the mass-weighted cartesian coordinate 
of the ith N atom.  
To construct the covariance matrix, the translation and rotation movements are initially 
excluded, which allows the 3N directions along which most of the protein motion to be 
identified. The covariance matrix is diagonalised to extracting a set of eigenvectors and 




carried out, which transforms the covariance matrix C into a diagonal matrix of the eigenvalues 
λi.: 
Λ = TTCijT                                                                      𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟖 
Extracting the essential principal modes provides insight into the conformational dynamics of 
biological molecules. The principal component analysis in the manuscript chapters that make 
up this thesis was computed with the Bio3D package in R (Grant et al., 2006). 
 
3.3.4 Estimation of binding free energies 
The application of computational approaches in binding free energy estimation has emerged as 
an essential tool in the drug design process (Pearlman & Charifson, 2001; Srivastava & Sastry, 
2012; Steinbrecher et al., 2017). These methods provide a guide in structure-based drug 
discovery and protein-ligand interaction analysis. Several of these computational approaches 
rely on molecular dynamics (MD) in providing a cost-effective conformational ensemble that 
is statistically relevant for thermodynamic calculations. The most popular MD-based binding 
free energy methods include thermodynamic integration (TI) (Bhati et al., 2017), free energy 
perturbation (FEP) (Lenselink et al., 2016; Deflorian et al., 2020), linear interaction energy 
(LIE) (Rifai et al., 2018), and Molecular Mechanics Poisson–Boltzmann/Generalized Born 
Surface Area (MM-PB/GBSA) (Aldeghi et al., 2017; Miller III et al., 2012). However, the first 
two methods are quite computationally demanding/expensive, while the MM-PB/GBSA 
approaches have been mainly used in virtual screening protocols due to their computational 
efficiency (Yau et al., 2020; Manhas et al., 2019). The AMBER MM-PB/GBSA calculations 
have successfully has been used to calculate the binding free energies in protein-protein 
complexes (Contini et al., 2012), DNA-ligand complexes (Ferri et al., 2011), and protein-ligand 
complexes (Manhas et al., 2019). 
 
3.3.4.1 AMBER MM/PBSA.py for binding free energy calculation 
The MM/PBSA.py is an AMBER package program for end-point free energy estimation which 
uses the Molecular Mechanics Poisson–Boltzmann/Generalized Born Surface Area (MM-
PB/GBSA) methods (Miller III et al., 2012). For the prediction of binding affinity, the MM-
PB/GBSA-based approaches are commonly used as they provide an intermediate compromise 
of accuracy and speed between the more robust free energy perturbation techniques and the 




MM/PBSA is more effective in computing absolute binding free energies, whereas MM/GBSA 
effectively computes relative binding energies. MM/GBSA is, therefore, the most appropriate 
approach compared to MM/PBSA to be employed in the correct ranking of inhibitors (Hou et 
al., 2011).  
The estimation of binding free energy (ΔG) by MM/PBSA or MM/GBSA is represented by 
Figure 3.5 and the following equations: 
∆Gbind = Gcomplex − (Gprotein + Gligand)                                𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟗 
∆Gbind = ∆H − T∆S                                                                        𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏𝟎 
The individual free energy components of Equation 3.9 is obtained from the molecular 
mechanical energy (EMM), entropy contribution (−T∆S), and solvation energy (Gsol) terms:  
∆H = ∆EMM + ∆Gsol − T∆S                                                      𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏𝟏 
The molecular mechanical energy term EMM of the total enthalpy contribution is expressed as: 
∆EMM = ∆Einternal + ∆Evdw + ∆Eele                                     𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏𝟐 
Where the  ∆EMM is comprised of the intramolecular energy term (∆Einternal; involving the 
system’s dihedral, angle, and bond energies), the van der Waals interactions (∆Evdw), and the 
electrostatic energy (∆Eele) in the gas phase. 
The free energy of solvation is described by Gsol composing of the nonpolar ∆Gnonpolar and 
polar ∆Gpolar solvation free energy terms:  
∆Gsol = ∆Gpolar(PB/GB) + ∆Gnonpolar                                     𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏𝟑 
The ∆Gpolar term is generally calculated using either the Generalized Born (GB) model in 
MM/GBSA and the Poisson-Boltzmann (PB) model in MM/PBSA.  
The solvent-accessible surface area (SASA) method is used to calculate the nonpolar solvation 
energy component (Gnonpolar):  
 Gnonpolar = 𝛾 ∗ (𝑆𝐴𝑆) + 𝛽                                                               𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑. 𝟏𝟒 
The 𝛽 and 𝛾 denote the offset and surface tension values, respectively. The conformational 
entropy (-T∆S) to the binding free energy is generally estimated by the AMBER normal mode 






Figure 3.5 Schematic illustration of the thermodynamic cycle according to which free energy 
of binding is calculated. (Image adapted from (Walker, 2008)).  
 
The MM-PBSA/GBSA approaches have been documented to predict experimental binding free 
energies successfully for diverse biological systems. (Chéron & Shakhnovich, 2017; Rastelli 
et al., 2010; Ferrari et al., 2007; Bonnet & Bryce, 2005; Wang et al., 2001). However, the MM-
PBSA/GBSA approach has also been shown to produce substandard results in predicting 
binding free energies (Singh & Warshel, 2010; Kuhn et al., 2005; Pearlman, 2005). MM-
PBSA/GBSA performance in predicting binding affinity was recently evaluated and reported 
for 934 known inhibitors against the crystal structures of twenty class A GPCRs (Yau et al., 
2019). The authors concluded that MM-PBSA/GBSA performance in GPCR ligands binding 
free energy prediction is highly system-specific (Yau et al., 2019).  
 
3.4 Computational Drug Design and Discovery  
Drug design, discovery and development require a laborious inter-disciplinary approach and 
are considered time consuming and expensive (DiMasi et al., 2003; DiMasi et al., 2016). The 
application of computational drug design and discovery (CDDD) techniques in drug design 
projects have assisted in expediting the process. The available computational methods in drug 




based drug design (LBDD) methods. Figure 3.6 summarises the position of CDDD methods in 
the drug design process.  
 
Figure 3.6 Computational drug design and discovery position in the drug discovery process 
(Image prepared by author). 
 
3.4.1 Structure-based drug design and discovery 
Structure-based drug design (SBDD) is a target-based computational method used to design or 
identify novel inhibitor that relies on the structural details of the biological target of interest 
(Batool et al., 2019). cryo-electron microscopy (cryo-EM), X-ray crystallography, and nuclear 
magnetic resonance (NMR) spectroscopy are experimental methods used to determine the 
three-dimensional (3D) structures of the macromolecules (Krishnan & Rupp, 2012; García-
Nafría & Tate, 2020). Homology/comparative models can be used based on the available 
structures of closely related proteins in the absence of an experimentally defined structure 
(Dong et al., 2013). SBDD is an efficient, more specific, and quick process for lead 
identification/discovery and lead optimisation since it utilises molecular level knowledge about 
the disease and the protein target structure (Lionta et al., 2014; Congreve & Marshall, 2010). 
The use of SBDD methods in academic research and the pharmaceutical industry have helped 
identify several FDA-approved medicines, including HIV-1 inhibitors (Wlodawer & 





3.4.1.1 Structure-based virtual screening 
The in silico high throughput screening (HTS) technique known as structure-based virtual 
screening (SBVS) is a technique used to screen large chemical compound libraries or 
compound databases against a molecular target (Wang et al., 2020; Liu & Jockers, 2020). The 
process requires the protein target structure to predict the best binding interaction between the 
compounds and the target to form a complex. The ligands or compound libraries are then 
ranked based on their binding affinity to the target, with the highly promising compound 
displayed at the top of the list (S. Liu et al., 2018). Molecular docking is a well-known 
technique applied in SBVS as it is fast, less computationally expensive and achieves good 
results (Meng et al., 2011).  
 
3.4.1.2 Fragment-based drug discovery 
Fragment-based drug discovery (FBDD) is an effective target-based technique used to develop 
potent small molecules with chemical fragments as starting points and optimised toward drug-
like leads. FBDD has become an attractive strategy in structure-based drug discovery with 
successes, even where other approaches failed for challenging targets (Erlanson et al., 2016; 
Murray et al., 2012). FBDD begins with screening very weak affinity low molecular weight 
compounds libraries (fragments) to identify “hits” against the target of interest. The identified 
hits are further optimised based on the target structural information to higher affinity small 
molecules using robust methods (Li, 2020; Erlanson et al., 2019).  
 
3.4.2 Ligand-based drug design 
Ligand-based drug design (LBDD) is a computational technique applied in the absence of a 
target 3D structural information. It depends on the knowledge of the molecules that bind to the 
biomolecular target of interest. The 3D quantitative structure-activity relationships (3D QSAR) 
and Ligand-based pharmacophore modelling are the most relevant and highly used methods in 
LBDD. These tools assist in lead identification and lead optimisation with appropriate 
predictive models (Acharya et al., 2011). 
 
3.4.3 Molecular docking 
Molecular docking is an extensively applicable computational technique in the process of 
structure-based drug design and discovery. Molecular docking is mainly used to predict the 
most favourable binding conformation and affinity of a ligand at the binding pocket of a 




the quantitative estimation of binding affinities through molecular docking protocols assist in 
the investigation of vital protein-ligand interactions. This then assists in analysing the structure-
activity relationship (SAR) for rational drug design and prioritising compounds/drug 
candidates that can be synthesised or experimentally tested.  
 
 
Figure 3.7 A schematic representation of the molecular docking of a ligand (green) into a 
protein target binding pocket (black) to produce a ligand-receptor complex (Image adapted 
from (Wikipedia, 2015)). 
 
The application of large drug-like compound libraries in virtual high-performance screening to 
obtain leads for further drug development is paramount for molecular docking. The molecular 
docking process can be divided into two separate stages: ligand conformational space search 
within the binding pocket and the binding affinity estimation for every predicted conformation 












3.4.3.1 Ligand Conformational Search 
Conformational search algorithms are utilised in molecular docking programs to search 
systematically for the orientations and conformations of a ligand at the binding pocket on a 
receptor target (Shen, Ding, et al., 2020). Thus, several poses of the ligand-receptor complexes 
are generated in the conformation space search. Translational and Rotational degrees of 
freedom are used in the case of rigid docking. In contrast, a conformational degree of freedom 
is added to the ligands’ rotations and translations in a flexible docking protocol. (Maia et al., 
2020).  
 
3.4.3.2 Binding Affinity Estimation 
Molecular docking programs employ different scoring functions to compute the molecular 
interaction force between a ligand and its molecular target. For each ligand-receptor complex 
conformation, a scoring function predicts the ligand-binding affinity at the receptor-binding 
pocket (Shen, Ding, et al., 2020). In modern docking programs, the molecular docking scoring 
functions used can be characterised as knowledge-based potential, physics-based methods (e.g. 
force-field or QM-based), descriptor-based scoring functions and empirical scoring functions 
(Liu & Wang, 2015). 
 
3.4.4 In silico physicochemical, and pharmacokinetic predictions 
In their safety and efficacy profiles, the absorption, delivery, metabolism, excretion, and 
toxicity (ADMET) properties of the prospective drug molecule are critical. However, it is time-
consuming and expensive to apply experimental methods that also require animal testing. Due 
to poor druggability, the disconnection between compound optimisation and ADMET 
assessments may sometimes lead to the dismissal of compound candidates, although they may 
have demonstrated excellent in vitro efficacy (Wang et al., 2015). The ability to early ascertain 
the druggability of candidate compounds improve drug development efficiency and 
productivity. The application of in silico physicochemical and ADMET profiling provides a 
cost-effective approach in prioritising the candidates. Thus, in silico ADMET profiling has 
emerged as a tool of choice in early drug discovery projects (Wang et al., 2015). The 
availability of high quality physicochemical and ADMET.predictive models provide avenues 
for the optimisation of druggability properties and compound efficacy (Huang et al., 2013). 
Applying these in silico models increases the probability of drug candidate success with 
reduced overall cost due to decreased attrition rate. The intelligent integration of in silico, in 




discovery (Wang & Collis, 2011). Various in silico tools exist to predict pharmacokinetic 
profiles and other molecular properties such as clogP, topological polar surface area (TPSA), 
drug score values, fragment-based drug-likeness, etc., of candidate molecules. A representative 
of these tools includes SWISSADME (Daina et al., 2017), pkCSM (Pires et al., 2015), and 
QikProp (Ioakimidis et al., 2008).  
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Dopamine receptors constitute a unique class of G-protein coupled receptors that mediate the 
activities of dopamine, a neurotransmitter implicated in diverse neurological diseases when 
dysregulated. Over the years, antipsychotic drugs have been primarily directed towards D2 
dopamine receptor (DRD2) while associable adverse effects have been centred on non-
selective targeting. The recent crystal structure of DRD2 in complex with atypical 
antipsychotic could further aid the structure-based design of highly DRD2-selective 
antipsychotics. Therefore, in this study, we comprehensively investigate the molecular 
recognition and differential binding landscapes of class-I and II DRD2 atypical antipsychotics, 
using membrane-bilayer molecular dynamics simulation and binding free energy techniques. 
Findings revealed that selected class-I antipsychotics exhibited binding dynamics and poses 
dissimilar to the class-II types with different interactive mechanisms at the binding cavity of 
DRD2. More interestingly, the class-II drugs established a highly coordinated binding at the 
DRD2 active site with a pertinent and recurrent involvement of Asp114 via strong hydrogen 
interactions. Furthermore, while these compounds exert distinct effects on DRD2 structure, 
findings revealed that the class-II types favourably engaged the deep hydrophobic pocket of 
DRD2 compared to the class-I drugs. We speculate that these findings will be fundamental to 
the discovery of highly selective DRD2 antipsychotics. 
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G protein-coupled receptors (GPCRs) play an important role in the cell signalling process, 
particularly in response to neurotransmitters and hormones (Congreve & Marshall, 2010). 
Dopamine is an important neurotransmitter exerting its effect via the activation of the five 
dopamine receptors subtypes belonging to the GPCR family, namely; D1, D2, D3, D4, and D5 
(Kebabian & Calne, 1979). These receptors are further grouped into two main subfamilies, D1-
like (D1 and D5) and D2-like (D2, D3, and D4) receptors, based on their sequence and structural 
similarities (Fuxe et al., 2014). Generally, these class of receptors mediate cell proliferation, 
and differentiation, cyclic adenosine monophosphate release and neurotransmission of other 
neurotransmitters (Mishra et al., 2018). 
Amongst these subtypes, D2 dopamine receptor (DRD2) is an important GPCR drug target that 
mediates signal transduction of neurotransmitters in the central nervous system as well as in 
neurological processes such as memory, attention, emotion, pleasure, lust, and love 
(Greengard, 2001). The dysfunction of the dopaminergic system has been associated with 
various neurodegenerative disorders such as depression, Parkinson’s disease, attention deficit 
hyperactivity disorder, and schizophrenia. DRD2 has been the main target for atypical and 
typical antipsychotic drugs (Creese et al., 1976),(Meltzer et al., 1989) as well as drugs 
employed in the treatment of Parkinson disease. Unfortunately, many of these antipsychotic 
drugs targeting DRD2 are accompanied by a plethora of severe side effects, due to off-target 
interactions with other related targets (Roth et al., 2004),(Roth, 2007). 
The crystal structures of D4 dopamine receptor (DRD4) in complex with antipsychotic 
nemonapride (Wang et al., 2017) and D3 dopamine receptor (DRD3) in complex with 
eticlopride (Chien et al., 2010) have earlier been resolved. However, the lack of crystalised 
structures of the DRD2 ligand complexes over the past years impeded the molecular 
understanding of receptor function and ligand recognition. The recent crystallisation of the 
DRD2 in complex with the widely prescribed antipsychotic drug risperidone in 2018 provided 
novel insights (Wang et al., 2018) (Figure 1). Previous studies of DRD2 have been based on 
homology modelled structures using either DRD3 or DRD4 crystal structures as templates  






Figure 1. Crystal structure of dopamine 2 receptor in complex with risperidone binding deep 
into the active site. Extracellular loops (ECL), intracellular loops (ICL), T4-Lysozyme (T4L) 
and risperidone are depicted in yellow, green, orange, and magenta, respectively (Image 
prepared by author).  
 
The solved crystal structure of DRD2 revealed an unexpected binding mode of risperidone 
which was contrary to findings from previous molecular docking studies that employed a non-
crystal homology model of DRD2 and used DRD3/DRD4 as structural templates (Duan et al., 
2015; Salmas et al., 2017). This approach failed to replicate the unique binding mode of 
risperidone as observed in the recent DRD2 crystal structure (Wang et al., 2018), which 
revealed that risperidone binds differently to DRD2. In the risperidone-DRD2 crystalised 
complex, the fluorobenzisoxazol ring orients deep in the hydrophobic cleft interacting with 
Trp386, Phe390, Phe382, Phe198, Ser197, Thr119 and Cys118 whereas the 
tetrahydropyridopyrimidinone ring interacts with residues Phe110, Thr412, Trp100, Tyr408 
and Val191 (Wang et al., 2018). Interestingly, in the recent crystal structure of serotonin 2A 
receptor (5-HT2AR) in complex with risperidone substantiates the observed binding mode in 
DRD2; the fluorobenzisoxazol ring of risperidone binds in the bottom of the hydrophobic cleft 
forming interactions with Trp336, Ile163, Phe340, Phe243, and Phe332 whereas the basic 
nitrogen of risperidone forms a salt bridge with the conserved residue Asp155 of  5-HT2AR 
(Kimura et al., 2019).  These, however, contradict the reported reversed binding mode of 




the binding modes of related atypical antipsychotic DRD2-targeting drugs remain unclear, and 
to make significant advancements in the structure-based design of these class of drugs. There 
is a need to identify definite binding modes and mechanisms for risperidone and related 
atypical antipsychotics at the binding cavity of DRD2. 
Understanding the binding modes and activation mechanisms of atypical antipsychotics at the 
binding cavity of DRD2 may assist in the rational-based drug design of highly selective drugs 
with minimal off-target tendencies. To further clarify the binding mechanisms of DRD2 
antagonists, we performed a comparative study of six (6) well known DRD2 atypical 
antipsychotic drugs to elucidate the mechanisms of ligand recognition, binding theme and 
conformational changes induced by these antipsychotics. The present study utilised molecular 
docking, explicit membrane-bound protein lipid bilayer molecular dynamics simulation, 
protein-ligand interaction fingerprint and binding energy analyses approach. Findings from this 
study will provide a further understanding of DRD2 ligand recognition and to guide future 
development of novel DRD2 selective as well as safer antagonists. 
 
2. Computational Methods 
2.1 Ligand structure preparations 
The 2D structures of DRD2 antagonists; aripiprazole (ZINC01851149), clozapine 
(ZINC19796155), olanzapine (ZINC52957434), quetiapine (ZINC19632628), ziprasidone 
(ZINC00538550) and risperidone (ZINC00538312)  were downloaded from the ZINC database 
for molecular docking (Irwin et al., 2012). Risperidone was also extracted from the dopamine 
crystalised structure (PDB ID: 6CM4) (Wang et al., 2018) from the Protein Data Bank 
(http://www.rcsb.org/) for the simulation. The retrieved compounds were prepared and 
minimised at physiological pH (7.4) using LigPrep module of Schrodinger suite software 
(Schrödinger, 2015). Figure 2 shows the 2D structures of the compounds employed in this 
study. 
 
2.2 Molecular Docking Analysis 
Molecular docking experiment was performed using Autodock Vina software package (Trott 
& Olson, 2010). The software’s default settings were used to rank the ligand conformation 
based on their predicted binding affinities during the docking experiments. Molecular docking 
was performed following receptor grid generation around the protein active site residues. The 
grid box was defined around the crystallised bound ligand (risperidone) active site residues. 




respectively whereas the X, Y, and Z centres were defined by 9.69473, 5.99816, and -8.89723 
respectively. Polar hydrogens and Gasteiger charge were assigned for all compounds. The best 
docking pose was output based on the best binding score. The 2D structures of risperidone and 
the related antipsychotics used in this study were docked to the crystal structure using the same 
grid box. The docked complex structures were visualised by the UCSF chimera (Pettersen et 
al., 2004) graphical user interface, and Molecular interactions were also visualised using 
Molegro Molecular Viewer (MMV) software program (http:www.clcbio.com). 
 
Figure 2. 2D structures of dopamine 2 receptor atypical antipsychotic drugs employed in the 
molecular dynamics simulations (Image prepared by author).  
 
2.3 Protein-Membrane System Setup 
The initial coordinates of the protein were taken from the Protein Data Bank (PDB ID: 6cm4) 
(Wang et al., 2018). The protonation state of the protein was determined using PROPKA 
(Dolinsky et al., 2007) at a 7.4 physiological pH. Missing loops were modelled using Modeller 
9.19 (Webb & Sali, 2014) plugins in chimera software. The T4-Lysozyme (T4L) residues 
(Val223-Arg361) fused in the ICL3 were deleted and the exposed residues Arg222 and Lys362 
capped. The protein-membrane bilayer and all the ligand-protein-membrane bilayers were 
assembled using the membrane builder module at the CHARMM-GUI website 
(http://www.charmm-gui.org/). The protein-membrane and the ligand-protein-membrane 
systems were aligned in dipalmitoylphosphatidylcholine (DPPC) lipid bilayer with knowledge 
of the protein orientation in the bilayer obtained from the Orientation of Protein Membranes 




molecules (Jorgensen et al., 1983) and neutralised with KCl counterions at a concentration of 
0.15M (Figure 3). The dimensions of the final simulated systems approximately measured 75 
x 75 x 100 Å3 and approximately contained 150 DPPC lipid molecules, 26 potassium ions (K+), 
37 chloride ions (Cl-), and 10,000 TIP3P water molecules.  
 
 
Figure 3. D2 dopamine receptor (purple) in complex with atypical antagonist risperidone (red) 
embedded in DPPC lipid bilayer (cyan) (Image prepared by author). 
 
2.4 Molecular Dynamic (MD) Simulations  
The AMBER18 package (Case et al., 2018) was used to perform all MD simulations. The 
solvated complex systems were used as the starting structures for the MD simulations. The 
charmmlipid2amber.py program in AmberTools 18 was used to convert the CHARMM lipid 
residue names to Amber format. The general Amber force field (GAFF) (Sprenger et al., 2015), 
Amber force field ff14B (Maier et al., 2015) and the Lipid14 (Dickson et al., 2014) force field 
were employed for the ligands, protein, and lipid molecules parameterisation, respectively. K+ 
and Cl ions were parameterised using the Joung-Cheatham TIP3P ion parameters (Joung & 
Cheatham III, 2008). The RESP model (Bayly et al., 1993) was used to derive the partial atomic 




GAUSSIAN 16 software package. The critical Cys182 and Cys107 disulfide bond were 
maintained during the simulations.  
All simulations were performed on Amber18 using the Particle Mesh Ewald Molecular 
Dynamics (PMEMD) program. The prepared systems were energy minimised and equilibrated 
as follow:  Energy minimisation of 10000 steps by hybrid methods of 5000 steps of steepest 
descent and remaining of conjugate gradient algorithm to relax the systems to remove any 
possible steric clashes.  Individual systems were heated from 0 K to 100 K in isothermal-
isochoric (NVT) ensemble using the Langevin thermostat (Larini et al., 2007) for 12.5 ps 
applying a 10.0 kcal mol−1 Å−2 harmonic restraint on non-hydrogen atoms of protein, ligand, 
and lipid with a collision frequency of 1.0 ps-1. Each system was further heated from 100 K to 
310 K for 125 ps with anisotropic pressure scaling and a pressure of 1 bar in isothermal-isobaric 
(NPT) ensemble. Equilibration was further performed for a total of 10 ns at 310 K in NPT 
ensemble.  A 2fs time step was used for heating and equilibration runs. Long-range electrostatic 
interactions were handled by particle mesh Ewald (PME) (Darden et al., 1999) algorithm, and 
non-bonded interactions were cut off at 10.0 Å. Covalent bonds involving hydrogen and heavy 
atoms were constrained with the SHAKE algorithm (Miyamoto & Kollman, 1992).  Finally, a 
200ns production run was carried out for each system at 310K and 1 bar in NPT ensembles 
without any restraint at a time step of 2fs and a cut-off of 10Å. Simulation snapshots were 
saved every 1ps.  
 
2.5 Post-MD Trajectories Analysis  
Prior to the analysis of trajectories, water molecules, counter ions and DPPC lipid molecules 
were stripped from the trajectories. The CPPTRAJ module (Roe & Cheatham, 2013) of 
AMBER18 was used to perform the analysis of the trajectories. Figures were prepared using 
UCSF Chimera (Pettersen et al., 2004). 
 
2.6 MM-GBSA Binding Free Energy Analysis 
The estimation of binding free energy for atypical antipsychotic was obtained from the stable 
MD trajectories using MM-GBSA method implemented in Amber18 package (Case et al., 
2018). 4000 snapshots were evenly extracted over the 200 ns of the MD trajectories at an 
interval of 50ps. Prior to MM-GBSA calculations, all water molecules, counterions, and lipids 
were stripped. Conceptual summary of the MM-GBSA method can be found in our previous 




2.7 Residue interaction energy analysis 
The energy contribution of the active site residues to the overall binding energy of the studied 
antipsychotics was also decomposed from their total binding energies.   
 
3. Results and Discussion 
3.1 Binding poses of atypical drugs to DRD2 
Molecular docking analysis was performed to predict the binding poses and affinities of 
aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone (Figure 2 & 4) at 
the binding site of the crystalised D2 dopamine receptor. Auto Dock Vina (Trott & Olson, 
2010), a molecular docking tool has successfully been employed in finding the appropriate 
binding poses/modes and affinities of ligand molecules inside the binding/active site of proteins 
(Nisha et al., 2016; Kumar et al., 2018; Seyedi et al., 2016). Prior to the docking of related 
atypical antipsychotics, the downloaded risperidone structure (ZINC00538312) from the ZINC 
database was initially docked into the DRD2 receptor (Figure 4b).   
 
Figure 4. Binding poses of (A) class-I atypical antipsychotics and (B) class-II atypical 
antipsychotics docked to DRD2 receptor binding site. Docked risperidone (ZINC00538312; 
magenta) superimposed over the crystallographic risperidone pose (PDB ID: 6CM4; green) in 
DRD2 receptor. The observed RMSD difference was 0.07 Å. Interacting residues were similar 






5a and 5b depict the average RMSD of the Cα atoms for atypical-receptor complexes over the 
entire 200ns MD simulations. In general, all complexed systems achieved conformational 
stability after 40ns simulations. The average apo and ligand-complex system RMSD values 
were 2.29Å (Apo), 1.95Å (clozapine), 1.93Å (quetiapine), 1.99 Å (olanzapine), 2.04Å 
(aripiprazole), 2.28Å (risperidone) and 1.82Å (ziprasidone). The ziprasidone-DRD2 complex 
relatively represents the most stable conformer. The above RMSD values seem to suggest that 
the DRD2 protein structure is less stable without inhibitor than with inhibitor. The relative 
dynamic stability of class-I and class-II atypical antagonists was also calculated to effectively 
assess the stability of these inhibitors at DRD2 binding pocket (Figure 5c & 5d). The observed 
averaged RMSD of the inhibitors was 0.92 Å, 1.69 Å, 0.91 Å, 1.98 Å, 1.06 Å, and 1.32 Å for 
clozapine, quetiapine, olanzapine, aripiprazole, risperidone, and ziprasidone, respectively.  
 
Figure 5. Conformational stability of protein-atypical drug complexes. The Cα RMSD of 
(a) atypical class-I drug-receptor complexes, (b) atypical class-II drug-receptor complexes, (c) 
atypical class-I drugs only and (d) atypical class-II drugs only relative to the starting minimised 






To determine the regions of the protein exhibiting higher structural flexibility, the average root 
mean square fluctuations (RMSF) per residue of Cα atoms were determined (Fig 6a & 6b).  
Relatively, minimal alterations were observed at the transmembrane (TM) domain regions of 
the unbound (apo) and ligand-bound compared to the loops regions where a considerable 
degree of residue fluctuations was observed as shown in Figure 6a & b. The difference in 
RMSF values was also identified for class-I and class-II inhibitors for ECL1 and ECL2 
residues. Risperidone and aripiprazole bound systems showed higher residue flexibility in the 
ECL2 compared with clozapine, olanzapine and quetiapine bound systems suggesting that the 
interactions of these different classes of inhibitors with DRD2 produced different restrictions 
on the motions of these residues. The above-observed differences in RMSF values may suggest 
the changes in interaction intensities and internal dynamics.  
 
To obtain insights into the different degrees of solvent accessibility, the hydrophobic regions 
of DRD2 in complex with class-I and class-II atypical antipsychotics were observed and 
compared over the 200 ns simulations (Figure 6c & 6d). The mean solvent accessible surface 
area (SASA) values for class-I antipsychotics were 16162.34 Å2, 16188.13 Å2, and 16211.95 
Å2 for clozapine, quetiapine, and olanzapine respectively compared with 16365.43 Å2, 
16568.53 Å2 and 16800.84 Å2 for class-II antipsychotics aripiprazole, ziprasidone, and 
risperidone, respectively. Evidently, the binding poses of class-II antipsychotics engage deeper 
into the hydrophobic pockets which may explain their relatively larger volume of solvent 





Figure 6. RMSF plot of Cα atoms in DRD2 systems for (a) class-I atypical and (b) class-II 
atypical over 200 ns of simulation. Solvent accessible surface area (SASA) for (c) class-I 
atypical and (d) class-II atypical over 200 ns of simulation (Image prepared by author). 
 
3.3 Analysis of binding free energy interaction. 
To further dissect contributions to the protein-inhibitor binding, the molecular mechanics-
generalised born surface area (MM-GBSA) method was employed to predict the binding free 
energy of atypical antipsychotics to DRD2 using snapshots from stabilised MD trajectories 
(Table 2). The predicted binding free energies for class-I atypical antipsychotics were -37.22 
± 0.06, -34.21 ± 0.09, and -34.05 ± 0.09 kcal/mol respectively for olanzapine, clozapine and 
quetiapine (Ki values of 30.75, 147.0 and 437.0 nM, respectively). In class-II atypical 
antipsychotics, the predicted binding free energies were -49.87 ± 0.09, -49.27 ± 0.06, and -
37.18 ± 0.08 kcal/mol respectively for aripiprazole, risperidone, and ziprasidone (Ki values of 
2.30, 3.70, and 4.75 nM, respectively). The above binding energy rankings provide a good 
correlation with the experimental binding affinities compared to the previously reported 






The observed differences in the formation of hydrogen bond by class-I and class-II atypical 
antipsychotics reflect their distinctive binding mode and interaction pattern in the DRD2 crystal 
structure.  
 
3.5 Residue interaction energy analysis 
To identify key residues that make important intermolecular interaction contribution to the 
binding of atypical antipsychotics, the total binding energy of each inhibitor was decomposed 
to obtain the energy contribution of active site residues. This decomposition was performed at 
the atomic level for the overall atoms of each residue to obtain individual residue contribution 
to inhibitor binding. The van der Waals energy, electrostatic interaction energy and the total 
energy of residues with high energy contribution are presented in Figure 7. The binding mode 
of the two classes of atypical antipsychotics and important residues are also shown in Figure 8 
& 9.  
In the class-I atypical drug-receptor interactions, all three drugs strongly interacted commonly 
with two residues, namely Ile184 and Tyr408 with energy values between -0.75 and -3.768 
kcal/mol. Olanzapine and quetiapine shared similar interactions with Trp100 and Val111, 
olanzapine and clozapine both interacted with Phe110 and Pro405, whereas clozapine and 
quetiapine made interactions Cys182 and Ala185. In the class-II drug-receptor interactions, 
residues Trp100, Phe389 and Tyr408 commonly interacted with all three drugs with energy 
values ranging from -0.512 to -2.882 kcal/mol. Aripiprazole and risperidone interacted with 
six similar additional residues including, Asp114, Cys118, Thr119, Trp386, Phe390, and 
Thr412 with energy values between -0.557 and -2.347 kcal/mol. These additional interactions 
pattern shared between aripiprazole and risperidone but not ziprasidone seems to suggest a 
similar binding mechanism exists in risperidone and aripiprazole toward DRD2 receptor.  
Class-II antipsychotics generally interacted with residues within the deep hydrophobic binding 
pocket characterised by Cys118, Thr119, Ser197, Phe198, Phe382, Phe390, and Trp386 with 
stronger and similar residue interaction pattern observed for aripiprazole and risperidone. 
Overall, the residue interaction energy analysis further clarifies the difference in binding mode 





Figure 7. Per-residue binding free energy decomposition of (a) aripiprazole (b) risperidone 
(c) ziprasidone (d) clozapine (e) olanzapine and (f) quetiapine to DRD2 receptor (Image 






3.6 The binding mode and interaction analysis of atypical antipsychotics 
To probe the binding mode and interactions pattern of atypical antipsychotics in the crystal 
structure of the DRD2 receptor, these drugs were first docked into DRD2 binding pocket 
followed by an all-atom membrane MD simulation. The protein-ligand interaction profiler 
(PLIP) software (Salentin et al., 2015) and the Discovery Studio protein-ligand interaction 
module (Accelrys, 2013) were used to perform drug-receptor interaction fingerprint analysis 
to identify non-covalent interactions such as hydrophobic contacts, hydrogen bonding, pi-
stacking, salt bridges, and pi-cation interactions.  
In the predicted binding mode and interactions of olanzapine using the x-ray structure (Figure 
8c & 9c), the protonated nitrogen atom of the thieno-benzodiazepine moiety forms a stable 
hydrogen bond with Thr412. Olanzapine is predicted to bind in the orthosteric and the extended 
binding pocket interacting with a cluster of aromatic and hydrophobic residues such as Val91, 
Leu94, Ile184, Trp100, Phe389 and Phe110. Additionally, olanzapine interacts with Phe389 
and Tyr408 via pi-sulphur and pi-cation interactions, respectively. The residue energy 
interaction shows residues that are critical to the binding of olanzapine, these residues include 
Tyr408, Thr412, Ile184, Trp100, Leu94, Ser409, Val91, Phe110, Pro405, and Val111 with 
binding energies greater than -0.50 kcal/mol (Figure 7e). Tyr408 was previously observed to 
contribute to olanzapine binding via a hydrogen bond with the nitrogen atom of the methyl 
piperazine (Salmas et al., 2017). However, it was observed that Tyr408 strongly interacts with 
olanzapine through a pi-cation interaction (Figure 8c) which could be attributed to its higher 





Figure 8.  2D inhibitor-complexes for (a) quetiapine (b) clozapine (c) olanzapine (d) 
aripiprazole (e) risperidone and (f) ziprasidone with D2 dopamine receptor showing important 





In the predicted binding mode of clozapine in DRD2 receptor (Figure 8b & 9b), clozapine 
extends its interactions above the orthosteric binding pocket into the extended binding pocket 
interacting strongly with Phe110, Cys182, Ile184, Ala185, Asn396, Tyr408 and Pro405 with 
interaction energies greater than -0.5 kcal/mol (Figure 7d). The protonated nitrogen of the 
methyl-piperazine ring forms stable hydrogen bonds with Asn396 and Asn402 (Table 3 and 
Figure 8b & 9b). Pi-alkyl interactions are also observed between the benzo-benzodiazepine 
group and Phe102, Pro405, and Ile184. Clozapine additionally forms hydrophobic interactions 
with Phe102, Ile180, Pro405, Ile184, Glu181 and Tyr408.  
The docking poses and molecular dynamics of quetiapine suggest a salt bridge interaction 
between Glu181 and the positively charged nitrogen of the piperazine ring. The hydroxyl in 
the ethoxyethanol group forms a stable hydrogen bond with Glu181 (Table 3 and Figure 8a & 
9a). Quetiapine was predicted to extends its binding above the orthosteric binding site into the 
extended binding pocket interacting strongly with Trp100, Ile184, and Tyr408. The residue 
interaction energy suggests Trp100, Cys107, Val111, Glu181, Cys182, ile184, Ala185 and 
Tyr408 to significantly contribute to the binding of quetiapine with interaction energies higher 
than −0.5 kcal/mol (Figure 7f). The high interaction energy of Trp100 (-3.0 kcal/mol) with 
quetiapine mainly stems from the observed π-cation interaction between Trp100 and the 
piperazine ring of quetiapine.  
The binding of risperidone in the D2 dopamine receptor is such that the fluorobenzisoxazol ring 
orients deep in the hydrophobic cleft interacting with Phe390, Trp386, Phe382, Phe198, 
Ser197, Thr119, Cys118, Val115 whereas the tetrahydropyridopyrimidinone ring of 
risperidone interacts with residues Phe110, Thr412, Trp100, Tyr408 and Val191 (Figure 8e & 
9e). The major residues with favourable interaction energy contribution to risperidone binding 
predominately originate from eleven residues (Asp114, Val115, Cys118, Thr119, Phe198, 
Trp386, Phe389, Phe390, Tyr408, Thr412, and Tyr416) with average energy contribution 
larger than −0.9 kcal/mol (Figure 7b). Asp114 forms hydrogen bond with the tertiary amine in 
the piperidine ring whereas a less stable hydrogen bond occurred between Thr412 and the 
oxygen atom in the tetrahydropyridopyrimidinone ring (Table 3). The fluorobenzisoxazol ring 
forms π-π interactions with Phe390, Trp386 and Phe198 whereas an alkyl-π interaction with 
Val115 and Cys118 were also observed. The piperidine ring also forms a π-cation interaction 





Figure 9. 3D Docked complex of (a) quetiapine (b) clozapine (c) olanzapine (d) aripiprazole 
(e) risperidone and (f) ziprasidone with D2 dopamine receptor showing important interacting 
residues (Image prepared by author).  
 
The predicted binding mode of aripiprazole in DRD2 active places the dihydro-quinolin-2-one 
moiety deep into the hydrophobic cleft below the orthosteric binding site interacting with 
residues Thr119, Ser197, Phe198, Phe390, Cys118, Trp386, Phe389, Phe390, and Phe382 
(Figure 8d & 9d). The residue interaction analysis indicates that residues Asp114, Cys118, 
Ile184, Ala185, Trp386, Phe389, and Tyr408 of DRD2 contribute strongly to the binding of 
aripiprazole with binding energies greater than -1.0 kcal/mol (Figure 7a). Among these 
residues, the interaction energy of Asp114 with aripiprazole is the strongest (-2.3 kcal/mol). 
This stronger interaction energy from Asp114 may be due to the strong and stable hydrogen 
bond interaction (~72% occupancy) between Asp114 and aripiprazole (Table 3). This observed 
hydrogen bond interaction appears to be significant for the potency and stability of the 




interactions with Phe390 and Trp386 whereas the dichlorophenyl group forms π-π stacking 
interactions with Trp100 and Tyr408 (Figure 8d).  
 
The binding mode of ziprasidone (Figure 8f & 9f) suggests a salt bridge between Asp114 and 
the nitrogen atom of the chloro-1,3-dihydroindol-2-one moiety. Additionally, the oxygen atom 
of chloro-1,3-dihydroindol-2-one ring is predicted to form less stable hydrogen bonds with 
Ser193 and Asn396 (Table 3). The chloro-1,3-dihydroindol-2-one moiety binds in a cavity 
surrounded by residues Phe389, Val111, Phe189, Ser193 and Ser194, forming π-π interactions 
with Phe189 and Phe389. The benzothiazole ring made interactions with Ala185, Ile184, 
Leu94, Pro405, and Trp100 during the simulation. The residues interaction energy analysis 
reveals that Trp100, Val111, Ile184, Phe189, Val190, Ser193, Phe389, His393, Pro405 and 
Tyr408 strongly contribute to ziprasidone binding with energies greater than − 0.5 kcal/mol 
(Figure 6d). The high interaction energy of Trp100 (-2.9 kcal/mol) stems from the π-cation and 
π-sulphur interactions with the piperazine ring and benzothiazole ring, respectively whereas 
that of Tyr408 (-2.1 kcal/mol) stems from the π-cation interactions with the piperazine ring. 
These residues may contribute significantly to the stability and binding of ziprasidone to DRD2 
receptor.   
Asp1143.32 (superscript denote Ballesteros Weinstein numbering system) elicits a unique 
interaction pattern common to all Class-II inhibitors, which further potentiates the importance 
of this interaction as primarily observed in the co-crystallised complex of DRD2 with 
risperidone (Wang et al., 2018). Asp3.32 is a conserved residue observed in the structures of 
aminergic receptors and has been observed to form vital interactions with their inhibitors. The 
importance of this conserved residue has been reported in several aminergic crystalised 
structures: Asp1143.32 forms a salt bridge with the tertiary amine of risperidone in DRD2 (Wang 
et al., 2018); the tertiary amine of eticlopride forms a salt bridge with Asp1103.32 in DRD3 
(Chien et al., 2010); the conserved Asp1153.32 also interacts with nemonapride in DRD4 (Wang 
et al., 2017); whereas risperidone and Zotepine also form a salt bridge between the basic 
nitrogen of these inhibitors and Asp1553.32 in 5-HT2A receptor (Kimura et al., 2019). This salt 
bridge appears to be vital for high-affinity inhibitor binding to aminergic subfamily of GPCRs 
(Shi & Javitch, 2002). 
 
4. Conclusions  
The recent availability of the crystal structure of DRD2-drug complex provides avenues for 




of ligand recognition at the molecular level. In this study, molecular docking, all-atom 
molecular dynamics simulations of D2 dopamine receptor in explicit lipid-bilayer were 
performed in complex with selected atypical antipsychotic drugs to decipher the binding 
mechanism and the effect of ligand binding on the conformational changes of the DRD2 
receptor. The dynamic interaction patterns analysis showed that DRD2 extracellular and 
intracellular loop flexibility are large and binding site residues dynamic behaviour is different 
due to the presence of structurally different ligands. The interaction energy calculation by MM-
GBSA method showed that van der Waals interaction dominates the binding of atypical 
antipsychotics to DRD2 receptor.  
Additionally, the binding of atypical antipsychotic ligands into DRD2 binding site displayed 
different interactions ranging from hydrogen bonding (salt bridge), hydrophobic CH-π and π-
π interactions formed between distinct subsite residues and the ligand atoms. Findings from 
this study further revealed a binding mode of atypical class-II drugs where the dihydro-2-
quinolinone moiety of aripiprazole, the dihydro-indol-2-one moiety of ziprasidone and the 
fluorobenzisoxazole moiety of risperidone bind deep into DRD2 hydrophobic pocket defined 
by residues Thr119, Ser197, Phe198, Phe390, Cys118, Trp386, Phe389, Phe390, and Phe382 
of transmembrane (TM) III, V and VI.  These residues significantly contributed to the binding 
and stability of these drugs as evident by the residue interaction energy analysis. Asp114 was 
observed to form a strong and stable hydrogen bond in all class-II atypical drugs. This hydrogen 
bond interaction seems to be important for potency as well as for the stability of atypical class-
II drugs.  
Contrary to the observed binding mode and interaction pattern of class-II antipsychotics, class-
I antipsychotics depict different interaction pattern and mode of action in DRD2 receptor. The 
binding of class-I antipsychotics extends into the extended binding pocket above the orthosteric 
binding pocket characterised by Trp100, Phe110, Val,91, Tyr408, Ile184 and Leu94. These 
residues made a significant contribution to the binding and stability of class-I antipsychotics. 
As reported by Wang et al. (Wang et al., 2018) neither DRD3 inhibitor eticlopride nor DRD4 
inhibitor nemonapride occupies the deep hydrophobic pocket. Hence, the binding of class-II 
atypical antipsychotic drugs in the deep opening hydrophobic sub-pocket can be exploited in 
the design of the next generation subtype selective DRD2 antagonists. 
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More recently, there has been a paradigm shift towards selective drug targeting in the treatment 
of neurological disorders, including drug addiction, schizophrenia, and Parkinson’s disease 
mediated by the different dopamine receptor subtypes. Antagonists with higher selectivity for 
D3 dopamine receptor (D3DR) over D2 dopamine receptor (D2DR) have been shown to 
attenuate drug-seeking behaviour and associated side effects compared to non-subtype 
selective antagonists. However, high conservations among constituent residues of both 
proteins, particularly at the ligand-binding pockets, remains a challenge to therapeutic drug 
design. Recent studies have reported the discovery of two small-molecules R-VK4-40 and Y-
QA31 which substantially inhibited D3DR with > 180-fold selectivity over D2DR. Therefore, 
in this study, we seek to provide molecular and structural insights into these differential binding 
mechanistic using meta-analytic computational simulation methods. Findings revealed that R-
VK4-40 and Y-QA31 adopted shallow binding modes and were more surface-exposed at 
D3DR while on the contrary, they exhibited deep hydrophobic pocket binding at D2DR. Also, 
two non-conserved residues; Tyr361.39 and Ser18245.51 were identified in D3DR, based on their 
crucial roles and contributions to the selective binding of R-VK4-40 and Y-QA31. Importantly, 
both antagonists exhibited high affinities in complex with D3DR compared to D2DR, while 
van der Waals energies contributed majorly to their binding and stability. Structural analyses 
also revealed the distinct stabilizing effects of both compounds on D3DR secondary 
architecture relative to D2DR. Therefore, findings herein pinpointed the origin and mechanistic 
of selectivity of the compounds which may assist in the rational design of potential small-
molecules of the D2-like dopamine family receptor subtype with improved potency and 
selectivity.  
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1 Introduction  
G-protein-coupled receptors (GPCRs) modulate the activity of a diverse range of stimuli signal 
pathways through heterotrimeric G proteins activation such as ions, peptides, small molecules, 
and globular proteins (Weis & Kobilka, 2018). Dopamine receptors belong to the GPCRs, 
which constitute seven transmembrane (TM) helical domains. The dopaminergic pathway is 
involved in diverse physiological processes such as motor behaviour, neuroendocrine function, 
cognitive function, and emotion. However, the dysfunction of the dopaminergic system and 
the closely related D3 and D2 dopamine receptors are implicated in neurological and psychiatric 
pathologies such as schizophrenia, Parkinson’s disease, substance abuse as well as attention 
deficit hyperactivity disorder (ADHD)(Rangel-Barajas et al., 2015; Maggio et al., 2015; 
Beaulieu & Gainetdinov, 2011; Heidbreder & Newman, 2010).  
The high-resolution structures of GPCRs have proven to be vital in structure-based drug design 
(SBDD) methods in tailoring ligand selectivity and inhibitor efficacy (Congreve et al., 2014; 
Liu et al., 2018). The crystal structures of the D2 receptor bound to risperidone(Wang et al., 
2018) and haloperidol (Fan et al., 2020), as well as the D3 receptor bound to eticlopride(Chien 
et al., 2010), have been solved. However, the estimated 78% high degree of transmembrane 
(TM) sequence similarity and the near-identity of binding site residues between D2 and D3 
dopamine receptors, poses a challenge toward the development of D2-like receptor subtype-
selective inhibitors with enhanced drug-like properties (Sibley & Monsma Jr, 1992). Current 
marketed antipsychotic drugs lack selectivity toward a given D2-like receptor subtype(Li et al., 
2016). They are associated with substantial side effects such as metabolic syndrome, 
cardiovascular hypertension, and neurological side effects, including tardive dyskinesia and 
extrapyramidal reactions (Kaar et al., 2020; Ballon et al., 2014; Álvarez et al., 2013). These 
adverse effects reduce compliance with medication and the quality of life (Lieberman et al., 
2005; Novick et al., 2010). 
The selective targeting of each D2-like receptor subtypes has been posited to produce fewer 
side effects(Li et al., 2016; Holmes et al., 2004). Among D2-like dopamine receptors, D3DR 
has received increasing pharmacotherapeutic interest in drug abuse disorders treatments 
(Micheli, 2011; Newman, Blaylock, et al., 2012). D3 dopamine receptor has the highest affinity 
for dopamine and displays limited distribution in the mesolimbic system compared to the other 
dopamine receptor subtypes (Keck et al., 2015; Sokoloff & Le Foll, 2017). As such, fewer side 
effects are anticipated to be exerted by pharmacological agents that selectively target D3DR 




receptors may demonstrate efficacy towards a wide range of schizophrenia symptoms with 
fewer side effects (Sokoloff et al., 2006; Girgis et al., 2016). The D3 dopamine receptor has 
been identified to improve some aspects of cognitive, negative (social withdrawal, mutism, and 
blunted effect) and positive (delusions and hallucinations) symptoms of schizophrenia, with 
reduced extrapyramidal side effects (EPS) caused by D2 dopamine receptor blockade 
(Miyamoto et al., 2012).  
Furthermore, the selective antagonism of D3DR has been shown to enhance the stimulant 
behaviour effects of cocaine in mice, which is opposite to the effect produced by selective 
antagonism of D2DR or nonselective D2-like receptor antagonists (Manvich et al., 2019). Also, 
selective antagonist binding at the D3 receptor has been shown to display promising results in 
reducing cocaine, and opioid reward and are highly effective in mitigating relapse to drug-
seeking behaviour in preclinical models (Andreoli et al., 2003; Higley et al., 2011; Galaj et al., 
2015). Extensive medicinal chemistry research efforts had led to the development of D3 
dopamine receptor selective partial agonists and antagonists such as BP 897, NGB 2904, SB 
277,011A and GSK598,809. However, the clinical development of D3DR-selective 
antagonists, including SB-277,011A and GSK598,809 have been halted due to an increase in 
blood pressure in the presence of cocaine in freely moving dog and rat models (Appel et al., 
2015; Appel & Acri, 2017; Appel & Acri, 2018). Presently, there exist no medications 
approved by the FDA for cocaine use disorder treatment. Moreover, currently approved drugs 
for opioid use disorder treatment, including buprenorphine and methadone, are opioid-based 
possessing several drawbacks such as respiratory suppression side effects and abuse liability 
(Jordan, Cao, et al., 2019).  
Shaik and colleagues recently identified a novel highly selective D3DR antagonist as R-VK4-
40 (Shaik et al., 2019), which is an R-enantiomer resolved from the compound (±)VK4-40 
reported earlier by Kumar and colleagues as compound 40 (Kumar et al., 2016). Also, Y-QA31 
is another novel D3DR selective antagonist recently identified to exhibit antipsychotic activity 
in preclinical studies of schizophrenia (Sun et al., 2016). These new D3 dopamine receptor 
antagonists demonstrated higher selectivity (over 180-fold in ligand binding studies) toward 
D3 over the D2 dopamine receptor (Jordan, Humburg, Rice, et al., 2019; Sun et al., 2016) 
(Figure 1). R-VK4-40 decreases oxycodone rewarding effects while augmenting oxycodone 
analgesic effect via the selective inhibition of D3DR (Jordan, Humburg, Rice, et al., 2019; de 
Guglielmo et al., 2020). Contrary to the side effect of  GSK598,809 and SB277011A in 




R-VK4-40 do not exhibit adverse cardiovascular effects when combined with cocaine (Jordan, 
Humburg, Thorndike, et al., 2019). Also, Y-QA31 exhibit antipsychotic effects in cognitive 
dysfunction, negative and positive symptoms without inducing extrapyramidal side effects in 
preclinical models of schizophrenia (Sun et al., 2016).  
However, the structural determinant and atomistic molecular mechanistic by which R-VK4-40 
and Y-QA31 achieved their selectivity at D3DR over D2DR remain uncertain. To address this 
gap, diverse in silico protocols have been utilised in this study to investigate the selective 
binding mechanistic of R-VK4-40 and Y-QA31 D3DR over D2DR. Firstly, molecular docking 
was performed to predict the potential binding modes of R-VK4-40 and Y-QA31 at D2 and D3 
dopamine receptors. Comparative molecular dynamics simulations of the four complexes were 
performed in a lipid bilayer environment and their dynamic properties compared. End-point 
binding free energy estimations were also utilized to assess the differential energetic 
contributions as well as critical residues driving the selectivity of R-VK4-40 and Y-QA31 
towards D3DR. The results presented highlights the structural basis of selectivity and could aid 
in the rational design of novel potential selective inhibitors of D3 dopamine receptor subtype. 
 
 
Figure 1. Chemical structures of R-VK4-40 and Y-QA31 and their binding affinities at D2 




2 Materials and Methods 
2.1 Protein preparation 
The crystallographic structures of the inactive D2 and D3 dopamine receptors were retrieved 
from the Protein Data Bank (RCSB PDB, http://www.rcsb.org/) with entries 6CM4 (Wang et 
al., 2018), and 3PBL (Chien et al., 2010), respectively. The engineered proteins with T4 
lysozyme (T4L) or nano antibody, co-crystallised molecular fragments, and water were deleted 
from the crystallographic structures. The thermostabilising crystallographic mutated residues 
(Ile1223.40A, L3756 37A, and L3796.41A) in D2DR and mutated residue Leu1193.41Trp in D3DR 
were reverted to their respective wild types. The protein structures were further pre-processed 
using the Protein Preparation Wizard module from the Maestro Schrodinger suite (Schrödinger 
Release 2019-4, 2019). The protein preparation involved the addition of hydrogens, assigning 
bond orders, and the removal of water molecules beyond 5 Å of any hetero group. Missing 
loops were also modelled. PROPKA was used to designate the protonation state at a 
physiological pH. The protein was further energy minimised at a 0.50 Å root mean square 
deviation using the OPLS3e force field (Schrödinger Release 2019-4, 2019). 
 
2.2 Ligand preparation 
The 3D structures of R-VK4-40 and Y-QA31 antagonists were retrieved from the PubChem 
database with the PubChem IDs 130431314, and 46195521, respectively. The selected 
antagonists were pre-processed using the LigPrep module of Maestro (Schrödinger Release 
2019-4, 2019) at a pH of 7.0 ± 2 to generate multiple states of possible protonation state, 
stereoisomers, ring conformations, and tautomer. The pre-processed ligands were then energy 
minimised to obtain a reasonable 3D conformation using the OPLS3e force field.  
 
2.3 Molecular Docking  
The Glide ligand docking panel (Friesner et al., 2004) implemented in the 2019 Schrödinger 
software package was utilized to predict the binding modes of R-VK4-40 and Y-QA31 at the 
active site of D3 and D2 dopamine receptors. The dimension of the grid box for the molecular 
docking was defined by the centroid of risperidone and eticlopride at D2DR and D3DR co-
crystallised structures, respectively. An outer receptor grid box of 28 × 28 × 28 Å3 with a default 
inner box size of 10 × 10 × 10 Å3 were assigned for D2DR with an X, Y and Z centre grid of 
9.66, 5.41 and -10.20, respectively. Similarly, an outer receptor grid box of 24 × 24 × 24 Å3 
with a default inner box size of 10 × 10 × 10 Å3 were assigned for D3DR with an X, Y and Z 




in predicting various poses per compound and scored using the extra precision (XP) (Friesner 
et al., 2006). The docked receptor-ligand complexes with the lowest binding energies were 
selected as complex structures for the MD simulation setup and production. To validate the 
molecular docking procedure, risperidone and eticlopride were redocked as a positive control 
at D2DR and D3DR, respectively. The re-docked D2DR-risperidone and D3DR-eticlopride 
mimicked the observed crystallised binding mode (Figure S1). 
 
2.4 D3 and D2 dopamine receptor complexes in lipid bilayer setup 
The docked D2 and D3 dopamine receptor-ligand complexes were embedded in palmitoyl-
oleoylphosphatidyl-choline (POPC) membrane lipid bilayer assembled with the CHARMM-
GUI membrane builder (Wu et al., 2014). Each complex was aligned in a 180 homogeneous 
POPC lipid bilayer using the orientation of proteins membranes (OPM) with a rectangular box 
type (Lomize et al., 2006). TIP3P water molecules and 0.15M KCl were utilised to solvate and 
ionise the oriented systems, respectively. The charmmlipid2amber.py script was further used 
to process the solvated membrane-bound systems by renaming the POPC lipid residues 
according to the Amber Lipid17 force field. Molecular dynamics starting coordinate and 
topology files were generated with tleap module in Amber 18 using lipid17, ff14SB, and TIP3P 
forcefields for the lipid bilayer, protein, and water, respectively.  
 
2.5 Molecular dynamics (MD) simulations 
The unbound and docked D2 and D3 dopamine receptor-ligand complexes embedded in ionised 
solvated lipid bilayer were used as the starting coordinates for the unbiased molecular dynamics 
simulation. The simulations were run using the CUDA version of Particle Mesh Ewald 
Molecular Dynamics (PMEMD) in Amber18 on GPU (Salomon-Ferrer et al., 2013; Le Grand 
et al., 2013). Energy minimisation was performed for each system to relax and remove possible 
steric clashes. An initial 15,000 steps minimisations were performed with a 10.0 kcal/mol/Å2 
constraint on all heavy atoms of the protein and the ligand. The initial minimization consisted 
of 5000 steps of steepest descent and 10000 steps of a conjugate gradient. An additional 10,000 
minimisation steps were performed without any restraints. The simulating systems were 
initially heated using the Langevin thermostat from 0 K to 100 K in isothermal-isochoric 
ensemble (NVT) ensemble with a 10.0 kcal/mol/Å2 harmonic restraints applied on the non-
hydrogen atoms of the protein and lipids for 12.5 ps. The systems were further heated to 310 
K in isothermal–isobaric (NPT) ensemble with anisotropic pressure scaling and pressure 




System equilibration was performed with an initial 5.0 kcal/mol/Å2 harmonic restraint of on 
the protein and ligand. This was further lowered by 1.0 kcal/mol/Å2 in a stepwise manner every 
4 ns for a total of 20 ns at 310 K. An additional 5 ns unrestrained equilibration was performed 
before production. Finally, a duplicate all-atom MD simulation of 600 ns were run for each 
system, with randomized initial velocities were performed. An integration time step of 2 fs was 
set for each system at 310 K, and 1 bar in isothermal–isobaric (NPT) ensemble. The subsequent 
analysis was performed on the system where the final structure showed the utmost 
conformational stability. The trajectory coordinates were saved at every 50 ps intervals for 
subsequent analysis. All hydrogen containing bonds were constraint with the SHAKE 
algorithm(Ryckaert et al., 1977). For each system, the Langevin thermostat with a 1.0 ps-1 
collision frequency, a 12.0 Å electrostatic cut-off, and the Particle Mesh Ewald method applied 
for long-range electrostatic interactions was set. The details of the simulation system 
parameters are shown in Table S1. 
 
2.6 Analysis of MD trajectories 
The simulation trajectories were analysed using the Amber 18 analysis tool CPPTRAJ(Roe & 
Cheatham, 2013). The overall complex root mean square deviation (RMSD) of each simulation 
was calculated. The radius of gyration (Rg) and the solvent-accessible surface area (SASA) 
values within 8 Å the binding site and the entire receptor for each system relative to the initial 
structural configuration were also analysed. The binding site was defined as all amino acid 
residues within 8 Å of the bound antagonist and the unbound binding pocket. The RMSD, 
SASA, and Rg values are expressed as mean ± standard deviation (Mean±SD). Snapshots of 
the complexes, average structures, and distances were also calculated using CPPTRAJ over the 
entire trajectories. Key biologically relevant protein-ligand interactions were generated with 
Discovery studio visualizer (Accelrys, 2013) and the Protein-Ligand Interaction Profiler 
(Salentin et al., 2015). The 3D visualised graphics designs of the protein-ligand interaction 
were done with PyMOL (Schrodinger, 2010) and Chimera (Pettersen et al., 2004). 
 
2.7 Residue indices and numbering in transmembrane (TM) and Extracellular loops 
(ECL)  
To enable comparison of residue among the two dopamine receptors, superscripts have been 
assigned to each residue denoting Ballesteros-Weinstein numbering (Ballesteros & Weinstein, 
1995) for the transmembrane regions and the GPCRdb (Isberg et al., 2016)  numbering for 




each transmembrane residue with an index number corresponding to the position of the residue 
in that transmembrane domain. For example, the conserved Asp residue in TM3 (which is 
Asp1103.32 in D3DR and Asp1143.32 in D2DR) is denoted as Asp3.32 where 3 stands for TM3 
and 32 stands for the position of the Asp residue in TM3.   
 
2.8 Clustering and Principal component analysis (PCA) 
The MD trajectories were subjected to clustering and principal component analysis (PCA) to 
probe the conformational relationships for the individual antagonist complex system. 
Individual frames were superposed to the original frame before the PCA calculations to 
eliminate rotation and displacement of structures. For each system having N atoms, the internal 
trajectory motion can be illustrated as 3 N_3 N of the covariance matrix C, where every column 
includes the cartesian coordinate X of every precise atom at each trajectory frame: 
Cij = < (Xi - < Xi >) (Xj - < Xj >) >                                              1  
The decomposition of the covariance matrix C generates the principal modes as 
C = VɅVT                                                                 2 
where V contains the eigenvector of matrix C and K denotes the eigenvalues of the diagonal 
matrix. In this study, the principal component analysis calculation and clustering analysis were 
calculated with the Amber 18 CPPTRAJ module and the R package Bio3D (Grant et al., 2006). 
The MD trajectories distribution was projected onto the first and second principal components. 
 
2.9 Binding free energy calculations  
The binding free energies were evaluated by the molecular mechanics/generalised Born solvent 
accessible surface area (MM/GBSA)(Miller III et al., 2012) method of Amber 18 to determine 
the interaction energies of R-VK4-40 and Y-QA31 at the D3 and D2 dopamine receptors. 
The ante-MMPBSA.py module (Miller III et al., 2012) of Amber 18 was utilized in generating 
the topologies of the ligands, receptor, and complex to be used in the MM/GBSA calculations. 
The MM/GBSA method estimates the relative binding free energy (∆Gbind) via the following 
equation: 
∆G𝑏𝑖𝑛𝑑 = ∆E𝑀𝑀 + ∆G𝑠𝑜𝑙 − T∆S                                                           3 
                              ∆E𝑀𝑀 = ∆E𝑣𝑑𝑤 + ∆E𝑒𝑙𝑒                                                                  4 
∆G𝑠𝑜𝑙 = ∆G𝑝𝑜𝑙 + ∆G𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟                                                             5 
Where, ∆EMM and ∆Gsol denote the molecular mechanics interaction energy and the solvation 




Waals (∆E𝑣𝑑𝑤) interaction energy and the electrostatic (∆E𝑒𝑙𝑒) interaction energy constitute the 
molecular mechanics interaction energy (∆E𝑀𝑀) between the receptor and ligand. The 
contribution of the solvation free energy is further decomposed into the polar (∆G𝑝𝑜𝑙) and the 
non-polar (∆G𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟) terms. 
In this study, the generalised Born approach was used with an implicit generalised Born solvent 
model and 0.15 M ionic strength. For each complex system, 2000 snapshots were extracted 
from the last 400ns trajectories at an interval of 200 ps. The entropy contribution was estimated 
using the normal mode harmonic approximation method. The decomposition of the pairwise 
interaction energies into active site residue contribution was also computed.  
 
3 Results  
3.1 Sequence and structural similarities between D2 and D3 dopamine receptors 
Pairwise sequence alignment of D2 and D3 dopamine receptor was performed to identify the 
level of conservations in the amino acid sequence of the transmembrane helices (TM1-TM7), 
extracellular loops (ECL1-ECL3), and intracellular loops (ICL1-ICL3) (Figure 2). The amino 
acid sequence analysis reveals that the transmembrane domains TM2-TM7 are mainly 
conserved compared to the TM1 domain. The extracellular half of TM1 (1.35 to 1.50) between 
D2DR and D3DR contains 44% non-conserved residues (Figure 2). A substantial diversity in 
amino acids was also observed in the extracellular loop regions. Although the design of D3/D2 
selective compounds has being a challenge; however, the observed differences between D3 and 







Figure 2 Comparison of amino acid sequences of D2 and D3 dopamine receptors showing 
conservation of residues and motifs. The black box markings on TM3, TM6 and TM7 
highlights the conserved Class-A GPCR motifs DRY, CWXP and NPXXY, respectively. The 
transmembrane sections indexing is based on the Ballesteros & Weinstein system (Ballesteros 
& Weinstein, 1995). PRALINE multiple sequence analyser was used to construct the sequence 
alignment (Simossis & Heringa, 2005; Simossis & Heringa, 2003) (Image prepared by author).  
 
3.2 Differential binding modes of R-VK4-40 and Y-QA31 to D2 and D3 dopamine 
receptors. 
The potential complex structures of D2DR/R-VK4-40, D2DR/Y-QA31, D3DR/R-VK4-40, 
and D3DR/Y-QA31 used in this study were predicted with the Glide extra precision (XP) 
docking protocol. The crystallographic structures of D2DR bound with risperidone (6CM4) 
and D3DR in complex with eticlopride (3PBL) were used to predict the potential binding mode 
of R-VK4-40 and Y-QA31. To validate the predictive accuracy of the of Glide XP docking 
scoring, the co-crystallised inhibitors were extracted and re-docked into their respective 
receptors. The predicted binding poses and the experimental binding conformation overlaps in 
the same binding site (Figure S1). The interaction mode of R-VK4-40 and Y-QA31 with best-
ranked conformers and lowest binding free energy score at D2DR and D3DR were selected for 
MD simulations. The predicted binding poses between the antagonists (R-VK4-40 and Y-




mode of R-VK4-40 and Y-QA31 at D2DR, the indole moiety and the 1-(2-
methoxyphenyl)piperazinyl moiety, respectively extend deeper into the orthosteric binding 
pocket (OBP) of D2DR defined by TM3, TM5 and TM6 side chains. In contrast, R-VK4-40 




Figure 3 Intermolecular interactions for D2DR/R-VK4-40 (A), D3DR/R-VK4-40 (B), 
D2DR/Y-QA31 (C), and D3DR/Y-QA31 (D) from molecular docking. Hydrogen bonds, π-π 
stacking, hydrophobic and salt-bridge interactions are depicted in blue, magenta, orange, and 
red, respectively. Hydrogen bond distances are displayed in Angstrom (Å) (Image prepared by 
author).   
 
3.3 Conformational dynamics of D2 and D3 dopamine receptors upon antagonist binding. 
Molecular simulations in the past decades have enabled the detailed structural configurations 
and interactions of macromolecules with other molecular species to be characterised in 




simulations were performed for each D3 and D2 dopamine receptor complexes and apo systems 
to investigate the detailed binding process and to access their dynamic structural characteristics. 
The dynamic stability, structural properties, as well as the energetics for all the complex 
systems, were assessed to obtain insights into the detailed structures of conformational change 
in each studied system.  
 
3.4 Interaction energy components clarify selective binding potency at D3DR over 
D2DR. 
The relative binding free energies were evaluated for the four complexes by the MM/GBSA 
approach and were decomposed into various energy contribution terms (solvation energies, 
gas-phase energies, and entropic contribution). Computing the binding free energy was to 
evaluate inhibitor binding selectivity towards D2DR and D3DR. The MM/GBSA method can 
provide a high correlation with experimental values and good ranking of protein-ligand 
complexes (Genheden & Ryde, 2015; Sun et al., 2018). Table 1 shows the estimated binding 
free energies (∆Gbind) by MM/GBSA from the MD trajectories, and the experimental binding 
energy (ΔGexp) obtained from the experimental inhibition constants (Ki) in Figure 1 (Sun et al., 
2016; Jordan, Humburg, Rice, et al., 2019). The experimental binding energies (ΔGexp) were 
calculated from the experimental inhibition constant (Ki) using the formula: 
ΔG(inhibition) = RTlnKi, where T is the temperature (298.15 K), and R is the universal gas 
constant (1.985 × 10−3 kcal/mol/K). The predicted MM/GBSA binding affinities for R-VK4-
40 and Y-QA31 at D3DR were -23.62 ± 1.37 kcal/mol and -24.65 ± 0.93 kcal/mol, whereas 
that of R-VK4-40 and Y-QA31 at D2DR were -11.05 ± 0.58 kcal/mol and -10.01 ± 1.36 
kcal/mol, respectively. Similarly, the experimental binding free energy (ΔGexp) calculated for 
R-VK4-40 and Y-QA31 at D3DR were -12.99 kcal/mol and -13.02 kcal/mol, whereas that of 
R-VK4-40 and Y-QA31 at D2DR were -9.70 kcal/mol and -9.93 kcal/mol, respectively. The 
above obtained quantitative theoretical and experimental binding free energies indicate that R-










Table 1 Individual energy component contribution to the overall binding free energy 
(kcal/mol) estimation using the MM-GBSA approach for D2DR and D3DR complexes.  
Energetic 
Terms 
       R-VK4-40         Y-QA31 
       D2DR                    D3DR       D2DR                   D3DR 
ΔGvdW -46.61 ± 0.06 -54.65 ± 0.08 -47.06 ± 0.10 -57.71 ± 0.08 
ΔGelec -13.29 ± 0.08 -20.40 ± 0.19 -8.24 ± 0.17 -11.96 ± 0.11 
ΔGpolar 30.25 ± 0.06 37.24 ± 0.14 24.89 ± 0.13 31.35 ± 0.08 
ΔGnonpolar -5.80 ± 0.01 -6.78 ± 0.01 -5.70 ± 0.01 -7.42 ± 0.01 
ΔGMM -59.90 ± 0.10 -75.05 ± 0.23 -55.30 ± 0.22 -69.67 ± 0.13 
ΔGsol  24.46 ± 0.06 30.46 ± 0.14 19.19 ± 0.12 23.93 ± 0.08 
ΔH -35.44 ± 0.08 -44.58 ± 0.15 -36.11 ± 0.14 -45.74 ± 0.10 
-ΔTS     24.39 ± 0.66     20.96 ± 1.52     26.10 ± 1.50    21.09 ± 1.03  
ΔGbind     -11.05 ± 0.58     -23.62 ± 1.37      -10.01 ± 1.36 -24.65 ± 0.93    
aΔGexp          -9.70          -12.99          -9.93         -13.02 
ΔGvdW = van der Waals energy; ΔGelec = Electrostatic energy; ΔGMM = molecular mechanics 
energy; ΔGsol = solvation energy contribution; ΔGnonpolar = Nonpolar solvation energy;  
ΔGpolar = Polar solvation energy; -ΔTS = Entropy contribution; ΔGbind = Binding free energy. 
 aΔGexp = The calculated experimental binding free energy (ΔG) obtained from the 
experimental inhibition constant (Ki) in Figure 1 using the formula: ΔG(inhibition) = RTlnKi, 
where T is the temperature (298.15 K), and R is the universal gas constant (1.985 × 10−3 
kcal/mol/K). 
 
From the analyses, van der Waals energy and electrostatic energy were observed to be the 
significant contributors to the overall binding of the antagonists. In the interactions of 
compounds R-VK4-40 and Y-QA31 with D2DR, the electrostatic (-13.29 and -8.24 kcal/mol, 
respectively) and the van der Waals (-46.61 and -47.06 kcal/mol, respectively) energy values 
suggest that van der Waals interactions (hydrophobic interactions) were the dominant binding 
forces of D2DR with its antagonists. Similarly, in the interactions of R-VK4-40 and Y-QA31 
with D3DR, electrostatic (-20.40 and -11.96 kcal/mol, respectively) and van der Waals 
interactions (-54.65 and -57.71 kcal/mol, respectively) also made favourable interactions with 
D3DR binding site residues. Thus, van der Waals interaction of R-VK4-40 and Y-QA31 were 
more dominant at D3DR than at D2DR. For all the ligand-receptor complexes, unfavourable 
polar solvation energy opposed the favourable electrostatic energies in the gas phase. 
Furthermore, conformational entropy (-ΔTS) contribution was observed to be relatively more 
unfavourable for inhibitor binding at D2DR than at D3DR. As highlighted in the above 
descriptions, the increase in binding enthalpy with the corresponding decrease in entropy of R-
VK4-40 and Y-QA31 at D3DR relative to D2DR seems to mainly drive the selective binding 
of these antagonists toward D3DR over D2DR. Thus, optimising the binding enthalpy of 






3.5 Inhibitor−residue interaction network reveals the basis of antagonist selectivity  
To uncover the atomistic interaction mechanistic of the antagonist selectivity and specificity at 
D3DR over D2DR, we investigated receptor residues that significantly interacted with the 
studied antagonists. The decomposition of the predicted binding affinities per active site 
residues was analysed to obtain further insight into the patterns of receptor-antagonist 
recognition and the distributions of the energy by active site residues. The residues with 
substantial energy contributions to antagonist binding are presented in Figure 4.  
 
3.5.1 Binding of R-VK4-40 to D3DR versus D2DR. As shown in Figure 4A, R-VK4-40 made 
favourable interactions greater than −0.6 kcal/mol with ten residues in D2DR. These are 
Val1153.33 (-1.43), Ile18445.52 (-0.67), Asn1865.35 (-0.64), Pro1875.36 (-2.53) Phe1895 38 (-1.93), 
Val1905.39 (-2.63), Ser1935.42 (-1.70), Phe3896.51 (-1.06), His3936.55 (-0.77), and Ile3976.59 (-
1.95). The interaction energies of Phe1895.38, Phe3896.51 and His3936 55 agree structurally with 
the π-π stacking interactions with the indole ring and the CH-π contacts of the alkyls of 
Val1905.39, Pro1875.36 and Ile3976.59 with the chloro-ethylbenzene ring of R-VK4-40 (Figure 
S2). The indole group also engaged in a π-sulphur and π-alkyl interaction with Cys1183.36 and 
Val1153.33, respectively. It is worth remarking that R-VK4-40 engages in three hydrogen bond 
interactions with D2DR, such as Ser1935.42, Ile18445.52 and His3936.55 (Figure S2). The 
hydrogen bond of Ser1935.42 is with the indole nitrogen, Ile18445.52 with the hydroxy group in 
the N-((S)-3-hydroxypentyl)acetamide linker, while His3936.55 with the oxygen atom in the 
acetamide unit (Figure S2).  
Compared to the D2DR/R-VK4-40 complex, the binding interactions of R-VK4-40 with D3DR 
are relatively different (Figure 4B and Figure S3). The interaction energies of R-VK4-40 with 
ten residues in D3DR are observed to have energy values stronger than −0.6 kcal/mol (Figure 
4B). These include Val1113.33 (-2.47), Cys1143.36 (-0.71), Thr1153.37 (-0.80), Ser18245.51 (-
1.11), Ile18345.52 (-1.50), Val1895.39 (-0.85), Phe3456.51 (-1.00), His3496.55 (-0.90), Tyr3657.35 
(-0.82) and Thr3697.39 (-1.19). The 1-(2-chloro-3-ethylphenyl)piperazinyl moiety engaged in 
π-π interactions with Phe1975.47, and Tyr3657.35, as well as π-alkyl interactions with Val1113.33, 
His3496.55, Ile18345.52, and Phe3456.51 (Figure S3). Additionally, π-sulphur interaction is 
observed with Cys1143.36 and the 1-(2-chloro-3-ethylphenyl)piperazinyl moiety. R-VK4-40 
forms a salt bridge interaction between the linker hydroxy and Asp1103.32. A hydrogen bond is 
also observed between the indole nitrogen and Ser3667.36. Additional hydrogen bonds are 
further formed between the carboxamide and Thr3697.39, and Tyr3657.35, whereas the hydroxy 




The binding of R-VK4-40 at D2DR made substantially distinct interactions with residues 
mainly in the TM5 and TM6 domains. In contrast, R-VK4-40 made significant interactions 
with residues in the TM3 and TM7 domains of D3DR. However, a few common interactions 
are observed for residues such as Val3.33, Ile45.52, Phe6.51 and His6.55 in both receptors, which 
cumulatively displayed higher inhibitor interactions at D3DR over D2DR.   
 
3.5.2 Binding of Y-QA31 to D3DR versus D2DR.  As observed in Figure 4C and Figure S4, 
Y-QA31 made favourable interactions with energy values stronger than -0.6 kcal/mol with 
eight residues in D2DR. These residues include Ile18445.52 (-0.82), Val1905.39 (-1.35), 
Ser1935.42 (-1.33), Ser1945.43 (-1.66), Phe1985.47 (-1.08), Phe3896.51 (-1.54), Phe3906.52 (-0.66) 
and His3936.55 (-0.65) (Figure 4C). The deep binding pocket residues Phe1985.47, Trp3866.48 
and Phe3896.51 structurally make π-π stacking interactions with the 1-(2-
methoxyphenyl)piperazinyl moiety of Y-QA31. Ile18445.52 engages in both hydrogen bond and 
π-alkyl interactions with the carboxamide nitrogen and benzo[d]thiazol-2(3H)-one, 
respectively (Figure S4). Additionally, the oxygen and the nitrogen atom of the 
benzo[d]thiazol-2(3H)-one moiety formed hydrogen bonds with Tyr371.35 and Thr4127.39, 
respectively. It is also noted that the benzo[d]thiazol-2(3H)-one moiety and the carboxamide 
oxygen engaged in π-π stacking and hydrogen bond interactions with Tyr4087.35, respectively. 





Figure 4 The interaction energy spectrum of the two antagonists with key active site residues 
in D2DR and D3DR. (A) D2DR/R-VK4-40 complex, (B) D3DR/R-VK4-40 complex, (C) 
D2DR/Y-QA31 complex, and (D) D3DR/Y-QA31complex systems (Image prepared by 
author).  
 
On the other hand, the binding interactions of Y-QA31 with D3DR are quite dissimilar to 
D2DR. It is observed that Y-QA31 made favourable interactions with 15 residues in D3DR 
with energy values stronger than -0.6 kcal/mol (Figure 4D). These critical residues are Tyr361.39 
(-0.64), Val862.61 (-1.60), Leu892.64 (-0.70), Phe1063.28 (-1.15), Val1073.29 (-1.28), Val1113.33 (-
2.83), Cys18145.50 (-0.71), Ser18245.51 (-0.85), Ile18345.52 (-1.27), Val1895 39 (-1.22), Ser1935.43 
(-1.20), His3496.55 (-1.07), Tyr3657.35 (-0.94), Ser3667.36 (-0.61) and Thr3697.39 (-1.35). The 
interaction energies are structurally consistent with the π−π interactions of Phe1063.28, and 
Tyr3657.35 with the benzo[d]thiazol-2(3H)-one group as well as the π-alkyl interactions of 
Val862.61 Val1113.33 Ile18345.52 Val1895.39 and His3496.55 with the benzo[d]thiazol-2(3H)-one 
and 1-(2-methoxyphenyl)piperazinyl moieties (Figure S5). Additionally, 1-(2-
methoxyphenyl)piperazinyl group further engaged in a π-sulphur and π-π interactions with 
Cys1143.36 and Phe3466.52, respectively. It is worth highlighting that Y-QA31 interacts with six 




Tyr3737.43, and His3496.55 (Figure S5). The oxygen and the nitrogen atom in the 
benzo[d]thiazol-2(3H)-one moiety constantly engaged in hydrogen bonding with Tyr361.39 and 
Tyr3737.43, respectively. Additionally, Ser3667.36 and Thr3697.39 made hydrogen bond contacts 
with the benzo[d]thiazol-2(3H)-one moiety (Figure S5). The carboxamide nitrogen was 
observed to make constant salt bridge interactions with Asp1103.32, which is critical for high-
affinity inhibitor binding of aminergic GPCRs. The binding of Y-QA31 at D2DR engaged in 
more interactions with residues, mainly in the TM5 and TM6 domains. In contrast, Y-QA31 
made significant interactions with residues in the TM3, ECL2, and TM7 domains of D3DR. 
However, a few common interactions were observed for residues such as Val5.39, Ser5.43, and 
His6.55 in both receptors.   
 
3.6 Conformational analyses upon ligand binding  
The Cα root mean square deviation (RMSD) values were calculated from initial structures to 
access the dynamic stability and convergence of the MD simulations for the unbound and 
bound systems. The RMSD of the Cα atoms of the apo and ligand-receptor complexes for each 
system conducted in duplicate runs is shown in Figure S6 and Table S2. Convergence were 
generally observed after 250 ns of the simulation with average RMSDs less than 3.0 Å.    
The radius of gyration (RoG) was computed to obtain a local (binding site residues within 8 Å 
of the inhibitor) and global assessment of the distribution of the receptor compactness. The 
radius of gyration of the receptor-ligand complex is a measure of how compact a protein is 
upon ligand binding (lower Rg values represent higher protein compactness) (Tanwar et al., 
2017). The analysis of the simulated systems showed lower average binding pocket RoG values 
of 5.98 ± 0.39 Å and 5.58 ± 0.37 Å for R-VK4-40 and Y-QA31 binding at D3DR compared 
with the observed 10.52 ± 0.10 Å, and 10.72 ± 0.14 Å for R-VK4-40 and Y-QA31 binding at 
D2DR, respectively The unbound binding pocket RoG were relatively higher than the bound 
conformation with values of  12.77 ± 0.17 Å and 12.42 ± 0.17 Å for D2DR and D3DR, 
respectively (Figure 5A and Table S2). The binding pockets of the systems showed distinct 
compactness compared to the entire bound and unbound systems (Figure 5C and Table S2). 
The predicted results suggest that R-VK4-40 and Y-QA31 induced a much compact binding 
pocket when bound to D3DR than when bound D2DR. The comparative analyses suggest a 
wider configurational binding site cavity conformation at D2DR, resulting in weaker binding 






Figure 5 The radius of gyration of the binding pocket (A) and entire system (C);  and the 
solvent accessible surface area of the binding pocket (B) and the entire system (D) for D2DR 
and D3DR as a function of simulation time (Image prepared by author). 
 
The accessibility of the binding site cavity to the solvent upon antagonist binding was further 
analysed. In general, decreasing SASA value corresponds to increasing hydrophobic 
interactions. The trend of solvent accessible surface area (SASA) profiles was similar to the 
Rg profiles. The average D2DR binding pocket SASA values for R-VK4-40 and Y-QA31 
complex were 2090.52 ± 143.14 Å2, 2166.47 ± 157.98 Å2, respectively; however, a 
significantly lower average SASA value of 153.63 ± 35.46 Å2, 94.15 ± 35.65 Å2 was observed 
for R-VK4-40 and Y-QA31 respectively at D3DR binding site. The average SASA values for 
the unbound D2DR and D3DR binding pocket were 3699.43 ± 166.47 Å2 and 3439.40 ± 152.35 
Å2, respectively, which were higher than the bound systems (Figure 5B and Table S2). Thus, 
R-VK4-40 and Y-QA31 engage in stronger nonpolar interactions with D3DR hydrophobic 
binding site residues compared with D2DR binding pocket. However, the difference in the 
computed average SASA values for the entire receptor in the bound and unbound 
conformations (Figure 5D and Table S3) were not highly significant as the binding pocket.   
 
3.7 Conformational clustering and principal component analysis (PCA) 
Principal component analysis (PCA) was performed to understand the dynamic behaviour of 
the receptors when inhibited by the selected antagonists. PCA captured the dominant motion 




covariance matrix were used to describe the overall coordinated movement of the Cα atoms, 
which relates to the coincident eigenvalues.  
In R-VK4-40 binding at D2DR and D3DR, the top 20 principal components (PCs) accounted 
for 82.3% and 74.9% of the total variance in the MD simulation, respectively. The contribution 
of the first two PCs to the total variance in D2DR/R-VK4-40 complex were 37.5% and 10.7%, 
respectively, whereas in D3DR/R-VK4-40 complex they accounted for 26.4% and 8.8%, 
respectively (Figure 6B and 6D). Similarly, the top 20 PCs for the Y-QA31 binding at D2DR 
and D3DR accounted for 81.8% and 74.4% of the total covariance, respectively (Figure 7B and 
7D). The contribution of PC1 and PC2 for D2DR/Y-QA31 complex were 32.8% and 9.9%, 
respectively, whereas accounting for 21.9% and 12.9%, respectively in D3DR/Y-QA31 
complex. Thus, the selective binding of R-VK4-40 and Y-QA31 at D3 dopamine receptor is 
associated with a relatively lower proportion of variance compared to their binding at the D2 
dopamine receptor. 
 
Figure 6 The projections of trajectories onto the first two principal components subspace and 
proportion of variance for D2DR/R-VK4-40 complex (A and B) and D3DR/R-VK4-40 




The overall contributions of the Cα atomic fluctuations variance relative to the first, second 
and the remaining PCs are summarised in Table S4. Hence, the first two PCs (PC1 and PC2) 
were sufficient in providing a valuable description of the significant fluctuations in the 
conformational ensembles. The conformational transitions of the studied systems were 
analysed based on the first and second PCs in two-dimensional subspace (Figure 6A and 6C; 
Figure 7A and 7C). The continuous transition of colour, which changed from red to white to 
blue, indicate periodic transitions between these conformations. Two distinct conformational 
regions were sequentially explored by D2DR/R-VK4-40 which displayed distinct periodic 
jumps with a substantial energy barrier while D3DR/R-VK4-40 complex showed an 
overlapping and uniform exploring of conformational subspace with minimal energy barrier 
(Figure 6). Similarly, two main conformational subspaces were visited by D2DR/Y-QA31 and 
D3DR/Y-QA31complexes, however wider displacement were observed along PC1 for 
D2DR/Y-QA31 compared to D3DR/Y-QA31complex (Figure 7). The wide displacement is an 
indicative of large conformational space explored by D2DR/Y-QA31. Thus, the studied D3 
selective antagonists displayed large conformational changes mainly along PC1 at D2DR than 






Figure 7 The projections of trajectories onto the first two principal components subspace and 
proportion of variance for D2DR/Y-QA31 complex (A and B) and D3DR/Y-QA31complex (C 
and D) (Image prepared by author).  
 
4 Discussion 
Drug binding selectivity and action are crucial in drug development that targets receptor 
subtypes. The availability of crystal structures provides an opportunity to identify structural 
differences at the atomistic molecular level between closely related GPCRs that can be 
exploited for novel drug design (Chien et al., 2010; Wang et al., 2018; Fan et al., 2020). 
However, the structural determining factors of inhibitor binding specificity at the D3 and D2 
dopamine receptors are highly subtle due to the nearly identical binding pocket residues. The 
discovery of selective and potent D2-like receptor inhibitors holds promise in the development 
of next-generation antipsychotic drugs in the treatment of neurological disorders (Holmes et 
al., 2004; Heidbreder & Newman, 2010; Xiao et al., 2014; Moritz et al., 2018). Herein, we 




structural basis and atomistic binding mechanistic of two selective D3 antagonists at D3 over 
D2 dopamine receptors.   
The structural and physical properties of ligand binding pockets are closely associated with the 
ligand-binding affinities (Li et al., 2015; Smith et al., 2012). Bitopic antagonists are depicted 
by two pharmacophores, a primary and secondary pharmacophore connected through a linker. 
According to a previous study, the antagonistic activities of these compounds is more 
pronounced against D3 dopamine receptor relative to D2 dopamine receptor (Chien et al., 2010). 
The crystal structure of D3DR revealed an extended binding pocket (EBP) above the 
orthosteric binding pocket (OBP), where one of the bitopic pharmacophores interacts with 
TM2, TM3 and TM7 (Chien et al., 2010). In the predicted binding modes of R-VK4-40 and Y-
QA31, the indole moiety and the 1-(2-methoxyphenyl)piperazinyl moiety of R-VK4-40 and Y-
QA31 extended deep into the OBP of D2DR defined by TM6, TM5 and TM3 side chains, 
respectively. 
On the other hand, the interaction patterns of R-VK4-40 and Y-QA31 extend higher above the 
OBP into the EBP, adopting a shallow binding mode at D3DR, making significant interactions 
with residues in the TM3 and TM7 domains. Newman and colleagues studied a series of D3DR 
bitopic selective 4-phenylpiperazine-substituted compounds. They found that the efficacy of 
these compounds depends on their binding mode in the OBP, whereas selectivity arises from 
their different interactions within the SBP (Newman, Beuming, et al., 2012). The longer linker 
between the binding moieties of R-VK4-40 and Y-QA31 enabled their binding at both the EBP 
and the OBP of D3DR (Heidbreder & Newman, 2010). The favourable flexibility of bitopic 
compounds seems to be conferred by the tetramethylene linker resulting in higher 
D3DR/D2DR selectivity (Newman, Beuming, et al., 2012). 
Identifying the differences in the binding pocket dynamics of closely related receptor subtypes 
provides information that may assist in the design of subtype selective ligands (Latorraca et al., 
2017). We further investigated the antagonist effect on the conformational dynamics 
(compactness and solvent accessibility) of D2DR and D3DR binding/active sites. These 
provide information on how the different inhibitors perturb the intrinsic dynamics of the 
binding site of the antagonist-bound complexes. The interactions of R-VK4-40 and Y-QA31 
at D3 dopamine receptor binding site is significantly associated with a lower average SASA 
and Rg values than at D2DR binding site. The radii of gyration within the binding pockets of 
D3DR reveals a more compact binding site with less accessibility to solvent compared to 
D2DR binding site. The observed binding sites conformational dynamics suggests that the 




with increased hydrophobic interactions compared to D2DR. This conformational change in 
D3DR binding site may result in the more potent inhibitor binding mode with a higher binding 
affinity. The relatively high hydrophobic interactions exhibited by R-VK4-40 and Y-QA31 at 
D3DR are consistent with an earlier report that hydrophobic interactions, particularly with TM7 
are significantly involved in the binding of D3DR selective bitopic compounds at the EBP of 
D3DR (Newman, Beuming, et al., 2012).  
The calculated binding free energies successfully predicted the higher binding affinities of R-
VK4-40 and Y-QA31 at D3 dopamine receptor over the D2  dopamine receptor. It is worth 
noting that, the selectivity of R-VK4-40 and Y-QA31 at D3DR over D2DR is principally 
contributed by the van der Waals interactions, enthalpic and entropic energy contribution 
difference. The selective binding of the selective antagonists (R-VK4-40 and Y-QA31) at 
D3DR showed higher enthalpic interaction energy contribution while inducing a relatively 
favourable entropic contribution to their total binding free energies when compared to their 
binding at D2DR. Generally, the entropy change upon ligand binding may arise from an 
alteration of the conformational flexibility of the binding associates, a decrease in the rotational 
and translational degrees of freedom, as well as from the restructuring of their solvation shells 
upon binding (Bezerra et al., 2012). Desolvation effects are usually considered to drive a 
favourable entropic contribution to the total binding free energy as the burial of hydrophobic 
surfaces results in the displacement of binding site water molecules into the bulk solvent 
(Bezerra et al., 2012). The relatively high hydrophobic interactions (lower binding pocket 
solvent accessible surface area) displayed by R-VK4-40 and Y-QA31 at D3DR compared to 
D2DR may explain their relatively favourable entropic contribution. Also, Yildirim and 
Colleagues found that an increase in the conformational entropy upon ligand (pollutant) 
binding was associated with TPK biomolecules undergoing large conformational changes 
(Yildirim et al., 2016). The clustering and principal component analyses indicate that the 
selective binding of R-VK4-40 and Y-QA31 at D2DR is associated with a higher proportion 
of variance and more substantial conformational changes along PC1 relative to D3DR. The 
increase in conformational change at D2DR from PCA is observed to correlate with the relative 
increase in conformational entropy at D2DR. 
The presence of water molecules in a hydrophobic enclosed pocket is less stable than the bulk 
water molecules due to less favourable enthalpy and/or entropy, and the ability of a ligand to 
displace these high-energy waters has been shown to affect selectivity (Beuming et al., 2009) 
and improve binding affinity (Higgs et al., 2010). In a WaterMap analysis to characterise the 




high-energy water molecules were continuously positioned in the EBP of both D2DR and 
D3DR. In contrast, less high-energy waters were found at the TM1, TM2 and TM7 interface 
(Newman, Beuming, et al., 2012). The authors observed that the indole moiety of the D3DR-
selective bitopic ligand (Compound 2) occupied the EBP region where several high-energy 
water molecules were displaced, which was consistent with compound’s higher affinity for 
D3DR over D2DR (Newman, Beuming, et al., 2012).  
The binding of R-VK4-40 and Y-QA31 made salt bridge interaction with the conserved 
Asp1103.32, which is critical for inhibitors displaying high affinity to GPCR aminergic 
subfamily (Shi & Javitch, 2002). The ECL2 has been posited to be important in the selective 
targeting between D3 and D2 dopamine receptors since it is highly non-conserved (Heidbreder 
& Newman, 2010). Three critical ECL2 residues (Cys18145.50, Ser18245.51, and Ile18345.52) of 
D3 receptor were observed to make significant interactions with Y-QA31. Similarly, two ECL2 
residues (Ser182 and Ile183) of D3 dopamine receptor were also found to make critical 
interactions with R-VK4-40. The critical D3DR residue (Ser18245.51) is non-conserved at 
D2DR (Ile182
45.51). Thus, Ser18245.51 of the ECL2 region of D3 dopamine receptor is a possible 
critical residue involved in the D3/D2 subtype selectivity of the studied antagonists. Feng and 
colleagues found Cys18145.50 and Ser18245.51 of the ECL2 of D3DR to make important 
interaction with the D3 selective antagonist R-22 (Feng et al., 2012). The non-conserved residue 
Tyr361.39 of D3DR, which corresponds to Leu411.39 in D2DR formed a critical hydrogen bond 
and made more substantial interaction energy with Y-QA31 at D3DR which were not observed 
at D2DR. The findings highlight the essential differences in the interactions of R-VK4-40 and 
Y-QA31 at the binding pocket of D3DR and D2DR.  
 
5 Conclusion 
This study aimed at probing the molecular mechanistic underlying the selective binding of two 
antagonists (R-VK4-40 and Y-QA31) toward D3DR over D2DR using conventional molecular 
dynamics simulations in a POPC lipid bilayer environment. The results highlighted in this 
study show how R-VK4-40 and Y-QA31 achieve selective interaction at D3 dopamine receptor 
over D2 dopamine receptor. The results reveal that conformational alterations in D2DR were 
more prominent compared to D3DR. The dynamic binding mode and the per-residue energy 
decomposition enabled the identification of residues responsible for the differential binding 
affinities at D2DR and D3DR. The estimated binding free energies not only corroborated with 
the experimental binding affinities but also indicate that an increase in van der Waals 




high-selectivity and affinity of the antagonists for D3DR relative to D2DR. We expect that our 
study may assist in gaining further insight into the selective mechanistic of D3DR antagonists 
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Figure S1 Redocking of Risperidone and Eticlopride at D2 dopamine receptor (A) and D3 
dopamine receptor (B), respectively. Crystallographic and redocked ligand binding 








Figure S2 Representative binding mode and binding interaction of R-VK4-40 at D2DR 















Figure S3 Representative binding mode and binding interaction of R-VK4-40 at D3DR 






Figure S4 Representative binding mode and binding interaction of Y-QA31 at D2DR extracted 












Figure S5 Representative binding mode and binding interaction of Y-QA31 at D3DR extracted 









Figure S6 The Root-mean-square deviation (RMSD) of Cα atoms plots of duplicate 600 ns 
simulation for D2DR unbound (A), D2DR/R-VK4-40 bound (B), D2DR/Y-QA31 bound (C), 
D3DR unbound (D), D3DR/R-VK4-40 bound (E), and D3DR/Y-QA31(F) as a function of 600 
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Introduction: Blocking Human Immunodeficiency Virus type 1 (HIV-1) entry via C-C 
chemokine receptor 5 (CCR5) inhibition has remained an essential strategy in HIV drug 
discovery. This underlies the development of CCR5 blockers, such as Maraviroc, which, 
however, elicits undesirable side effects despite its potency.  
Background: Recent lead optimization efforts led to the discovery of novel 1-heteroaryl-1,3-
propanediamine derivatives; Compd-21 and -34, which were ~3 times more potent than 
Maraviroc, with improved pharmacokinetics. However, atomistic molecular interaction 
mechanism of how slight structural variance between these inhibitors significantly affects their 
binding profiles have not been elucidated.  
Method: This study employed explicit lipid bilayer molecular dynamics (MD) simulations, 
and advance analyses to explore these inhibitory discrepancies.  
Results: Findings revealed that the thiophene moiety substitution common to Compd-21 and -
34 enhanced their CCR5-inhibitory activities due to complementary high-affinity interactions 
with Trp862.60, Tyr1083.32, Tyr2516.51, Glu2837.39. These cumulatively accounted for their 
ΔGbind, which were higher than Maraviroc. Binding dynamics further revealed that the 
compounds mediated direct competitive inhibition at CCR5 by blocking the gp120 V3 loop. 
Furthermore, constituent tropane and triazole moieties in the compounds commonly engaged 
in interactions with Glu2837.39 and Trp862.60, respectively. Structural analyses also revealed 
that both Compd-21 and -34 elicited distinct internal dynamic effect on CCR5 relative to 
Maraviroc.   
Conclusion: Structural modifications at the thiophene substituent and the addition of new 
functional groups to the triazole ring may enhance inhibitor competition with gp120 V3-loop. 
Findings herein highlighted would contribute to future structure-based design of inhibitors of 
HIV-1 CCR5 with improved potencies. 
Keywords: G protein-coupled receptor, HIV-1, Maraviroc, lipid bilayer, C-C chemokine 









1. Introduction  
Human immunodeficiency virus type 1 (HIV-1) continues to threaten the quality of life, being 
the causal agent of acquired immunodeficiency syndrome (AIDS). Despite the progress made 
in the prevention of the HIV/AIDS epidemic evidenced by the development of various 
treatment strategies, the disease remains a global health threat.  Different drugs and inhibitors 
have been developed over the past years toward the inhibition of  HIV-1 via viral proteins 
targeting such as gp41, gp120, integrase, protease, and reverse transcriptase (Dyda et al., 1994; 
Huff, 1991; Kohlstaedt et al., 1992). However, there is the need for the development of novel 
HIV treatment drugs due to incidences of drug resistance easily triggered by mutations in these 
targets (Wensing et al., 2019).   
G protein-coupled receptors (GPCRs) represent critical therapeutic intervention targets 
towards the development of new drugs due to their varied functions in many various cell 
responses (Rosenbaum et al., 2009). C-C chemokine receptor 5 (CCR5) is a member of the 
GPCRs family involved in immune function regulation (Flanagan, 2014; Sorce et al., 2011; 
Oppermann, 2004). In 1996, the chemokine receptors CXCR4 and CCR5 were found to be co-
receptors for HIV-1 (Berger et al., 1999). HIV-1 envelope protein (Env) is made up of the 
gp160 trimeric (gp160)3, which cleaves with three fragments of gp41 (fusion) and gp120 
(receptor binding). The fusing of HIV-1 Env with viral and cell membrane enables host cells 
entry by the virus (Harrison, 2008). gp120 sequentially binds to its primary receptor CD4 and 
a co-receptor, thereby inducing conformational changes that result in gp120 dissociation and 
gp41 refolding (Harrison, 2008).  
CCR5 represents the major HIV-1 co-receptor during entry into CD4+ T-cells (Berger et al., 
1999). This significant role played by CCR5 in HIV-1 infection was defined when a naturally 
occurring mutation in the CCR5 gene (CCR5-Δ32) mediated resistance to HIV-1 disease 
(Allers et al., 2011). Compared with HIV-1 targets such as reverse transcriptase, protease, 
gp120, integrase, and gp41, the CCR5 receptor has been identified to have a low probability of 
mutations. Antiretroviral therapy (ART) administration slows the progressing of  HIV to AIDS 
by decreasing viral loads in affected individuals (Detels et al., 1998; Peng et al., 2018). 
However, the current highly active ARTs (HAART) are associated with various setbacks, 
which include viral resistance, drug-drug interactions, and unwanted side effects (Günthard et 
al., 2014).  Thus, the ability to prevent HIV-1 entry into host cells represents an attractive 
therapeutic approach in blocking HIV-1 infection and replication (M Gibson & J Arts, 2012). 




CCR5 lead to the identification of the first CCR5 HIV-1 entry drug Maraviroc, which was 
approved in 2007 by the Food and Drug Administration (FDA) (FDA, 2007). Maraviroc is the 
only marketed CCR5 drug but with limited prescription due to identified factors such as its 
drug-drug interactions (especially when co-administrated with CYP3A4 inhibitors), CYP450 
inhibition, and viral resistance (Garcia-Perez et al., 2015; Peng et al., 2018). The rapid 
worldwide increase in patients diagnosed with HIV, therefore, necessitates the discovery of 
novel therapeutics for HIV treatment with fewer side effects and better efficacy.  
Recently, a new series of 1‑Heteroaryl-1,3-propanediamine derivatives [N-((S)-3-(exo-3-(3-
Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-
yl)propyl)cyclopentane Carboxamide (Compd-21) and 4,4-Difluoro-N-(3-((1R,3S,5S)-3-(3-
isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-3-yl)-
propyl)cyclohexane-1-carboxamide (Compd-34)] (Peng et al., 2018) were synthesized as 
CCR5 antagonists (Fig. 1). These inhibitors have displayed lower cytotoxicity, exceptional in-
vitro anti-HIV-1 activity, and tolerable pharmacokinetic profile compared with Maraviroc 
(Peng et al., 2018). The crystal structure of Maraviroc in complex with CCR5 has previously 
been reported (Tan et al., 2013). Previous computational studies on CCR5 have been done to 
probe the interaction of Maraviroc with CCR5 through Molecular dynamics (MD) (Bai et al., 
2014; Salmas et al., 2015), identify potential CCR5 inhibitors via pharmacophore-based 
screening and MD (Wang et al., 2016) and MD studies on CCR5 dimerization (Zhang et al., 
2019). However, atomistic molecular details of the interaction mechanisms of how slight 
structural variance between these inhibitors (Compd-21, Compd-34, and Maraviroc) 
significantly affects their binding profiles at the CCR5 receptor has not been elucidated. Such 
an atomistic understanding would be beneficial in the identification of molecular properties 
and receptor interactions, which can be useful in the design of more effective HIV-1 





Fig. (1). 2D Chemical structures of the selected HIV-1 entry inhibitors used as co-crystallized 
inhibitors in the simulated complex systems. Key functional group variation highlighted in 
dashed circles (Image prepared by author).  
 
In this present work, lipid bilayer molecular dynamics (MD) simulations in ionized explicit 
solvent, binding energy interactions, and conformational analyses have been employed to 
investigate the atomistic molecular basis for the higher inhibitory potency possessed by 
Compd-34 and Compd-21 relative to Maraviroc. Their respective molecular binding 
interactions provide mechanistic insights into their receptor recognition and shows how 
understanding ligand-receptor interaction and activation may eventually enable drug design at 
the CCR5 receptor for HIV treatment. This study provides novel insights into the structural 
determinants and interaction patterns that drive the differential binding profile of Maraviroc 
and the 1‑heteroaryl-1,3-propanediamine derivatives (Compd-34 and Compd-21) which have 
vital implications for the design of improved HIV-1 agents. 
 
2. Materials and Methods 
2.1. Starting Structures  
The initial coordinates for molecular dynamic simulations were obtained from the crystal of 
CCR5 bound to Maraviroc (PDB entry 4MBS), CCR5 bound to Compd-21 (PDB entry 6AKX) 




removed to obtain the apoprotein. The rubredoxin molecule was removed from the receptor 
and the intracellular loop 3 (ICL3) missing residues Cys2245.68, Arg225, Asn226, and Glu227 
were reconstructed and missing residues modelled using modeller (Webb & Sali, 2014) based 
on CCR5 sequence (UniProtKB ID: P51681). The thermostabilizing mutations (Cys581.60Tyr, 
Gly1634.60Asn, Ala2336.33Asp and Lys3038.49Glu) in the crystal structures were reverted to 
their wild types. 
 
 2.2. Ligand and Protein Preparations 
The Maestro LigPrep module (Schrödinger Release 2019-4, 2019) was used to generate 
ionization and tautomeric states of the ligands and minimized using OPLS3e force field. The 
Protein Preparation Wizard (Schrödinger Release 2019-4, 2019) was used to pre-process the 
protein using default parameters. Epik was used to generate ionization states at pH 7.0±4.0 and 
water molecules beyond 5 Å from the ligand deleted. The protein was subsequently refined by 
optimizing the hydrogen bonds and minimized using the OPLS3e force field. 
 
2.3. Membrane-protein complex system setup 
The simulated systems were assembled using the CHARMM-GUI membrane builder module 
(Jo et al., 2008) (http://www.charmm-gui.org/). The apo and inhibitor-complexed systems were 
embedded in a homogenous palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid bilayer. The 
orientations of CCR5 Apo and CCR5 ligand complexes were aligned to the orientation of 
CCR5 in the membrane obtained from the Orientation of Protein Membranes (OPM) server 
(Lomize et al., 2006). The systems were then solvated using the TIP3P water model (Jorgensen 
et al., 1983), followed by a 0.15M concentration of KCl counterions for neutralization. (Fig. 2 
and Table 1). The simulated systems had an average dimension of 95 x 95 x 104 Å3. The 
charmmlipid2amber.py script was used in processing structure files in renaming lipid residues 
according to the Amber lipid14 force field. The two essential disulphide bonds between Cys20-
Cys269 and Cys101-Cys178 residues were maintained during topology and coordinate 











mesh Ewald was used to treating long-range electrostatic interactions (Darden et al., 1993) 
under periodic boundary conditions with nonbonded interactions cut-off of 12 Å.  
2.4.1. Trajectory analysis 
To comprehend the structural as well as functional implications of the studied systems, various 
structural property analyses were performed as a function of time on the obtained trajectories. 
The Amber CPPTRAJ module (Roe & Cheatham, 2013) was used to analyse the generated 400 
ns trajectories. To assess the stability and conformational dynamics during the simulations, the 
root mean square fluctuation (RMSF), root mean square deviation (RMSD), the solvent-
accessible surface area (SASA), the radius of gyration (Rg) and secondary structure analysis 
(DSSP) were computed. Similarly, hydrogen bonds formed between the inhibitors and specific 
residues were calculated.  
 
Fig. (2). CCR5-ligand lipid bilayer system setup showing side view (left) and top view (right) 
of CCR5-inhibitor complex (CCR5 represented in a cyan cartoon and inhibitor in yellow 
sphere) embedded in an ionized solvated POPC lipid bilayer (POPC lipids, water, K+, and Cl- 
are depicted in grey wire, red, purple and green, respectively) (Image prepared by author).   
 
2.5. End-point interaction energy calculations 
The Molecular Mechanics-Generalized-Born Surface Area (MM-GBSA) approach is a widely 
used method in analysing relative binding energies protein-ligand complexes (Ylilauri & 
Pentikäinen, 2013; Chen et al., 2016; Sun et al., 2018). Various binding energy components 
such as the molecular mechanics potential energy (van der Waals and electrostatic energies), 
polar and nonpolar interaction energies were obtained for each CCR5-inhibitor complex. A 




ensemble. The binding free energy (ΔGbind) is computed by the MM-GBSA approach via the 
set of equations below.  
ΔGbind = Gcomplex − (Greceptor + Gligand)  (1) 
       ΔGbind = Egas + Gsol − TΔS   (2) 
           Egas = Eint + Evdw + Eele   (3) 
               Gsol = Gpol + GSA               (4) 
                 GSA = SASA + b   (5)  
Where Gligand, Greceptor, and Gcomplex denote the relative free energies of the ligand, unbound 
protein, and protein-complex, respectively. The ΔGbind was decomposed into (equations 2 to 
5): the solvation energy term (Gsol) which is the sum of the polar (Gpol) and nonpolar (GSA) 
solvation terms; the gas-phase (Egas) energy contribution which is a summation of the 
nonbonded [van der Waals (Evdw) and electrostatics (Eele)] and the bonded [internal energy 
(Eint)] energy terms, and the entropy term (-TΔS). The conformational entropy contribution to 
the total binding free energy was calculated by normal mode analysis using 10 snapshots evenly 
extracted from the 500 snapshots.  
2.5.1 Decomposition of the overall interaction energy  
The total binding free energies were reduced into each residue contribution to identifying active 
site “hot spot” residues involved in the preferential binding of the novel inhibitors, using the 
MM-GBSA per-residue energy decomposition utility of Amber. 
 
2.6. Clustering and Principal Component Analysis (PCA) 
The principal component analysis (PCA) is routinely applied to MD trajectory analysis in 
reducing large-dimensional observations sets onto collective data. Obtaining principal 
components (PCs) for MD trajectories involves two key steps: 
(i) Covariance matrix (C) generation,  
Cij =  <  ( Xi - < Xi>) ( Xj - < Xj>) >          (1) 
(ii) The 3N x 3N covariance matrix C diagonalization that can be computed by 
eigenvalue decomposition (EVD) as,  
          C = VɅVT              (2) 
Where V denotes a matrix, which includes eigenvectors, and Ʌ, describes the eigenvalues 
contained in the diagonal matrix. The eigenvalues display the mean squared displacements 
(MSD) of the Cα atoms throughout the used eigenvector. The principal component analysis in 




2.7. Graphical tools used in the study 
Molecular visualizations were done with Chimera (Pettersen et al., 2004), Schrodinger 
Maestro(Schrödinger Release 2019-4, 2019), Origin software for plotting all graphs (Seifert, 
2014), the protein-ligand interaction profiler (Salentin et al., 2015) and Bio3D package in R 
(Grant et al., 2006) for PCA analysis. 
 
2.8. Transmembrane (TM) and Extracellular loops (ECL) residue numbering  
The superscripts assigned to each residue denote GPCRs Ballesteros-Weinstein numbering 
(Ballesteros & Weinstein, 1995) for the transmembrane domains and the GPCRdb (Isberg et 
al., 2016)  numbering for intracellular and extracellular loops.  
 
3. Results  
3.1. Phenyl → thiophen-2-yl (Compd-21) and thiophen-3-yl (Compd-34) substitutions 
improved binding affinities over Maraviroc. 
The key structural variation between Maraviroc and the novel series of 1‑heteroaryl-1,3-
propanediamine derivatives (Compd-34, and Compd-21) is the substitution of the phenyl group 
in Maraviroc with a thiophen-2-yl and thiophen-3-yl moieties in Compd-21, and Compd-34, 
respectively. This substitution was observed to exhibit excellent in vitro anti-HIV-1 activity 
and improved pharmacokinetics (Peng et al., 2018). The interaction energies between the 
CCR5 and the selected inhibitors were evaluated to assess the mechanistic binding of Compd-
34, Compd-21 and Maraviroc at the active site of CCR5 using MM-GBSA method (Hou et al., 
2011; Sun et al., 2014; Chen et al., 2016). The estimated relative binding free energies and 
individual energy terms of Compd-34, Compd-21, and Maraviroc are listed in Table 2. The 
computed binding energies (ΔG) (mean ± SEM) obtained for Maraviroc, Compd-21 and 
Compd-34 were -31.45 ± 2.2 kcal.mol−1, -41.15 ± 1.0 kcal.mol−1, and -44.94 ± 0.9 kcal.mol−1, 
respectively. These energy values correlate in their ranking order with the experimentally 
reported IC50 values of 8.0 ± 2.7 nM for Maraviroc, 3.1 ± 0.2 nM for Compd-21, and 3.0 ± 0.2 
nM for Compd-34. Compd-21 and Compd-34 relatively displayed more favourable binding 
than Maraviroc, which could be attributed to the stronger interactions elicited by Compd-21 
and Compd-34 at CCR5 binding sites, as would be explained in subsequent sections. Aside 
from the ability for MM-GBSA to rank inhibitor in the order of their binding free energies, it 
also provides detail understanding of the inhibitor-target binding process (Yang et al., 2011) 





3.51), Phe1093.33 (-1.88), Phe1123.36 (-1.25), Ile1985.42 (-1.56), Tyr2516.51 (-2.37), Leu2556.55 (-
1.04), and Met2877.43 (1.00) for Compd-21; whereas Trp862.60 (-1.58), Tyr1083.32 (-2.207), 
Phe1093.33 (-2.08), Phe1123.36 (-1.0), Ile1985.42 (-1.48), and Gln2807.36 (-1.0) for Maraviroc. 
Most of the binding site residues of CCR5 critical for the binding of gp120 V3-loop such as 
Trp862.60, Tyr1083.32, Phe1093.33,  and Tyr2516.51 made stronger interactions with the 1-
heteroaryl-1,3-propanediamine derivatives (Compd-21 and Compd-34) than with Maraviroc.  
 
 
Fig. (3). Per-residue interaction energy decomposition (a) and hydrogen bond occupancy plot 
(b) for Compd-21, Compd-34 and Maraviroc at CCR5 binding site. The dashed line denotes 
residues with contribution from -1.0 kcal.mol−1 (Image prepared by author). 
 
The MD trajectories were further analysed to gain an understanding of the dynamic variation 
in the number and strength of hydrogen bond formation throughout the simulation (Table 3 and 
Fig. 3b). The inhibitors were stabilized in the active site of CCR5 receptor via hydrogen bonds 
involving: Glu2837.39, Gln2807.36, Tyr2516.51, Thr2847.40, and Tyr371.39 (with Compd-34); 
Glu2837.39, Tyr2516.51, Tyr371.39 and Gln280 (with Compd-21); and Glu2837.39, Tyr371.39 and 
Tyr2516.51, (with Maraviroc). In the CCR5-Maraviroc system, the protonated nitrogen of the 
tropane linker moiety maintained the most stable hydrogen bond/salt-bridge interaction with 
Glu2837.39 (54.77 % occupancy). The triazole moiety also maintained a hydrogen bond with 
Tyr371.39 (26.20 % occupancy) whereas the carboxamide nitrogen formed a stable hydrogen 
bond with Tyr2516 51 (25.87 % occupancy). The dynamic hydrogen bond analysis indicates that 
the observed two hydrogen bond formed by Thr1955.39 and Thr2596.59 with one of the 
cyclohexane ring fluorines in the crystal structure(Tan et al., 2013) are weak interactions which 





Phe1093.33, Phe1123.36,  and Ile1985.42 were also observed to engage in interactions with the 
phenyl group of Maraviroc whereas the triazole moiety made more contacts with Val251.27, 
Leu331.35, Tyr371.39 and Trp862.60. 
 
3.3. Distinctive Structural Dynamics of CCR5 upon Inhibitors Binding Revealed by MD 
Simulations 
Explicit MD simulations of CCR5 embedded in a hydrated ionized POPC lipid bilayer were 
performed to elucidate the inhibitory mechanism and the conformational dynamics associated 
with CCR5 by the novel 1‑heteroaryl-1,3-propanediamine derivatives HIV-1 entry inhibitors. 
Presented in Table 1 are the different simulated systems in this study with a detailed description 
of system preparations outlined in the methodology section.  
3.3.1. Structural Stability Evaluation  
The Root Mean Squared Deviation (RMSD) of Cα atoms with respect to the minimized starting 
crystal structure was calculated to evaluate the structural stability of each of the studied systems 
throughout the simulation (Fig. 5a). The MD simulations ultimately produced relatively stable 
trajectories with respect to backbone structural changes. The RMSD curves show that all the 
unbound and bound-complexed systems under study were evolving until 100 ns.  
The overall average RMSD for the entire protein structures were 2.2 ± 0.3 Å, 2.1 ± 0.3 Å, 2.0 
± 0.3 Å, and 1.7 ± 0.2 Å for CCR5-21, CCR5-34, CCR5-MVR, and CCR5-APO, respectively. 
From the RMSD results, the mean deviation of all systems was lower than 2.3 Å, and a 
maximum RMSD value smaller than 3.0 Å. The dynamic stability of Maraviroc, Compd-21, 
and Compd-34 was also calculated from the RMSDs of heavy atoms of the inhibitors to 
adequately assess their stability at the CCR5 binding site (Fig. S1a). The observed average 
active site RMSD within 8Å of the inhibitors were 1.3 ± 0.2 Å, 1.7 ± 0.5 Å, and 2.1 ± 0.4 Å 
for Compd-21, Compd-34, and Maraviroc, respectively (Fig. S1a).  
3.3.2. Alterations in CCR5 Solvent Accessibility  
The Solvent Accessible Surface Area (SASA) was examined to explore the behaviour of 
hydrophobic and hydrophilic residues of the CCR5 complexes with water molecules during the 
simulation (Fig. 5c). The SASA assessment is capable of predicting the extent of protein 
conformational changes occurring upon binding (Marsh & Teichmann, 2011). An average 
SASA value of 16329.8 ± 310 Å2, was observed for the Apo system, while CCR5-21, CCR5-




Å2, respectively. In addition, the observed average active site SASA within 8Å of the inhibitors 
were 118.70 ± 26.7 Å, 135.69 ± 30.4 Å, and 146.67 ± 27.4 Å for Compd-21, Compd-34, and 
Maraviroc, respectively (Fig. S1c).  
 
 
 Fig. (4). Dynamic binding mode and receptor-ligand interaction fingerprint for (a) Compd-34, 
(b) Compd-21 and (c) Maraviroc at CCR5 binding site. Key functional group variations 
highlighted in dashed circles (Image prepared by author).  




The radius of gyration (Rg) was computed to estimate the overall change in the total 
compactness, folding and shape of CCR5 protein mass upon binding to the inhibitors during 
the simulations. The Rg graph for Cα atoms of apo and CCR5-complexed systems are shown 
in Fig. 5d with average values of  21.07 ± 0.1 Å, 21.15 ± 0.1 Å, 20.98 ± 0.1 Å, and 20.89 ± 0.1 
Å for CCR5-21, CCR5-34, CCR5-MVR, and CCR5-APO, respectively. Similarly, the average 
active site Rg values within 8 Å of the inhibitors were calculated to be 5.14 ± 0.1 Å, 5.57 ± 0.1 
Å, and 5.68 ± 0.1 Å for Compd-21, Compd-34, and Maraviroc, respectively (Fig. S1b). The 
Rg results showed that the binding of the inhibitors did not significantly affect the active site 
and the overall conformational diversity of the CCR5 protein system.  
 
 
Fig. (5). Time series of (a) RMSDs for complexed and apo systems (b) RMSF for complexed 
and apo systems (c) SASA for complexed and apo systems and (d) Rg for complexed and apo 
systems over 400ns (Image prepared by author).  
3.3.4. Flexibility Analysis 
The Root Mean Square Fluctuation (RMSF) for each system Cα atom was calculated to gain 
insight into the extent to which amino acid residues mobility varies in CCR5 receptor in the 
bound and unbound state (Fig. 5b). The results suggest that while transmembrane regions 
(TMI-TMVII) showed high stability for all systems (~ 1.0 Å RMSF), higher residual 




ECL2, and ECL3) loop regions (up to 7 Å RMSF). This increased loop residual fluctuations 
were prominent in the ICL3, ECL2 and ECL3 regions. The observed higher intra- and 
extracellular residual mobility is expected since they belong to the outer parts of the receptor 
that is solvent exposed. 
3.3.5. Secondary Structural Analysis 
The DSSP analysis was further carried out to provide an overview of the gain and loss of 
secondary structure of both the CCR5 and CCR5-inhibitor complexes throughout the 
simulations (Fig. 6). The results showed that the majority of the secondary structure elements 
were stable. All the seven-transmembrane α-helices [TMI (22-58); TMII (63-92); TMIII (97-
132); TMIV (141-167); TMV (186-224); TMVI (228-265); and TMVII (268-300)] persisted 
throughout the simulation in the bound and unbound state. Also, the parallel and antiparallel 
sheet of the β-hairpin in the ECL2 (Thr167-Tyr184) were stable and unaltered throughout the 
entire simulation in all systems. However, slight structural changes were observed in the 
inhibitor bound and unbound state. For instance, the Turn and Bend in the ECL3 (266-267) of 
the unbound state (Fig. 6a) extended into the TMVI (228-265) in the bound state (Fig. 6c-d). 
Similarly, helix-8 (301-313) was more α-helix in Maraviroc bound than in Compd-21, Compd-
34 and the unbound state.   
 
Fig. (6). DSSP analysis for secondary structure prediction for (a) CCR5-apo, (b) CCR5-21, (c) 
CCR5-34 and (d) CCR5-MVR (Image prepared by author). 




To identify dominant motion in CCR5 complexes, the principal component analysis (PCA) was 
performed to capture the combined movements of the Cα atoms in the protein for the first few 
essential eigenvectors of the covariance matrix. The principal component and clustering 
analysis provide considerable insight into the nature of conformational differences associated 
with the binding of an inhibitor to a receptor (Desdouits et al., 2015; Martínez-Archundia et 
al., 2019). The sum of eigenvalues increases as a function of the number of eigenvalues 
resulting from the collected MD trajectories is shown in Fig. 7. The obtained spectrum of 
eigenvalues displays the proportion of variances against the eigenvalues for the inhibitor-






Fig. (7). Clustering and principal component projection of the trajectory conformers unto the 
planes formed by the first two principal components based on the dominant motion of the 
complex system for (a) Maraviroc (b) Compd-21, and (c) Compd-34 using the Bio3D package 





The PCA showed that the proportion of variance of the first two principal components (PCs) 
accounted for 25.3%, 31.8%, and 34.4% of the overall variation in the detected motion of 
CCR5-MVR, CCR5-Compd21, and CCR5-Compd34 complexed trajectories, respectively. 
The clustering of the complex protein structures for PC1 and PC2 unto two-dimensional 
subspace (Fig. 7) indicates conformational distribution variance in the different CCR5 complex 
systems. Whereas the subspace of PCs 1 and 2 of CCR5-MVR complex showed a uniform and 
overlapping conformational subspace, CCR5-Compd24 and CCR5-Compd34 depict distinct 
periodic jump within the conformational subspace. The internal dynamics of CCR5 when 
bound to Compd34 and Compd21 are diverse from when bound to Maraviroc.  
 
4. Discussion 
In this study, we investigated the binding energy interactions, the structural basis and 
conformational changes associated with the higher binding affinity of Compd-34 and Compd-
21 compared with Maraviroc at CCR5 binding site. An integrated in silico approach that 
combines explicit lipid bilayer MD simulation, principal component analysis, and MM-GBSA 
binding free energy calculations were employed to obtain atomistic molecular details of the 
interaction mechanisms of how slight structural variance between these inhibitors significantly 
affects their binding profiles at CCR5 receptor.  
The predicted binding free energies of the studied inhibitors corroborates with the experimental 
bioactivity data. Furthermore, the decomposition of the total interaction energy components 
suggests that van der Waals interactions appear to dominate in stabilizing the CCR5-inhibitor 
complexes. The dynamic hydrogen bond analysis showed that hydrogen bond interactions 
between the antagonists and the active site residues Glu2837.39, Gln2807.36, Tyr2516 51, 
Thr2847.40, and Tyr371.39 (with Compd-34); Glu2837 39, Tyr2516.51, Tyr371.39 and Gln2807 36 
(with Compd-21); and Glu2837.36, Tyr371.39, and Tyr2516.51 (with Maraviroc) are vital for the 
stability of the ligand-bound conformations. Bai et al. (2014) demonstrated that residues 
Tyr371.39, Tyr2516.51 and Glu2837.39 form stable hydrogen bonds with Maraviroc (Bai et al., 
2014). The overall hydrogen bond strength and stability were observed to be higher for Compd-
34 and Compd-21 than for Maraviroc at CCR5 active site.  
The binding of gp120 to CCR5 has been reported to be sensitive to the mutations of active site 
residues such as Trp862.60, Trp9423 50, Tyr1083.32, Trp2486.48, and Tyr2516.51. These residues 
were suggested to form a potential binding cavity for gp120 (Garcia-Perez et al., 2011).  The 




reveals that the gp120 V3 loop makes extensive contacts with residues of the chemokine 
recognition site 2 (Phe1093 33, Tyr1083.32, Trp862.60, Tyr892.63, Glu2837.39, and Tyr2516.51) 
(Shaik et al., 2019). The gp120 V3 loop of HIV-1 has been observed to predominantly occupy 
the minor sub-pocket formed by the transmembrane helices I-III and VII of the chemokine 
recognition site 2 (CRS2) of CCR5. The V3 loop Arg313 residue seems to be sandwiched 
between Glu2837.39 and Tyr2516.51 of CCR5(Shaik et al., 2019). The per-residue interaction 
energy decomposition reveals that Trp862.60, Tyr1083.32, Tyr2516.51 make overall stronger 
interactions with Compd-21 and Compd-34 compared with Maraviroc. Similarly, Tyr2516.51 
and Glu2837.39 further engage in stronger hydrogen bond interactions with Compd-21 and 
Compd-34 compared to Maraviroc. These observed interactions cumulatively accounted for 
Compd-21 and Compd-34 higher ΔG binding energies than Maraviroc. These findings further 
support the experimental findings (Tan et al., 2013) and the theoretical result (Bai et al., 2014) 
demonstrating that Tyr371.39, Tyr2516.51, Glu2837.39 of TMI, TMVI and TMVII play a vital role 
in the binding of inhibitors to CCR5 binding site. 
The Principal component analysis (PCs 1 and 2) revealed a subspace of CCR5-MVR complex 
with a uniform and overlapping conformational subspace, whereas CCR5-Compd31 and 
CCR5-Compd-21 complexes showed distinct periodic jump within the conformational 
subspace. The SASA results showed that active site amino acid residues within 8 Å of CCR5-
21 and CCR5-34 inhibitors had lower SASA values compared to CCR5-MVR. 
The MD simulations and atomistic interaction analysis of the studied compounds substantiate 
the recent findings that Maraviroc blocks gp120 binding to CCR5 via direct competitive 
inhibition in contrast to earlier views of allosteric inhibition via conformational availability 
restriction (Shaik et al., 2019). As evident by the hydrogen bond analysis, residue energy 
decomposition analysis, and the protein-ligand interaction, the studied inhibitors made 
important contacts with the residues that are critical in gp120 V-loop binding. The gp120 V3 
loop has been observed to overlap mainly with Maraviroc in the minor sub pocket, which is 
occupied primarily by the triazole moiety of Maraviroc, Compd-31, and Compd-34. Structural 
modifications at the thiophene substituent with functional group(s) that may maintain strong 
hydrogen bond with Glu2837.39 and Tyr2516.51 as well as the addition of new functional groups 
to the triazole ring may increase inhibitor competition with gp120 V3-loop with enhanced 







In summary, the findings highlighted in this work provide a structural understanding of the 
novel 1-heteroaryl-1,3-propanediamine derivatives (Compd-21 and Compd-34) and Maraviroc 
targeting the CCR5 receptor. The MD simulation analyses reveal that Trp862.60, Tyr1083.32, 
Tyr2516.51 make overall stronger interaction with Compd-21 and Compd-34 compared with 
Maraviroc. Similarly, Tyr2516.51 and Glu2837.39 further engage in stronger hydrogen bond 
interactions with Compd-21 and Compd-34 compared with Maraviroc. Thus, the substitution 
of the thiophene moieties in Compd-34 and Compd-21 cumulatively made stronger interactions 
with residues critical for V3-loop binding compared with the phenyl group in Maraviroc. 
Further structural modifications at the thiophene substituent and the addition of additional 
functional groups to the triazole ring may increase inhibitor competition with gp120 V3-loop 
with enhanced potency. This offers a foundation for the onward structural modifications and 
rational design of novel potent antagonists of CCR5 in HIV-1 treatment.  
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The C-C chemokine receptor 5 (CCR5) viral coreceptor belonging to the G protein-coupled 
receptor family is one of the families of chemokine receptors. The interactions of CCR5 with 
HIV-1 during viral entry positions it as an effective therapeutic target for the design of potent 
antiviral therapies. The FDA approved the small-molecule Maraviroc as CCR5 drug in 2007, 
while clinical trials failure has characterised many of the other CCR5 inhibitors. Thus, the 
continual identification of potential CCR5 inhibitors is, therefore, warranted. In this study, a 
structure-based discovery approach has been utilised to screen and retrieved novel potential 
CCR5 inhibitors from the Asinex antiviral compound (~ 8,722) database. Explicit lipid-bilayer 
molecular dynamics simulation, in silico physicochemical and pharmacokinetic analyses, were 
further performed for the top compounds. A total of 23 structurally diverse compounds with 
binding scores higher than Maraviroc were selected. Subsequent molecular dynamics (MD) 
simulations analysis of the top four compounds LAS 51495192, BDB 26405401, BDB 
26419079, and LAS 34154543 maintained stability at the CCR5 binding site. Furthermore, 
these compounds made pertinent interactions with CCR5 residues critical for the HIV-1 gp120-
V3 loop binding such as Trp86, Tyr89, Phe109, Tyr108, Glu283 and Tyr251. Additionally, the 
predicted in silico physicochemical and pharmacokinetic descriptors of the selected 
compounds were within the acceptable range for drug-likeness. The results suggest positive 
indications that the identified molecules may represent promising CCR5 entry inhibitors. 
Further structural optimisations and biochemical testing of the proposed compounds may assist 
in the discovery of effective HIV-1 therapy. 
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C-C chemokine receptor 5 (CCR5) is a member of the G protein-coupled receptors (GPCRs) 
and is essential in the amelioration of human immunodeficiency virus (HIV) infection 
(Oppermann, 2004). C-C chemokine receptor 5 plays a critical role in the early stages of HIV-
1 infection and is a functionally co-receptor for HIV-1 viral entry (Tan et al., 2013). The human 
immunodeficiency virus-1  penetrates cells by binding its envelope glycoprotein gp120 to the 
CD4 receptor and co-receptors like CCR5 and CXCR4 (Woollard & Kanmogne, 2015). CCR5 
is the most prominent of all chemokine co-receptors employed by HIV-1 for cell penetration, 
typically at the onset of infection with the R5-tropic HIV-1 strains being transmitted the most 
(Vangelista & Vento, 2018). CCR5 is also a potential target for ameliorating inflammatory, 
allergic, infectious, and autoimmune diseases such as diabetes and rheumatoid arthritis (Pereira 
et al., 2009; Spagnolo et al., 2005).  
Extensive research in the development of inhibitors that could block the entry of HIV-1 through 
the target of CCR5 resulted in the approval of Maraviroc for the treatment of HIV-1 infection 
(FDA, 2007; Tan et al., 2013). Maraviroc is the first CCR5 drug approved by the FDA to inhibit 
HIV-1 entry (FDA, 2007). However, its prescription is limited due to identified factors such as 
its CYP450 inhibition, drug-drug interactions, particularly with CYP3A4 inhibitors, and viral 
resistance (Peng et al., 2018). Clinical studies on other CCR5 antagonists like Aplaviroc 
(Nichols et al., 2008), Vicriviroc (Schürmann et al., 2007; Gulick et al., 2007) and Cenicriviroc 
(Klibanov et al., 2010) failed at some stages of their clinical trials such as lack of efficacy 
and/or hepatotoxicity.  
The limitations of the approved drug and clinical drugs targeting CCR5, as well as the reported 
case of clinical drug failures, necessitate the identification and development of novel effective 
and enhanced inhibitors of CCR5. Structure-based virtual screening incorporated in computer-
aided drug design has contributed immensely to advancing the drug discovery process (Jin et 
al., 2020; Hughes et al., 2019; Rodríguez et al., 2014). This is because of its cost-effectiveness 
in the identification of novel therapeutics within a short time frame. Structure-based drug 
discovery enhances database screening by employing the principle of molecular docking, 
which predicts the best conformation for target-ligand interaction. Recent advancement in X-
ray crystallography and nuclear magnetic resonance and electron cryo-microscopy (cryoEM) 
has promoted structure-based drug discovery (SBDD) due to the availability of diverse 3D 
protein crystal structures (Wang et al., 2018). Structure-based drug discovery can be employed 
to investigate the binding mode and ligand binding process with substantial accuracy, which 




al., 2018). Data like these can be harnessed toward the design of potent high-affinity ligands 
with basic moieties that produce the needed pharmacological and therapeutic activities 
(Ferreira et al., 2015; Llanos et al., 2017; Macalino et al., 2015).  
Computational strategies employed in the past years toward the identification of potential 
CCR5 inhibitors due to the absence of CCR5 crystal structures were restricted to ligand-based 
approaches such as; shape-based virtual screening (Pérez-Nueno et al., 2008), quantitative 
structure activity relationship (QSAR) (Xu et al., 2004), and ligand-based pharmacophore 
modelling (Debnath, 2003). The first CCR5 crystal structure in complex with Maraviroc was 
reported in 2013 (Tan et al., 2013). More recent approaches following the availability of CCR5 
crystal structure have focused on structure-based methods (Wang et al., 2016; Lin et al., 2019). 
These studies have used compounds from databases such as the National Cancer Institute 
(NCI), ChEMBL database, and ZINC database.  
The recent crystallisation of the full-length CCR5 in complex with gp120 V3 loop suggests 
that Maraviroc blocks gp120 binding to CCR5 via direct competitive inhibition in contrast to 
earlier views of non-competitive allosteric inhibition through conformational availability 
restriction (Shaik et al., 2019). Herein, we screened the unexplored antiviral compound library 
of the Asinex database against the recently crystalised full-length CCR5 in complex with gp120 
V3 loop (Shaik et al., 2019). Multistep structure-based virtual screening techniques were 
employed in this study to identify potential CCR5 inhibitors. The best four hits of the identified 
compounds in complex with CCR5 were subjected to conventional computational molecular 
dynamics simulations to understand their atomistic mechanism of action and conformational 
dynamics. The identified compounds could be optimised/tested as potent CCR5 HIV-1 entry 
inhibitors.  
 
2. Materials and Methods  
In this work, diverse pharmacoinformatic techniques, including molecular docking, in silico 
physicochemical and pharmacokinetic analysis, and molecular dynamics simulation, have been 
applied to identify novel potential CCR5 HIV1 entry inhibitors.  
2.1 Compound library and protein preparation 
A total of 8722 antiviral compounds were freely downloaded from the antiviral sub-class of 
the Asinex database (ASINEX, 2020) for the virtual high throughput screening. The Asinex 




fragment-based drug design, and structure-based drug design. The single structural data format 
(SDF) of the 8722 compounds were downloaded and further prepared for Autodock Vina and 
Schrodinger Maestro to eliminate unwanted elements and improper valency and converted into 
individual three-dimensional (3D) mol2 format.  
2.2 Ligand and Receptor Preparations for Autodock Vina Screening 
The compounds were initially prepared and converted to pbdqt with raccoon (Forli, 2010). The 
pdbqt format incorporated partial charges and AutoDock atom types acceptable by AutoDock 
Vina (Trott & Olson, 2010). The protein was prepared by adding polar hydrogen atoms and 
Gasteiger charges. All nonstandard residues were deleted from the crystal structure. The grid 
box centre coordinates were 159.28, 148.39 and 161.65 in the X, Y, and Z axes, whereas the 
size of 25.20 × 20.86 × 24.85 Å was assigned to the pocket X, Y, and Z axes with 
exhaustiveness set to 8.  The receptor, ligand, and grid parameters were written in the format 
that is acceptable by the Autodock Vina program. 
2.3 Ligands and Protein Preparation procedure for Glide docking 
The LigPrep module implemented in Maestro v12 (Schrödinger Release 2019-4, 2019) was 
used to generate low energy 3D structures of the compounds. The protonation states of the 
compounds were estimated at a pH 7.4 ± 0.2 using the program EpiK (Greenwood et al., 2010) 
and three-dimensional conformations generated. The compounds were desalted, and the 
possible tautomeric conformations set to ~32 tautomer per compound. Minimisation was 
finally performed for the compounds using the OPLS3e force field. The structure of the full-
length CCR5 receptor in complex with the gp120 V3 loop (PDB ID: 6MEO) was used in the 
receptor grid generation for the Glide docking. The centre of the active site grid was defined 
around the binding position of the gp120 V3 loop in the structure. 
The full-length CCR5 receptor was prepared using the Protein Preparation Wizard 
implemented in Maestro v12 (Schrödinger Release 2019-4, 2019) before the Glide docking. 
Pre-processing and energy minimisation of the receptor with OPLS3e force field was 
performed. Protonation states were assigned at physiological pH, followed by the addition of 
hydrogen atoms using the default parameters. The side chains stereochemistry was checked to 
avoid significant induced perturbations during the structure preparation.  
2.4 Structure-based Virtual High Throughput Screening 
The current study followed the schematic workflow presented in Fig. 1. The binding poses and 




docking program (Trott & Olson, 2010). Maraviroc was docked and analysed as a positive 
reference control (Maraviroc Autodock Vina Score = -9.0 kcal/mol). A minimum binding 
affinity score of -10.0 kcal/mol threshold was chosen as the cut-off, and compounds with a 
binding affinity lower than the selected threshold were subsequently chosen for the Maestro 
virtual screening workflow (VSW) (Schrödinger Release 2019-4, 2019).  
To further remove possible false-positive results, the top 500 compounds obtained from the 
Autodock molecular docking were gradually subjected to filtering steps via the Glide virtual 
screening workflow of Schrodinger Glide. The Glide virtual screening workflow module 
(Friesner et al., 2004) possesses unique virtual screening features like the high throughput 
virtual screening (HTVS), standard precision (SP) and extra precision (XP) for improved and 
efficient docking accuracy (Friesner et al., 2006). The above mentioned three docking precision 
levels implement an efficient search for the orientational, conformational and positional space 
of the docked ligand (Friesner et al., 2004; Friesner et al., 2006). Each compound docking 
progressed from HTVS to SP to XP, which involved Glide predicting the binding affinity and 
ranking the compounds. The top 20 % of compounds from the HTVS and SP docking levels 
were selected for XP docking.  
Finally, the top four candidate compounds showing the best possible inhibitor binding pose 
from both the Autodock Vina and Glide-XP dockings were selected for binding mode analyses, 
MD simulations and molecular trajectory analyses. The type and pattern of binding interaction 





Fig. 1. Structure-based virtual screening and assessment workflow to identify potential CCR5 
entry inhibitors (Image prepared by author). 
 
2.5 Pharmacokinetics profiling and physiochemical property predictions 
In silico pharmacokinetic profiling and drug-likeness estimations were further performed on 
the top compounds retrieved from the VSW using SwissADME (Daina et al., 2017) and 
pkCSM-pharmacokinetics (Pires et al., 2015) online software.  Lipinski’s rule of five (RO5) 
for empirical drug-likeness prediction was used to evaluate drug-likeness of the selected 
compounds (Meanwell, 2011). The rule includes: 1) hydrogen bond donors not more than five, 
2) hydrogen bond acceptors not more than ten, 3) an octanol-water partition coefficient logP 




bonds less than eight. Several vital molecular properties such as hydrophobicity (SlogP), and 
polar surface area (PSA) were also analysed. Additionally, pharmacokinetic parameters such 
as absorption, distribution, metabolism, excretion, and toxicity (ADMET)  were analysed for 
the selected top four compounds relative to Maraviroc using the pkCSM-pharmacokinetics 
algorithm protocol.  
2.6 Membrane-protein complex system setup. 
The prepared docked complex structures were embedded in palmitoyl-oleoyl-
phosphatidylcholine (POPC) lipid bilayer using the CHARMM-GUI membrane builder 
(http://www.charmm-gui.org/?doc=input/membrane.bilayer) (Jo et al., 2008). The orientations 
of the complexes were aligned on the CCR5 transmembrane helices obtained from the 
Orientation of Protein Membranes (OPM) server (Lomize et al., 2006).  The complexes were 
then neutralised and solvated with 0.15M of KCl counterions in explicit solvent using the 
TIP3P water model (Jorgensen et al., 1983). The dimension of the final systems approximately 
measured 86 x 86 x 140 Å3, consisting of about 60 potassium ions, 71 chloride ions, 180 lipids 
and 22500 water molecules.  
The charmmlipid2amber.py script was used in the renaming of lipid residues according to the 
Amber lipid14 force field. The Lipid14 force field (Dickson et al., 2014) was used to describe 
the lipids. The general AMBER Force Field (GAFF) (Sprenger et al., 2015) was utilised in 
parameterising the inhibitors via the ANTECHAMBER (Wang et al., 2001) and LEaP module 
of AMBER 18. The coordinate and topology files for the simulations were generated with tleap 
software using the ff14SB, TIP3P, and lipid14 forcefields.  
2.7 Molecular Dynamics (MD) Simulation Protocol 
Molecular dynamic (MD) simulations were performed on the selected ligand-CCR5 complexes 
in an ionised explicit POPC lipid bilayer performed using the Particle Mesh Ewald Molecular 
Dynamics (PMEMD) on the graphical processing unit (GPU) implemented in AMBER 
18(Case et al., 2005).   
An initial minimisation of 6000 steps consisting of 3000 steps of steepest descent and 3000 
steps of conjugate gradient method with harmonic restrain potential of 10 kcal.mol-1.Å-2 on the 
protein and lipids. The entire system was relaxed in a second minimisation step of 15000 
cycles. The systems were heated from 0 to 100 K using the Langevin thermostat in an 
isothermal-isochoric (NVT) ensemble over 30 ps with 10.0 kcal·mol−1·Å−2 harmonic restraints 




The system was further heated to 310 K over 260 ps in an isothermal-isobaric (NPT) ensemble 
with an anisotropic pressure coupling and a pressure of one bar. Additional equilibration at 310 
K was performed with harmonic restraints on the protein and ligand beginning at 5.0 
kcal·mol−1·Å−2. This was decreased by 1.0 kcal·mol−1·Å−2 in every 4 ns, for a total of 20 ns of 
additional restrained equilibration under the NTP ensemble. A subsequent unrestrained 5 ns 
equilibration was performed before production. 
Finally, 100 ns unrestrained production at 310 K was run under NPT ensemble with SHAKE 
constraints for bonds with hydrogen. The anisotropic pressure coupling with a pressure 
relaxation time of 1.0 ps was used to control the systems' pressure. Long-range electrostatic 
interactions were treated with the particle mesh Ewald  (Darden et al., 1993) under periodic 
boundary conditions with nonbonded interactions cut-off of 12 Å. 
2.7.1 Analysis of MD simulations trajectories 
Post-MD analysis such as the radius of gyration (rGyr), root mean square deviation (RMSD), 
root mean square fluctuation (RMSF), intermolecular hydrogen bond analysis was computed 
using the CPPTRAJ module (Roe & Cheatham, 2013) of the Amber18 suite. All visualisations 
and plots were respectively performed with UCSF Chimera molecular modelling tool and 
Origin data analysis software version 6 (http://www.originlab.com) (Seifert, 2014).  
 
3. Results and Discussion 
3.1 Structure-based Virtual High throughput Screening  
Virtual high throughput screening of databases for novel inhibitors is a useful approach to 
identify potential hit-to-lead candidates for further biological testing with a higher likelihood 
of blocking or triggering the activity of a drug target (Jin et al., 2020; Hughes et al., 2019; 
Rodríguez et al., 2014). The AutoDock Vina was initially used to dock the antiviral compounds 
at the CCR5 binding pocket due to its high scoring function with improved speed and docking 
accuracy (Trott & Olson, 2010). We further performed serial docking on high-ranking 
molecules using the virtual screening workflow (VSW) in Maestro (Schrödinger Release 2019-
4, 2019). The Schrodinger VSW, which uses the grid-based ligand docking energetics (Glide) 
algorithm, was further used to screen down the number of ligands. The Glide docking program 





docking protocols (Friesner et al., 2006; Friesner et al., 2004). These tools are ranking filters 
that try to locate the precise positions of ligands in the binding pocket of CCR5 as well as 
predict an accurate ligand pose in the binding pocket. The top four (4) compounds with the 
lowest binding scores and a good binding pose compared with Maraviroc were selected for 
further analysis (Table 1). Also, Table S1 and Table S3 present the chemical structures and 
binding scores, respectively, for the remaining 19 compounds that can further be 
optimised/tested toward CCR5. The 2D structures of the best four hits and Maraviroc are 
presented in Fig. 2, and the other 19 compounds shown in Table S1. 
 
 
Fig. 2. The selected top four compounds following Autodock Vina, Glide HTVS, Glide SP and 
Glide XP docking and the reference drug (Maraviroc) used for molecular dynamics simulation 
(Image prepared by author). 
 
The docking scores of selected four best-hit compounds (LAS 51495192, BDB 26405401, 
BDB 26419079, LAS 34154543) ranged from -10.0 kcal/mol to -10.5 kcal/mol for Autodock 
Vina and from -6.91 kcal/mol to -7.63 kcal/mol for Glide XP scores. These binding energies 
were higher than that of Maraviroc (Autodock Vina score = 9.0 kcal/mol: Glide XP score = 
6.73 kcal/mol) (Table 1). The docking results of the remaining 19 compounds that exhibited 









Fig. 3. The two-dimensional (2D) ligand-protein interactions diagram of Maraviroc and the 
best-hit compounds (LAS 51495192, BDB 26405401, BDB 26419079, and LAS 34154543) at 







Fig. 4. Three-dimensional (3D) binding poses of the top four compounds and Maraviroc at 
CCR5 binding site overlapping with gp120 V3 loop (yellow). The binding poses of BDB 
26405401 (A), BDB 26419079 (B), LAS 34154543 (C), LAS 51495192 (D), Maraviroc (E), 
Superposition of all top four compounds, Maraviroc and gp120 V3 loop (F) in the active site 





3.3 Conformational dynamic interaction patterns of the identified compounds revealed 
by molecular dynamics 
Molecular dynamics simulations provide valuable information on ligand binding stability 
within the active site of a target as well as the dynamic behaviour of the receptor (Yang et al., 
2011; Podder et al., 2016; Chaudhary & Aparoy, 2017). To obtain an ensemble understanding 
of the dynamic behaviour of the best-hit compounds relative to Maraviroc at CCR5, MD 
simulations were used to evaluate the stability of the CCR5-inhibitor complex interactions. The 
structural stability and residue fluctuations of the individual complex binding site were 
monitored for 100 ns. 
 
 
Fig. 5. The active site root mean square deviation (RMSD) (A), the active site solvent 
accessible surface area (SASA) (B), the binding site radius of gyration (rGyr) (C) and root 
mean square fluctuation (RMSF) (D) as a function of the 100 ns simulation time (Image 
prepared by author). 
 
The RMSD plot for the active site showed an initial conformational fluctuation and stabilising 
with average values of  1.42 Å, 1.81 Å, 1.68 Å, 2.42 Å, and 1.16 Å for LAS 51495192, BDB 
26405401, BDB 26419079, LAS 34154543, and Maraviroc, respectively (Fig. 5A and Table 




averaged RMSD below 2 Å. The degree of protein binding site volume expansion of each 
complex system was subsequently assessed by computing the solvent accessible surface area 
(SASA) from individual MD trajectories (Fig. 5B) and their average SASA values provided in 
Table S5. The SASA values of CCR5-BDB26419079 (86.37 Å2) and CCR5-LAS34154543 
(95.38 Å2) complexes were lower than CCR5-Maraviroc (113.66 Å2) system, whereas CCR5-
BDB26405401 (119.92 Å2) and CCR5-LAS51495192 (136.05 Å2) were slightly higher than 
that of  Maraviroc system.  
The radius of gyration (rGyr), which shows the compactness of a biomolecular system, was 
computed within 8 Å of the ligand binding site (Fig. 5C and Table S5). Apart from LAS 
34154543 complex system (5.98 Å), the remaining three compounds had relatively lower rGyr 
values (4.50 Å–5.25 Å) compared to Maraviroc complex system (5.52 Å). To further probe the 
receptor residue mobility of CCR5 during the simulation, the RMSF of the individual CCR5 
residues were monitored for each complex system. As presented in Fig. 5D, compounds LAS 
51495192 and LAS 34154543 displayed lower residue fluctuation than BDB 26405401 and 
BDB 26419079, which showed similar residue mobility patterns like Maraviroc. Additionally, 
essential residues such as Tyr37, Trp86, Tyr89, Thr105, Tyr108, Phe109, Phe112, Ser180, 
Trp190, Tyr251, and Glu283 showed very low mobility. High residue mobilities were also 
observed in all inhibitors at the intracellular loop (ICL) and extracellular loop (ECL) regions 
compared to the transmembrane domains.  
Additionally, the stability of the best-hits and Maraviroc complexes were observed throughout 
the simulation process for the averaged volume, pressure, temperature, the total energy 
(ETOT), and potential energy (EPtot) values and presented in Table S6. The overall simulation 
quality shows that these parameters were stable over the 100 ns simulation (Fig. S1.). 
Noticeably, the best-hits were observed to relatively have lower total energy and potential 
energy compared to Maraviroc. In contrast, the other parameters were observed to be in a 
similar range (Table S6). 
3.4 In silico evaluation of molecular properties and pharmacokinetics of best hits 
To gain insight into the drug-likeness (molecular properties) and potential pharmacokinetic 
properties of the final hits, a comparative in silico analysis was performed. The physiochemical 
properties of the top four compounds and the additional 19 compounds were also analysed and 
presented in Table 3 and Table S4, respectively. The in silico physicochemical properties and 
pharmacokinetic profiling were carried out using SwissADME (Daina et al., 2017) and 





LogP measures the hydrophilicity of chemical compounds, which is the logarithm of the 
coefficient of their permeation across n-octanol and water (Octanol/Water) (Lipinski, 2000). 
Hence, a high MLogP value indicates a reduction in aqueous solubility, leading to a decrease 
in absorption. All the top four hits had MLogP lower than Maraviroc (Table 3). Besides 
compound BDG 51127568 in Table S4, all the other compounds displayed lower MLogP 
values than Maraviroc.  
Also, LogS was employed to estimate the aqueous solubility of the retrieved compounds 
relative to the approved drug. The LogS, in addition to contributing to the determination of 
membrane permeability, equally provide an idea of the oral bioavailability of drugs (Wang & 
Hou, 2011). A minimum acceptable range of 0 to -6 for aqueous solubility accounts for 95 % 
of the existing drugs (Wang & Hou, 2011). The obtained values in Table 3 revealed that all the 
chemical compounds fall within the acceptable range for being optimally absorbed in the body. 
The retrieved compound solubility ranged from moderately soluble to soluble, whereas poor 
solubility was attributed to Maraviroc. Also, except compound BDG 51127568, the remaining 
compounds in Table S4 had good LogS values compared to Maraviroc.   
The topological polar surface area (TPSA) puts together the surface polar atoms, most notably 
the oxygen and nitrogen, in connection with the hydrogen atoms that they are attached. It aids 
in predicting the ability of a chemical compound to pass through the cells, where a low TPSA 
score indicates the compound can permeate the cell (Ertl et al., 2000; Prasanna & Doerksen, 
2008). It also provides a picture of the molecular size and volume, which regulates its 
physiological transport across the lipid bilayer, which includes the gastrointestinal tract (GIT) 
and blood-brain barrier (BBB) (Shityakov et al., 2013). High TPSA has been posited to disrupt 
the transportability of drug candidates, which in turn impact the bioactivity of these drugs 
(Daga et al., 2018; Di & Kerns, 2016a). From the indications in Table 3, Maraviroc had the 
least TPSA; however, all the evaluated top four and the 19 compounds were within the 
acceptable range of TPSA of  ≤140 Å2. The compounds BDF 33909572, BDG 34130390,  BDF 
34027559, BDG 33694125, BDG 51127568, BDG 34042546, BDG 33691535, BDF 
34035988, BDG 33694314, and BDF 33909571 in Table S4 had TPSA values lower than 
Maraviroc.  
Hydrogen bond has been suggested to affect the solubility of therapeutic compounds since they 
must get broken to facilitate the transportation of these compounds across the lipid bilayer 
membrane (Di & Kerns, 2016b; Sun et al., 2018). Thus, a high number of hydrogen bond 
influences permeation by passive diffusion due to the decline in partitioning from the aqueous 




of hydrogen bond donors (HBD) and hydrogen bond acceptors (HBA) in a molecule. This has 
been extensively employed in the estimation of drug-likeness of a chemical compound. The 
Lipinski RO5 states that a drug-like compound should have HBD count of ≤5 and HBA of ≤10; 
this is the basis for oral bioavailability and activity(Lipinski et al.; Lipinski, 2000). The 
calculation in Table 3 and Table S4 indicate that all the retrieved top compounds passed the 
score for adequate hydrogen bond donation and acceptance.  
The ADMET descriptors' profiling was determined using the pkCSM-pharmacokinetics 
algorithm protocol (Pires et al., 2015). The predictive factors for drug absorption include 
human intestinal absorption, skin permeability levels, water solubility and Caco-2 
permeability. The factors affecting the distribution of a drug include the volume of distribution 
(VDss), CNS permeability, and the blood-brain barrier (logBB). The predictions of drug 
metabolism are based on the inhibitor or substrate CYP models (CYP3A4, CYP2D6, CYP1A2, 
CYP2C19, CYP2D6, CYP3A4, and CYP2C9). Also, the renal Organic Cation Transporter 2 
(OCT2) substrate and the total clearance model were used to predict the excretion of the 
potential drug. The estimation of potential drug toxicity was based on models such as skin 
sensitisation, AMES toxicity, and Oral rat acute toxicity. These predictive parameters were 
estimated for the top four compounds and the reference drug Maraviroc (Table 4).  
Regarding the parameters for absorption, the percentage of human intestinal absorption (HIA) 
were higher for all the top four compounds (88.7 – 93.6%) except for LAS 34154543 (80.3 %) 
when compared to Maraviroc (88.2%). Also, optimal Caco-2 permeability, which is a 
predictive indicator for the absorption of orally administered drugs (> 0.9 suggests high Caco-
2 permeability) were observed for the selected compounds (~0.9 – 1.2), which outscored 
Maraviroc (0.7) (Pires et al., 2015). The predictive absorption indicators of selected compounds 
demonstrate their potential for good oral bioavailability.  
The volume of distribution in human (VDss) is a predictive parameter that describes the extent 
of drug distribution (VDss < -0.15 and VDss > 0.45 denote low and high distribution, 
respectively). The compounds LAS 51495192, BDB 26405401, and BDB 26419079 shows 












CCR5 inhibitors have been demonstrated to display great potential strides in HIV-1 infection 
treatment. However, the risk of life-threatening adverse effects, such as allergic reaction, skin 
reaction, liver and damage heart attack is caused by the FDA approved drug, Maraviroc (FDA, 
2007; Peng et al., 2018). Hence, identifying novel potential inhibitors of CCR5 with new 
chemical scaffolds, relatively less adverse effects and displaying improved binding affinity are 
highly desired. The structure of the full-length CCR5 is significantly beneficial in the discovery 
and designing of potential lead candidates as HIV-1 entry inhibitors. Structure-based virtual 
screening remains an integral approach in the identification of new chemical scaffolds against 
the active site of a known protein target. 
 In this study, structure-based virtual screening of the Asinex antiviral database and further 
analyses lead to the identification of novel potential CCR5 inhibitors. In summary, the Asinex 
antiviral database was screened against CCR5. The applied in silico approaches identified 
compounds LAS 51495192,  BDB 26405401, BDB 26419079, and LAS 34154543 with 
binding scores higher than Maraviroc. These compounds were also observed to make 
interactions with residues critical for gp120 V3 loop binding. Additional 19 compounds with 
similar or improved physiochemical properties and higher binding scores compared with 
Maraviroc that could be further optimised have also been reported. Furthermore, in silico 
pharmacokinetics and physiochemical estimations also indicated the predicted values of the 
physicochemical descriptors were within the acceptable range for drug-likeness, therefore 
suggesting positive indications that the identified potential molecules are promising drug-like 
entities. The successful application of multidisciplinary computational drug discovery 
approaches has allowed the identification of diverse potential compounds laying the 
groundwork for experimental exploration of the suggested compounds. Further optimisations 
and testing of these compounds may assist in the discovery of effective HIV-1 therapy.  
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Entry number: 8354 
Asinex compound ID: LAS 51495184 
Entry number: 1093 
Asinex compound ID: BDC 23205804 
 
 
Entry number: 3673 
Asinex compound ID: BDF 33909572 
Entry number: 5477 
Asinex compound ID: BDG 34130390 
 
 
Entry number: 1077 
Asinex compound ID: BDC 23205600 
Entry number: 8530 






Entry number: 4856 
Asinex compound ID: BDG 34037901 
Entry number: 543 
Asinex compound ID: BDB 26418354 
 
 
Entry number: 4055 
Asinex compound ID: BDG 33691535 
Entry number: 995 
Asinex compound ID: BDC 23197464 
 
 
Entry number: 4156 
Asinex compound ID: BDG 33694125 
Entry number: 5573 






Entry number: 4946 
Asinex compound ID: BDG 34042546 
Entry number: 3742 
Asinex compound ID: BDF 34027559 
 
 
Entry number: 3746 
Asinex compound ID: BDF 34035988 
Entry number: 5582 
Asinex compound ID: BDG 51129965 
 
 
Entry number: 4157 
Asinex compound ID: BDG 33694314 
Entry number: 3672 
Asinex compound ID: BDF 33909571 
 








Fig. (S1). Analysis of the average energetics for potential energy (A),  kinetic energy (B), and 
















8.0 Conclusions, Recommendations and Future Perspectives 
In this thesis, the binding mechanistic of inhibitors targeting the human GPCRs, i.e. C-C 
chemokine receptor 5 (CCR5), D2 and D3 dopamine receptors (D2DR and D3DR), were studied 
to provide a multifaceted and novel understanding of inhibitor/drug-receptor interactions at the 
selected GPCR targets. In this concluding chapter, novel insights are highlighted, and 
recommendations for future investigations in this research area are outlined. 
 
8.1 Conclusions from this thesis 
The current availability of resolved drug/ligand complex structures for GPCRs such as the D2-
like dopamine receptors and CCR5 provide avenues to uncover atomic molecular level ligand 
recognition mechanisms and conformational dynamics. Understanding the dynamic signalling 
properties of GPCRs and the structural basis of their ligand recognition/binding interactions 
enable full leverage on the power of rational drug design. The main aim of this thesis was to 
provide novel mechanistic insights into how dopamine receptors and CCR5 interact with their 
small molecule inhibitors and apply a structure-based discovery approach to identifying new 
potential CCR5 inhibitor scaffolds.  
 
The following conclusions were made in deciphering the binding mechanism of atypical 
antipsychotic drugs and their effect on D2DR conformational dynamics. 
i. Class II atypical antipsychotics adopts a favourable binding mode and interactions at the 
D2DR deep hydrophobic pocket. In contrast, the binding conformations of Class I atypical 
antipsychotics is shallow, reaching out above the orthosteric binding pocket into the D2DR 
extended binding pocket. 
ii. van der Waals interaction energy contribution dominates the higher binding affinity of 
Class II atypical antipsychotics at D2DR receptor compared to the relatively lower binding 
affinities of the Class I antipsychotics. 
iii. A unique salt bridge interaction with Asp1143.32 is common to all the studied Class II 
atypical antipsychotic drugs. This salt bridge is vital for inhibitors displaying high binding 






In addition, the molecular mechanistic and conformational dynamics underlying the selective 
binding of the two bitopic antagonists, R-VK4-40 and Y-QA31, toward D3DR over D2DR 
were explored. R-VK4-40 and Y-QA31 adopt shallow binding modes at D3DR orthosteric 
binding pocket (OBP) and extended/second binding pocket (E/SBP), on the contrary, they 
display deep hydrophobic pocket binding at D2DR. The efficacy of bitopic compounds has 
been found to depend on their binding mode in the OBP, whereas their selectivity arises from 
their different interactions within the SBP (Newman et al., 2012). The favourable flexibility of 
bitopic compounds seems to be conferred by their linker, allowing R-VK4-40 and Y-QA31  to 
bind in the S/EBP of D3DR with higher selectivity. Also, two non-conserved residues 
(Tyr361.39 and Ser18245.51) have been identified in D3DR, due to their essential role in the 
selective binding of R-VK4-40 and Y-QA31. The estimated binding free energies also suggest 
an increase in van der Waals interactions and a relative decrease in entropy contribution were 
crucial factors that underlie the high selectivity and affinity of the studied antagonists for D3DR 
relative to D2DR. 
 
Furthermore, this thesis has also provided a structural understanding and binding mechanistic 
of the novel 1-heteroaryl-1,3-propanediamine derivatives (Compd-21 and Compd-34) and 
Maraviroc at CCR5. The findings from this study have shown the structural basis for Compd-
21 and Compd-34 higher binding profile at CCR5 binding pocket compared to Maraviroc. The 
binding dynamics have revealed that the substitution of the phenyl group in Maraviroc with the 
thiophene moieties cumulatively engaged in higher affinity interactions with CCR5 binding 
pocket residues critical for gp120 V3-loop binding. These results corroborate the recent 
findings that Maraviroc blocks gp120 binding to CCR5 via direct competitive inhibition as 
opposed to earlier views of allosteric inhibition through conformational availability restriction 
(Shaik et al., 2019). 
 
Finally, the successful application of structure-based virtual screening techniques identified 
potentially new inhibitor scaffolds that displayed binding modes and interaction profiles at the 
CCR5 binding pocket. These compounds made substantial interactions with residues vital for 








8.2 Limitations of the Study 
The validity of the binding affinities, the physicochemical and pharmacokinetic properties of 
identified potential CCR5 inhibitors is subject to experimental evaluations. Thus the results are 
to be interpreted as theoretical findings.  
8.3 Recommendations and Future Perspectives 
The deep hydrophobic sub-pocket binding of Class II atypical antipsychotic drugs may be 
explored in the design of the next generation of D2 dopamine receptor subtype-selective 
antagonists. The role of the unique salt bridge interaction of D2DR Asp1143.32 should be 
considered during the rational design of potential D2DR inhibitors. 
 
Bitipic compound design and their optimisation for their different interactions at D3DR E/SBP 
(selectivity) and OBP (higher affinity) may assist in the rational design of novel D3 dopamine 
receptor-selective antagonists with higher binding affinity. 
 
Further structural modifications at the thiophene substituent with functional groups that make 
stronger interactions with the identified residues critical for gp120 V3 loop binding will be 
beneficial. Also,  the addition of additional functional groups to the triazole ring may increase 
inhibitor competition with gp120 V3-loop with enhanced potency at CCR5 (Shaik et al., 2019). 
This offers a foundation for the onward structural modifications and rational design of novel 
potent antagonists of CCR5 in HIV-1 treatment. 
 
The identified potential CCR5 inhibitors have displayed promising interactions with residues 
critical for gp120 V3 loop binding. However, biochemical investigations of these compound 
scaffolds obtained from the in silico structure-based studies are still needed to verify their 
antiviral activity at CCR5. Furthermore, the selected compounds toward CCR5 add to the 
available chemical scaffolds for structural modifications and optimisations that may assist in 
the lead identification of more potent antiviral drugs of HIV-1. 
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